

Index to Volume 56

The index to Volume 56 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Society of Health-System Pharmacists" as well as being

covered by IPA in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: Alternative Therapies, Book Reviews, Editorials, Frontline Pharmacist, Letters, Managed Care Forum, Management Consultation, News, Questions and Answers, and Self-study Materials. The page numbers of articles that appear in ASHP Affiliates are listed under that heading by the names of the societies. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-96
January 15	97-192
February 1	193-292
February 15	293-392
March 1	393-492
March 15	493-588
April 1	589-686
April 15	687-830
May 1	831-928
May 15	929-1036
June 1	1037-1166
June 1 Supplement	S1-S24
June 15	1167-1274
July 1	1275-1372
July 15	1373-1470

Issue	Pages
August 1	1471-1578
August 15	1579-1686
September 1	1687-1792
September 1 Supplement	S1-S25
September 15	1793-1902
October 1	1903-2000
October 15	2001-2166
November 1	2167-2260
November 15	2261-2360
November 15 Supplement	S1-S28
December 1	2361-2496
December 1 Supplement	S1-S24
December 15	2497-2596
December 15 Supplement	S1-S20

Subject Index

A

Abacavir sulfate; adverse reactions; warning card, 304

Academy of Managed Care Pharmacy; formularies; definitions, 467

Accreditation
home health care; quality assurance, 911
hospital pharmacy; sentinel event policies, 2031
hospitals; JCAHO surveys, 1699
managed care systems; NCOA standards, 846, 2270
residencies; ASHP meetings, 2454

Acetaminophen
allergies; infliximab, 11
combination, codeine phosphate; overdose, 1774
combination, hydrocodone bitartrate; overdose, 1774
combination, oxycodone; overdose, 1774
combination, propoxyphene napsylate; overdose, 1774
liquids; pediatrics, 1094
pain; nonprescription, 1126
therapy; promethazine extravasation, 1742
toxicity; overdose, 1081

Acetazolamide; errors, medication; acetohexamide substitution, 2463

Acetohexamide; errors, medication; dispensed for acetazolamide, 2463

Acetylcysteine; antidotes; acetaminophen overdose, 1081

Acids, fatty; overview, 719

Acquired immunodeficiency syndrome

foscarnet; cytomegalovirus retinitis, 1314
ganciclovir; cytomegalovirus retinitis, 1314
pediatrics; ASHP protocols, 1201
zidovudine; cytomegalovirus retinitis, 1314

Actein; *Cimicifuga racemosa*; overview, 1400

Acupuncture; hyperalgesia; morphine toxicity, 1009

Acyclovir
concomitant therapy, 1831
use; benchmarking, 1102

Acyclovir sodium; incompatibilities; levofloxacin, 1458

Additives; injections; doxorubicin, etoposide, vincristine, 985; levofloxacin stability, 1458; milrinone incompatibilities, 63; promethazine-dihydroergotamine incompatibilities, 1835; sumatriptan incompatibilities, 983; tacrolimus, 164; tirofiban incompatibilities, 1627

Administration

ambulatory care; computer protocols, 225; hospital pharmacy, 1974; hospitals, 1974
American Journal of Health-System Pharmacy; continuing education, 21

American Society of Health-System Pharmacists; publications, 1301

Eli Lilly; postmarketing surveillance, 1559

Food and Drug Administration; drug approvals, 31
formularies; managed care systems, 467; U.S., 2338
home health care; ASHP guidelines, 629; decision-making, 473; parenteral nutrition, 270; quality assurance, 911

hospital pharmacy; adverse drug reactions, 1769; antidote carts, 2537; automated dispensing machine, 1398; clinical services, 1945; clinical studies, 252, 337; computers, 674, 675; discharge consultation, 1074; dofolotide dispensing, 2375; drug diversion, 1823; drug use, 1102; filgrastim protocols, 1330; formularies, 818; generic substitution, 615; glipizide conversions, 454; intranet, 2290; investigational drugs, 249; investigational drug services, 344; medication errors, 1319; medication tracking system, 1190; metformin use, 2535; pain management, 1119; P&T committee, 1132; patient-focused care, 324; pharmacists' interventions, 2444; pharmacoeconomics, 1630; quality assurance, 909; sentinel events, 2031; sterile products, 1978; student interventions, 882; survey, 142; Y2K, 1922; year 2000, 1066

hospitals; inpatient physicians, 596; Medicaid databases, 1326; medication errors, 1765; Y2K, 1922; year 2000, 1048

IGIV Safety Net Program; immune globulin distribution, 599

industry, pharmaceutical; pharmacogenomics, 40
integrated health care; pharmaceutical services, 2431; statistics, 1392

leadership; residencies, 2454
long-term-care facilities; prospective-pricing system, 2012

managed care systems; β -blocker use, 858; managed care systems; drug costs, 313; managed care systems; standards, 846

nursing; state boards, 707

pharmaceutical services; ambulatory care, 443; anesthesiology, surgery, 887; home health care, 603; strategic planning, 2533

pharmacy; employment, 2518; practice change, 2458; sexual harassment, 117

pharmacy and therapeutics committee; survey, 622
pharmacy, community; practice models, 2235

pharmacy, institutional; drug costs, 1710; practice models, 2235

policies and procedures; ambulatory care pharmacy, 1744; APHA, 706; hospital pharmacy, 1721; immune globulin protocols, 1546; managed care formularies, 1499; medication errors, 907; parenteral nutrition compounding, 815; TPN automation, 25

universities; clinical studies, 171

Administrators

hospital pharmacy; employment, 2518

pharmacists; smoking cessation, 425

pharmacy; practice changes, 2235; sexual harassment, 117; survey, 1342

Admixtures, see **Additives**

Adolescents; cystic fibrosis; clinical pharmacists, 158

Adrenergic agents, see **Sympathomimetic agents**

Advertising

dietary supplements; FTC guidelines, 308; health claims, 942

prescription drugs; direct to consumer, 307, 706; FDA regulations, 1815

prescriptions; Internet, 1812

Advertising Index, 96, 192, 292, 392, 492, 588, 686, 830, 928, 1036, 1166, 1274, 1372, 1470, 1578, 1686, 1792, 1902, 2000, 2166, 2260, 2360, 2496, 2566

Advisory Committee on Immunization Practices; protocols; combination childhood vaccines, 1179

Advisory Council to Improve Outcomes Nationwide in Heart Failure; protocols; heart failure, 503

Aerosols; antibiotics; cystic fibrosis, 2271

Age
patients; adverse reactions, 450; HMG-CoA reductase inhibitors, 1726
pharmacists; job satisfaction, 1733

Agency for Health Care Policy and Research
protocols; evidence-based therapy, 501
reports; antidepressants, sinusitis, 853

AHFS/firstFAX New Drug Overview, 1031, 1191, 1364, 1404, 1924, 2036, 2190, 2298, 2410, 2528
Amprenavir, 1365
Celecoxib, 1031
Doxercalciferol, 2410
Ganirelix acetate, 2299
Ketotifen fumarate, 1926
Levalbuterol hydrochloride, 1191
Orlistat, 1364
Perindopril erbumine, 2037
Quinupristin and dalbapristin, 2530
Rabeprozole sodium, 2300
Rofecoxib, 1404
Rosiglitazone maleate, 1925
Temozolamide, 2529
Zanamivir, 2190

AIDS, see **Acquired Immunodeficiency Syndrome**

AJHP, see **American Journal of Health-System Pharmacy**

AJHP Continuing Education, 139, 534, 974, 1016, 1091, Jun 1 suppl S22, 1638, Sep 1 suppl S23, 1936, 1971, 2203, 2428, Dec 1 suppl S22

Albendazole; toxicity; liver failure, 1388

Albumin; rational therapy; meta-analysis, 1451

Alcohol withdrawal delirium; phenobarbital, 175

Alcoholism; alcohols, ethyl; withdrawal, 175

Alcohols, ethyl
dependence; evidence-based therapy, 501
withdrawal; phenobarbital therapy, 175

Alitretinoin; approvals; FDA, 603

Allergies
abacavir sulfate; warning card, 304
food; medication errors, 907
influximab; retreatment, 11

Alprostadil; incompatibilities; levofloxacin, 1458

Alteplase; stability; cryopreserved, 2056

Alternative medicine
acids, fatty; overview, 719
Cimicifuga racemosa; overview, 1400
consumers; attitudes, 307; survey, 942
creatine; overview, 1608
Echinacea species; overview, 121
Hypericum perforatum; overview, 329
hyperlipidemia, 1668
kava; overview, 957
pharmaceutical services; year 2000, 2533
phosphatidylserine; overview, 2038

Alternative Therapies, 121, 329, 519, 719, 957, 1195, 1400, 1608, 2038, 2523

Black cohosh: *Cimicifuga racemosa*, 1400

Coenzyme Q₁₀, 519

Creatine, 1608

Echinacea, 121

Kava: *Piper methysticum*, 957

Melatonin, 2523

Milk thistle: *Silybum marianum*, 1195

Omega-3 essential fatty acids, 719

Phosphatidylserine, 2038

St. John's wort: *Hypericum perforatum*, 329

Alzheimer's disease
phosphatidylserine; overview, 2038
trichlorfon; review, 427

olanzapine; psychotic disorders, 2245

Amantadine; influenza; prophylaxis, 2303

Ambulatory care
antiemetics; prophylaxis, 728
cimetidine; drug interactions, 1890
clinical pharmacists; nutrition support clinic, 2324
drug distribution; emergency services, 2554
drug use; geriatrics, 2022
formularies; managed care systems, 467
HIV infections; clinical pharmacy services, 420
immunization; pharmacists' role, 2398
injections; infusion services, 1974

integrated health care; pharmaceutical services, 2431

pharmaceutical services; anticoagulation clinics, 443; ASHP guidelines, 1744; technicians' role, 1602; therapeutic substitution, 1307; warfarin clinics, 1540; year 2000, 2533

pharmacists; hospital; computer protocols, 225; errors, medication, 1319

pharmacists; job satisfaction, 1733; organizations, 1775; survey, 1342

American Academy of Family Physicians; protocols; combination childhood vaccines, 1179

American Academy of Pediatrics; protocols; combination childhood vaccines, 1179

American Cancer Society; charity; cosmetology services, 208

American College of Cardiology; protocols; HMG-CoA reductase inhibitors, 1179

American College of Chest Physicians; protocols; cystic fibrosis, 2271; warfarin, 1505

American Consulting Engineers Council Insurance Fund; cases; reimbursement lawsuits, 257

American Heart Association; protocols; heart diseases, 503; HMG-CoA reductase inhibitors, 1179

American Journal of Health-System Pharmacy
acknowledgment of reviewers, November 1, 1998, to October 31, 1999, 2547
education, pharmaceutical; continuing, 21
instructions for submitting computer disks, 71
procedure for submissions to, 69
sections, 71

American Medical Association
attitudes; Internet prescribing, 1174; Internet prescribing, dispensing, 500
legislation; Internet advertising, 1812

American Pain Society; protocols; sickle-cell pain, 2272

American Pharmaceutical Association
policies and procedures; 1999 annual meeting, 706
strategic planning; pharmacy practice, 1915

American Society for Parenteral and Enteral Nutrition; guidelines; home health care, 815

American Society of Health-System Pharmacists
Annual Meeting, call for papers, 1754; program, 765
attitudes; standards, 846
Board of Directors; actions, November 14-15, 1998, meeting, 562; actions, April 19-21, 1999, meeting, 1455; actions, June 6, 1999, meeting, 1888; September 16-17, 1999, meeting, 2546
Council on Administrative Affairs; report on, 641
Council on Educational Affairs; report on, 648
Council on Legal and Public Affairs; report on, 652
Council on Organizational Affairs; report on, 660
Council on Professional Affairs; report on, 664
education, pharmaceutical; continuing, 21
Executive Vice President; report of, 1653
formularies; definitions, 467
guidelines; assisted suicides, 1661; development process, 1829; home health care, 629; investigational drug services, 344; patient confidentiality, 1664; pharmaceutical services, 887; primary care, 1665
Harvey A. K. Whitney Lecture Award; 1999, 1613
Home, Hospice, and Long-Term-Care '99 meeting; call for posters, 465; program, 1251
House of Delegates; 1999 session, members of, 640; professional policies adopted by 51st annual session, 1658
meetings; poster presentations, 277; students' reactions, 1991
Midyear Clinical Meeting; call for papers, 558; program, 2058
pharmaceutical services; integrated health care, 2431; survey, 142
Pharmacy Student Forum, report, 670
policy recommendations—invitation to comment, 639
Practitioner Recognition Program—1999 fellows, 895
President and Chair of the Board; report of, 1644
President-elect and Vice Chair of the Board; report of, 1641
protocols; antiemetics, 728, 729; antimicrobial prophylaxis, 1199, 1201, 1839; nonprescription analgesics, 1126; smoking cessation, 460; ulcer prophylaxis, 347
publications; production, 1301
residencies; preceptors' meetings, 2454
role; year 2000, 1048
roster of residents completing ASHP-accredited programs in calendar year 1999, 1001
Section of Clinical Specialists, report, 669

Section of Home Care Practitioners, report, 668

suicides; assisted, 1672

Treasurer; report of, 1649

Amino acids
creatine; overview, 1608
cysteine hydrochloride; interactions, 1950

Aminoglycosides
gentamicin; blood levels, 1457
gentamicin sulfate; dosage, 440
interactions; vancomycin, 161

Amiodarone; heart failure; congestive, 1445

Amiodarone hydrochloride; atrial fibrillation; cost-benefit analysis, 2211

Amisulpride; rational therapy; geriatrics, 433

Amphotericin B
candidiasis; review, 525
mycoses; dosage, 872
urinary tract infections; mycoses, 1929

Amprolium; approvals; FDA, 1057

Analgesics and antipyretics
acetaminophen; infliximab adverse reactions, 11; nonprescription, 1126; overdose, 1081, 1774; pediatric, 1094; promethazine extravasation, 1742
clonidine; morphine toxicity, 1009
levorphanol; morphine toxicity, 1009
nonprescription; rational therapy, 1079
pain; sickle-cell trait, 2272
propoxyphene; rational therapy, 433

Anesthesia; pharmaceutical services; ASHP guidelines, 887

Anesthetics, local
bupivacaine hydrochloride; promethazine extravasation, 1742
levobupivacaine hydrochloride; FDA approvals, 1912
lidocaine hydrochloride; promethazine extravasation, 1742

Angioneurotic edema; lisinopril; toxicity, 1773

Angiotensin antagonists; heart failure; congestive, 1445

Angiotensin-converting-enzyme inhibitors
heart failure; combined therapy, 503; congestive, 1445; geriatrics, 1334
perindopril erbumine; overview, 2037

Anorexia; cannabis; smoking, 940

Anorexia; orlistat; FDA approvals, 1058

Antacids; ulcers; prophylaxis, 347

Anthrax vaccines; storage; temperature, 2052

Antiallergic agents; ketotifen fumarate; overview, 1926

Antidiuretics; prostatic neoplasms; AHCPR protocols, 501

Antianemia agents; prescribing; kidney failure, 1961

Antiarrhythmic drugs, see **Cardiac drugs**

Antibiotics
cystic fibrosis; protocols, 2271
fumagillin bicyclohexylammonium; ophthalmic solutions, 547
prophylaxis; ASHP protocols, 1839
quinupristin, combination, dalbapristin; FDA approvals, 2174
sinusitis; evidence-based reports, 853
vancomycin; blood levels, 1457; interactions, 161; resistance, 2174
vancomycin hydrochloride; incompatibilities, 246

Antibodies; monoclonal; infliximab, 11

Anticoagulants
heparin sodium; levofloxacin incompatibilities, 1458
warfarin; ambulatory care, 443; cimetidine interactions, 1890; interactions, 676; laboratory tests, 1619; protocols, 1505; toxicity, 1540, 2312
warfarin sodium; rectal administration, 2140

Anticonvulsants
carbamazepine; alcohol withdrawal delirium, 175; interactions, 1890
lamotrigine; incompatibilities, 240
phenobarbital; alcohol withdrawal delirium, 175
phenytoin; drug interactions, 1890

Antidepressants
amisulpride; rational therapy, 433
citalopram hydrobromide; comparisons, 2242
fluoxetine hydrochloride; comparisons, 2242
fluvoxamine; comparisons, 2242
serotonin-reuptake inhibitors; evidence-based reports, 853; pharmacoeconomic comparisons, 23
sertraline hydrochloride; comparisons, 2242
tricyclic; evidence-based reports, 853

Antidiabetic agents
acetohexamide; toxicity, 2463
diabetes mellitus; patient consultation, 1535
glipizide; immediate vs. sustained release, 454
metformin; use, 2535

- pioglitazone hydrochloride; FDA approvals, 1698
rosiglitazone maleate; FDA approvals, 1292; overview, 1925
troglitazone; toxicity, 840
- Antidotes**
acetylcysteine; acetaminophen overdose, 1081
charcoal, activated; acetaminophen overdose, 1081
cimetidine; acetaminophen overdose, 1081
poisoning; carts, 2537
- Antiemetics**
nausea; ASHP protocols, 729; pharmacists' role, 728
prochlorperazine hydrochloride; promethazine extravasation, 1742
promethazine hydrochloride; extravasation, 1742
vomiting; ASHP protocols, 729; pharmacists' role, 728
- Antifungals**
amphotericin B; candidiasis, 525; mycoses, 872;
urinary tract infections, 1929
candidiasis; *Candida* species, 523
fluconazole; urinary tract infections, 1929
itraconazole; onychomycosis, 865
SCH56592; candidiasis, 525
terbinafine hydrochloride; incompatibilities, 243;
onychomycosis, 865
voriconazole; candidiasis, 525
- Antihistamines**
allergies; infliximab adverse reactions, 11
diphenhydramine hydrochloride; toxicity, 555
promethazine hydrochloride; incompatibilities, 1835
protocols; nausea and vomiting, 729
- Anti-infective agents**
clavulanate potassium, combination, ticarcillin disodium; protocol incompatibilities, 875
costs; comparisons, 2217
heilcobacter infections; combined therapy, Dec 1 suppl S5
prescribing; kidney failure, 1961
prophylaxis; ASHP protocols, 1199, 1201
resistance; respiratory-tract infections, Nov 15 suppl S4
respiratory-tract infections; pharmacodynamics, pharmacokinetics, Nov 15 suppl S17; pharmacoeconomics, Nov 15 suppl S25
thalidomide; hospital pharmacy policies, 1721
trimethoprim, combination, sulfamethoxazole; toxicity, Dec 15 suppl S5
- Anti-inflammatory agents**
celecoxib; arthritis, 106; FDA approvals, 403
glucosamine sulfate; osteoarthritis, 267
ibuprofen; osteoarthritis, 267
indomethacin sodium; levofloxacin incompatibilities, 1458
infliximab; adverse reactions, 11
nonsteroidal; contraindications, 1334; nonprescription, 1126; toxicity, Dec 1 suppl S5
rofecoxib; arthritis, 106; FDA approvals, 1294; overview, 1404
- Antipileptic agents**
cholestyramine resin; formulations, 80
coronary disease; pharmacists' interventions, 2319
fluvastatin; therapeutic substitution, 1437
HMG-CoA reductase inhibitors; cost-benefit analysis, 1726; postmenopause, 1179
lovastatin; dietary supplements, 604; therapeutic substitution, 1437
neomycin sulfate; hypercholesterolemia, 2227
pravastatin; therapeutic substitution, 1107, 1437
simvastatin; therapeutic substitution, 1107, 1437
- Antineoplastic agents**
alitreinoin; FDA approvals, 603
breast neoplasms; combined therapy, 939
carmustine; gloves permeation, 2450
cisplatin; cervix neoplasms, 702
colorectal neoplasms; review, 2417
compounding; barrier isolators, 1433
cyclophosphamide; surface contamination, 1427
denileukin difitox; FDA approvals, 502
doxorubicin hydrochloride; incompatibilities, 985
epirubicin hydrochloride; FDA approvals, 2177
etoposide; incompatibilities, 985
exemestane; FDA approvals, 2378
fluorouracil; surface contamination, 1427; topotecan incompatibilities, 875
hydroxyurea; HIV infections, 1554
ifosfamide; surface contamination, 1427
mitomycin; topotecan incompatibilities, 875
paclitaxel; gloves permeation, 2450
permeation; gloves, 2450
temozolomide; FDA approvals, 1910
- topotecan hydrochloride; incompatibilities, 875
toxicity; cosmetics, 208; nausea and vomiting, 728, 729; neutropenia, 1330; state nursing boards, 707
vincristine sulfate; incompatibilities, 985
- Antioxidants**; heart diseases; AHA protocols, 503
- Antiparkinson agents**
carbidopa, combination, levodopa; combined therapy, 2376
entacapone; FDA approvals, 2376
prescribing; risperidone use, 2139
ropinirole hydrochloride; review, 217
tolcapone; adverse reactions, 8; Parkinson's disease, 2195
- Antipsychotic agents**
loxapine hydrochloride; subcutaneous, 1259
olanzapine; neuroleptic malignant syndrome, 1558, 1559; schizophrenia, 1559, 1560
risperidone; geriatrics, 2139
- Antiretroviral agents**
abacavir sulfate; hypersensitivity warning card, 304
amprenavir; FDA approvals, 1057
HIV infections; ambulatory care, 420; combined therapy, 1057, 1554; prophylaxis, 1011
protease inhibitors; combined therapy, 273; toxicity, 2343
zidovudine; AIDS, 1314; toxicity, Dec 15 suppl S5, Dec 15 suppl S17
- Antituberculars**; rifabutin; stability, 333
- Antivirals**
acyclovir; use, 1102
acyclovir sodium; levofloxacin incompatibilities, 1458
amantadine; influenza prophylaxis, 2303
cidofovir; toxicity, Dec 15 suppl S5
foscarnet; cytomegalovirus retinitis, 1314; toxicity, Dec 15 suppl S5
ganciclovir; cytomegalovirus retinitis, 1314; toxicity, 257, Dec 15 suppl S5
ganciclovir sodium; cytomegalovirus infections, 1831; stability, 1738
interferon alfa-2a; hepatitis C, 961
interferon alfa-2b; hepatitis C, 961
interferon alfa-2b, combination, ribavirin; hepatitis C, 961
interferon alfacon-1; hepatitis C, 961
oseltamivir phosphate; FDA approvals, 2376
valacyclovir hydrochloride; incompatibilities, 1957
zanamivir; FDA approvals, 1696; overview, 2190
- Anxiety**; *Hypericum perforatum*; overview, 329
- Anxiolytics, sedatives and hypnotics**
chloridiazepoxide; rational therapy, 433
costs; combined therapy, 23
diazepam; rational therapy, 433
kava; overview, 957
operating rooms; pharmaceutical services, 977
zaleplon; FDA approvals, 1912
- Apparatus**, see **Equipment**
- Aprenavir**; overview, 1365
- Arthritis**
acids, fatty; rheumatoid, 719
celecoxib; rheumatoid, 106, 403
rofecoxib; rheumatoid, 106
- Ascorbic acid**; hyperlipidemia; alternative medicine, 1668
- Aseptic areas**
cleanrooms; barrier isolators, 1403, 1433
hospital pharmacy; planning and design, 1978
- ASHP**, see **American Society of Health-System Pharmacists**
- ASHP Affiliates**, 114, 321, 514, 712, 948, 1186, 1394, 1597, 1820, 2288, 2516
Alabama, 323, 1601
Arkansas, 514, 951
ASHP hosts state society executive meeting, Congressional visits, 514
California, 115, 715, 2517
Chapter Briefs, 115, 323, 715, 951, 1187, 1397, 1820, 2288, 2517
Colorado, 114, 1397
Connecticut, 115, 514, 948, 1396, 2517
Delaware, 514
Educational Meetings, 116, 323, 514, 712, 948, 1188, 1396, 1601
Florida, 115, 1189, 2516
Georgia, 715, 2288
Hawaii, 1186
Idaho, 2516
Illinois, 323, 1187, 1394, 1820, 2516
Iowa, 116, 712, 1601, 2288
Kansas, 323, 2288
Kentucky, 2516
Louisiana, 1597
- Maine, 323, 712, 1396
Maryland, 116, 323, 515, 715, 948, 1397
Massachusetts, 948, 1822
Minnesota, 1188
Mississippi, 1186
Missouri, 1187
Montana, 515
Nebraska, 1395
Nevada, 116, 2288
New Hampshire, 116, 323, 712, 948, 1188, 1601
New Jersey, 116, 1187, 1396
New Mexico, 712
New York State, 715, 1598, 2288
North Carolina, 322, 712, 2288, 2517
North Dakota, 323
Ohio, 323, 1187, 1396
Oklahoma, 1188
Oregon, 514, 1597
Pennsylvania, 951, 1397, 2517
South Carolina, 948
State society members take care of business at ASHP Midyear, 323
Texas, 1394, 1820
Upcoming Meetings, 116, 322, 515, 715, 951, 1189, 1395, 1598, 1822
Utah, 1188
Vermont, 951
Virginia, 948, 2516
Washington Metropolitan, 116, 323, 712, 715, 948, 1396, 2288
Washington State, 114
West Virginia, 1188
Wisconsin, 2288
- Aspirin**; coronary disease; pharmacists' interventions, 2319
- Assisted living facilities**; General Accounting Office; reports, 1484
- Asthma**
levalbuterol hydrochloride; FDA approvals, 849
quality of life; instrument evaluation, 1965
- Astrocystoma**; temozolomide; FDA approvals, 1910
- Athletes**; creatine; overview, 1608
- Atorvastatin**
concomitant therapy, 2227
coronary disease; cost-benefit analysis, 1726
- Atacurium**; overview, Jun 1 suppl S4
- Atrial fibrillation**
amiodarone hydrochloride; cost-benefit analysis, 2211
dofetilide; FDA approvals, 2375
- Attention deficit disorder with hyperactivity**; central nervous system stimulants; NIH protocols, 111
- Audiovisual aids**; patient information; hearing loss, 610
- Automation**
compounding; TPN, 25
dispensing; acetaminophen overdose, 1774; hospital pharmacy, 1190; selections, criteria, 1398; time studies, 1542; Y2K, 1922
hospital pharmacy; costs, 1945
- Autonomic drugs**; nicotine; smoking cessation, 460
- Azathioprine**; use; benchmarking, 1102
- Azithromycin**
pneumonia; comparisons, 1521
toxicity; hearing loss, 380
- AZI**, see **Zidovudine**
- B**
- Bacteremia**; quinupristin, combination, dalbapristin; FDA approvals, 2174
- Benchmarking**
clinical pharmacists; services, 516
hospital pharmacy; drug costs, 1102
managed care systems; community pharmacists, 566
- Benzamides**; protocols; nausea and vomiting, 729
- Benzodiazepines**
alcohol withdrawal delirium, 175
myoclonus; morphine toxicity, 1009
protocols; nausea and vomiting, 729
- Beta carotene**; heart diseases; protocols, 503
- Beverages**; juices; nasogastric drug administration, 2327
- Bid contracting**, see **Purchasing**
- Bioavailability**, see **Drugs, availability**
- Biologicals**; approvals; 1998, 412
- Bipolar disorder**
gabapentin; overview, 1939
lamotrigine; overview, 1939

Annual Index

Blood derivatives; documentation; FDA regulations, 2274

Blood levels

acetaminophen; overdose, 1081
aminoglycosides; vancomycin interactions, 161
chromium; parenteral nutrition, 1950
gentamicin; collection tubes, 1457
levodopa; entacapone interactions, 2376
pentoxifylline; sustained-action medications, 1529
vancomycin; aminoglycoside interactions, 161;
collection tubes, 1457
zinc; parenteral nutrition, 1950

Board of Pharmaceutical Specialties; certification; examinations, 419

Book Reviews, 94, 190, 490, 585, 926, 1033, 1271, 1370, 1468, 1576, 1789, 1900, 1999, 2164, 2495

Access to Experimental Drugs in Terminal Illness: Ethical Issues, 1033

Activity-Based Costing and Activity-Based Management for Health Care, 490

Antimicrobial Therapy and Vaccines, 2164

Applied Drug Information: Strategies for Information Management, 1034

The Art, Science, and Technology of Pharmaceutical Compounding, 926

Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, Fourth Edition, 1468

Drugs in Pregnancy and Lactation, Fifth Edition, 1900

Drugs, Therapy, and Professional Power: Problems and Pills, 94

The Effects of Neurologic and Psychiatric Drugs on the Fetus and Nursing Infant: A Handbook for Health Care Professionals, 1271

The Family Encyclopedia of Disease: A Complete and Concise Guide to Illnesses and Symptoms, 1791

First Do No Harm: A Practical Guide to Medication Safety and JCAHO Compliance, 1900

Handbook of Basic Pharmacokinetics...including Clinical Applications, 5th Edition, 1999

HMO and PBM Strategies for Pharmacy Benefits: Recent Results, Current Practices, Future Plans, 1469

Improving the Quality of the Medication Use Process: Error Prevention and Reducing Adverse Drug Events, 1034

Living with Lung Cancer: A Guide for Patients and Their Families, 4th Edition, 190

Making Medical Decisions: An Approach to Clinical Decision Making for Practicing Physicians, 1272

Medical Abbreviations: 14,000 Conveniences at the Expense of Communications and Safety, Ninth Edition, 2565

On the Pill: A Social History of Oral Contraceptives, 1950-1970, 1789

Peaceful Dying: The Step-By-Step Guide to Preserving Your Dignity, Your Choice, and Your Inner Peace at the End of Life, 1370

A Practical Guide to Pharmaceutical Care, 1901

Practical Pharmacoeconomics: How To Design, Perform and Analyze Outcomes Research, 585

Preparing the Pharmacy for a Joint Commission Survey, Fourth Edition, 1576

Professional's Handbook of Complementary & Alternative Medicines, 2495

Stand Tall! Every Woman's Guide to Preventing and Treating Osteoporosis, 2nd Edition, 1272

Books Received, 94, 391, 586, 926, 1035, 1371, 1576, 1685, 2165

Breast neoplasms

antineoplastic agents; combined therapy, 939
epirubicin hydrochloride; FDA approvals, 2177
exemestane; FDA approvals, 2378
transplantation; bone marrow, 939

Budgets

ambulatory care; ASHP guidelines, 1744
hospital pharmacy; clinical studies, 249
pharmacy, institutional; managed care systems, 313

Bupivacaine hydrochloride; therapy; promethazine extravasation, 1742

Burns; albumin; rational therapy, 1451

Butyrophenones; protocols; nausea and vomiting, 729

C

Cachexia; melatonin; overview, 2523

Calcium antagonists; heart failure; congestive, 1445; contraindications, 1334

Calcium regulators; prescribing; kidney failure, 1961

Calculations; methodology; medication errors, 57

Caloric agents; dextrose; hypoglycemia, 2463

Cancer, see **Antineoplastic agents**

Cancer drugs, see **Antineoplastic agents**

Candida species

candidiasis; antifungals, 523
resistance; antifungals, 525

Candidiasis

antifungals; *Candida* species, 523
review, 525

Cannabinoids

protocols, 940
protocols; nausea and vomiting, 729

Cannabis; smoking; medical use, 940

Capecitabine; colorectal neoplasms; review, 2417

Capsules

mycophenolate mofetil; suspension compounding, 2224

rifabutin; suspension compounding, 333

Carbamazepine

alcohol withdrawal delirium, 175
interactions; cimetidine, 1890

Carbidopa; combination, levodopa; combined therapy, 2376

Carbonic anhydrase inhibitors; acetazolamide; medication errors, 2463

Cardiac drugs

amiodarone; congestive heart failure, 1445

amiodarone hydrochloride; atrial fibrillation prophylaxis, 2211

digoxin; congestive heart failure, 1445; heart failure, 503;

dipyridamole; rational therapy, 433

doxetilide; FDA approvals, 2375

heart failure; pharmacists' interventions, 1339

isosorbide dinitrate; congestive heart failure, 1445

milrinone lactate; incompatibilities, 63

nitroglycerin; levofloxacin incompatibilities, 1458

procainamide; cimetidine interactions, 1890

quinidine; interactions, 1890

sodium nitroprusside; levofloxacin incompatibilities, 1458

ubidecarenone; overview, 519

Cardiovascular diseases; insulins; comparisons, 542

Career Opportunities, 82, 181, 279, 385, 480, 577, 677, 821, 916, 1022, 1136, 1265, 1354, 1461, 1567, 1677, 1778, 1892, 1992, 2144, 2248, 2352, 2466, 2558

Careers; pharmacy; interdisciplinary education, 12

Caregivers; home health care; parenteral nutrition, 270

Carmustine; permeation; gloves, 2450

Case Law

Catheters; toxicity; thrombosis, 1350

CD-ROM; International Pharmaceutical Abstracts; databases, 1719

Cefepime hydrochloride; incompatibilities; diluents, 457; i.v. injections, 1134

Ceftazidime; incompatibilities; peritoneal dialysis solutions, 246

Ceftazidime sodium; incompatibilities; tacrolimus, 164

Celecoxib

approvals; FDA, 403

arthritis; rheumatoid, 106

overview, 1031

Centers for Disease Control and Prevention; protocols; polio vaccines, 1480

Central nervous system stimulants

attention deficit disorder with hyperactivity; NIH protocols, 111

modafinil; FDA approvals, 304

Cephalosporins

cefepime hydrochloride; incompatibilities, 457, 1134

ceftazidime; incompatibilities, 246

ceftazidime sodium; tacrolimus incompatibilities, 164

injections; i.v. push, 76

Cerivastatin; coronary disease; cost-benefit analysis, 1726

Certification; pharmacists; immunization, 2398; specialties, 419, 1715

Cervix neoplasms

antineoplastic agents; combined therapy, 702

radiation; combined therapy, 702

Charcoal, activated; antidotes; acetaminophen overdose, 1081

Charity

drug distribution; developing countries, 2016

immunization; pharmacists, 2398

industry; cosmetics, 208

industry, pharmaceutical; databases, 2181

Cherry syrup; sweetening agents; rifabutin suspensions, 333

Chlordiazepoxide; rational therapy; geriatrics, 433

5-Chloro-2,4-dihydroxypyridine; colorectal neoplasms; review, 2417

Cholestyramine resin; formulations; taste, 80

Chromium; parenteral nutrition; pediatrics, 1950

Cidofovir; toxicity; neutropenia, Dec 15 suppl S5

Cilostazol; approvals; FDA, 404

Cimetidine

antidotes; acetaminophen overdose, 1081
interactions; ambulatory care, 1890

Cimicifuga racemosa; overview, 1400

Cimicifugoside; *Cimicifuga racemosa*; overview, 1400

Ciprofloxacin; use; comparisons, 2217

Cisplatin; cervix neoplasms; combined therapy, 702

Citalopram hydrobromide; depression; comparisons, 2242

Civil Rights Act of 1964; sexual harassment; pharmacy administration, 117

Classified advertising, see **Career Opportunities**

Clavulanate potassium; combination, ticarcillin disodium; topotecan incompatibilities, 875

Clearance, see Excretion

Clinical pharmacists

data collection; dialysis traineeship, 1623
documentation; progress note forms, 420

hospitals; pain management, 1119

interventions; coronary disease, 2319; cost-benefit analysis, 2230; heart failure, 1339; nutrition support clinic, 2324; operating rooms, 977

patient care; cystic fibrosis, 158

pharmaceutical care; collaborative drug therapy management, 2018

professional competence; practice models, 1981

role; medication use, 2549

services; benchmarking, 516; hemophilia, 1303

Clinical pharmacy

home health care; pharmacist competence, 1549

hospitals; survey, 142

pharmacists; professional competence, 1981

practice; models, 1758

services; cystic fibrosis, 158; dialysis traineeship, 1623; hemophilia, 1303; HMOs, 1710; hospitals, 1945, 2230

technicians; role, 1602

Clinical studies

acids, fatty; overview, 719

administration; competition trends, 171

antidepressants; comparisons, 2242

cilostazol; intermittent claudication, 404

Cimicifuga racemosa; anxiety, 1400

clonidine; hypertensive emergencies, 572

creatine; athletic performance, 1608

data collection; fax technology, 2540

denileukin diftitox; lymphoma, 502

drugs, investigational; ASHP guidelines, 1554

pharmaceutical services, 249, 337; regulations, 252

Echinacea species; overview, 121

errors, medication; hospital pharmacists, 907

gabapentin; bipolar disorder, 1939

ganirelix acetate; overview, 1810

glucosamine sulfate; osteoarthritis, 267

hydroxyurea; HIV infections, 1554

Hypericum perforatum; overview, 329

itraconazole; onychomycosis, 865

kava; anxiety, 957

lamotrigine; bipolar disorder, 1939

lanoprazole; suspensions, Dec 1 suppl S18

levothyroxine; generic equivalency, 1912

Lyme disease vaccines; FDA approvals, 206

melatonin; overview, 2523

new drugs; pediatrics, 203

olanzapine; Alzheimer's disease, 2245

omeprazole; suspensions, Dec 1 suppl S18

pharmacogenomics; overview, 27, 40

phosphatidylserine; cognition disorders, 2038

protease inhibitors; combined therapy, 273

quinolones; pneumonia, Nov 15 suppl S21

rapacuronium; pharmacokinetics, pharmacodynamics, Jun 1 suppl S14

ropinirole hydrochloride; review, 217

Silybum marianum; overview, 1195

terbinafine hydrochloride; onychomycosis, 865

ubidecarenone; overview, 519

Clonidine

alcohol withdrawal delirium, 175

hyperalgesia; morphine toxicity, 1009

hypertension; emergencies, 572

Cluster headache; melatonin; overview, 2523

Codes

bar, medication tracking system, 1190

records; hospitals, 1326

Coenzyme Q₁₀, see **Ubidecarenone**

Cognition disorders; phosphatidylserine; overview, 2038

Collaborative drug therapy management; laws; Minnesota, Virginia, 943

Colloids; rational therapy; meta-analysis, 1451

Colorectal neoplasms; antineoplastic agents; combined therapy, 2417

Combined therapy
aminoglycosides and vancomycin; pharmacokinetics, 161

ampranavir and antiretroviral agents; HIV infections, 1057

angiotensin-converting-enzyme inhibitors, β -blockers, digoxin and diuretics; heart failure, 503

antifungals; candidiasis, 525

anti-infective agents and proton-pump inhibitors; helicobacter infections, Dec 1 suppl S5

antineoplastic agents; colorectal neoplasms, 2417

antineoplastic agents and radiation; cervix neoplasms, 702

antineoplastic agents and transplantation; bone marrow, breast neoplasms, 939

antiretroviral agents and hydroxyurea; HIV infections, 1554

anxiolytics, sedatives and hypnotics and serotonin-reuptake inhibitors; costs, 23

β -blockers, angiotensin-converting-enzyme inhibitors, digoxin and diuretics; heart failure, 503

carbidopa, combination levodopa and entacapone; Parkinson's disease, 2376

digoxin, angiotensin-converting-enzyme inhibitors, β -blockers and diuretics; heart failure, 503

diuretics, angiotensin-converting-enzyme inhibitors, β -blockers and digoxin; heart failure, 503

entacapone and carbidopa, combination, levodopa; Parkinson's disease, 2376

foscarnet and ganciclovir; cytomegalovirus retinitis, 1314

ganciclovir and foscarnet; cytomegalovirus retinitis, 1314

hydralazine and isosorbide dinitrate; congestive heart failure, 1445

hydroxyurea and antiretroviral agents; HIV infections, 1554

insulin and troglitazone; diabetes mellitus, 840

isosorbide dinitrate and hydralazine; congestive heart failure, 1445

protease inhibitors; HIV infections, 273

proton-pump inhibitors and anti-infective agents; helicobacter infections, Dec 1 suppl S5

radiation and antineoplastic agents; cervix neoplasms, 702

ropinirole hydrochloride; Parkinson's disease, 217

serotonin-reuptake inhibitors and anxiolytics, sedatives and hypnotics; costs, 23

transplantation and antineoplastic agents; bone marrow, breast neoplasms, 939

troglitazone and insulin; diabetes mellitus, 840

vancomycin and aminoglycosides; pharmacokinetics, 161

Commentaries, 72, 260, 467, 566, 672, 904, 1445, 1672, 2336, 2549

Communication
hospital pharmacy; adverse drug reactions, 1769

managed care systems; patients, 2391

patients; health professions, 212

pharmacists; ASHP meetings, 277; patient counseling, 576; physicians, 1307

pharmacists, hospital; computer protocols, 225; health professions, 1546

writing; journals, 1353

Compliance
Joint Commission on Accreditation of Healthcare Organizations; standards, 887

patients; cardiac drugs, 1339; glipizide, 454; hospital admissions, 450; NABP regulations, 699; NABP reports, 1486; protease inhibitors, 273; somatropin, 51; tablet splitting, 2542

physicians; formularies, 596

protocols; filgrastim, 1330

regulations; hospital pharmacy, 952

Compounding
antineoplastic agents; contamination, 1403; surface contamination, 1427

fungicidal bicyclic hexammonium; ophthalmic solutions, 547

ganciclovir sodium; stability, 1738

hazardous substances; barrier isolators, 1433; contamination, 1403

lamotrigine; suspensions, 240

lanoprazole; suspensions, 81

levofloxacin; stability, 2316

mycophenolate mofetil; suspensions, 2224

omeprazole; suspensions, 81

parenteral nutrition; automation, 25; home health care, 815

pharmacy; practice models, 1758

regulations; FDA, 1388

rifabutin; suspensions, 333

terbinafine hydrochloride; suspensions, 243

valacyclovir hydrochloride; suspensions, 1957

Comprehension; patients; diabetes mellitus, 1535

Computers
databases; clinical studies, 2540; hospitals, 1326

drug distribution; year 2000, 1383; year 2000 problems, 727

electronic mail; managed care systems, 2391; metformin protocols, 2535

hospital pharmacy; administration, 674, 675; survey, 142; technicians' role, 324; Y2K, 1922

International Pharmaceutical Abstracts; pharmacy information, 1719

Internet; prescribing, dispensing, 500; prescription advertising, 1812; prescriptions, 1174

Intranet; hospital pharmacy, 2290

pharmaceutical services; clinical studies, 337; telemedicine, telepharmacy, 1405

pharmacy, community; electronic prescriptions, 1351

programs; year 2000, 1048, 1066

protocols; ambulatory care, 225

records; ambulatory care, 443

residencies; ASHP meetings, 2454

technology; Y2K, 2181

World Wide Web; drug information, 212, 2308

Concentration
cefepime hydrochloride; incompatibilities, 457

dextrose; incompatibilities, 246

drug information; WWW, 2308

etoposide; incompatibilities, 985

lanoprazole; suspensions, 81

mitomycin; topotecan incompatibilities, 875

omeprazole; suspensions, 81

tacrolimus; incompatibilities, 164

topotecan hydrochloride; incompatibilities, 875

urokinase; stability, 2047

Conjunctivitis; ketotifen fumarate; overview, 1926

Consumers
attitudes; advertising, alternative medicine, 307; dietary supplements regulations, 942; generic drugs, 2276; health trend survey, 942

drug information; WWW, 2308

Internet; prescribing, dispensing, 500; prescriptions, 1174

prescriptions; Internet advertising, 1812

Containers
glass; valacyclovir incompatibilities, 1957

plastics; lamotrigine incompatibilities, 240; terbinafine incompatibilities, 243

polyethylene terephthalate; ganciclovir stability, 1738; mycophenolate incompatibilities, 2224

polypropylene; alteplase, 2056; doxorubicin, etoposide, vincristine, 985; promethazine-dihydroergotamine incompatibilities, 1835

polyvinyl chloride; plasticizers, 1490; tirofiban incompatibilities, 1627

Contamination
antineoplastic agents; compounding, administration, 1427

diethylhexyl phthalate; polyvinyl chloride labeling, 1490

hazardous substances; compounding, 1403

microbiological; urokinase dilutions, 1350

Contracts
managed care systems; community pharmacists, 566

pharmacy benefit management companies; Internet pharmacy services, 1918

Contract services
clinical studies; competition trends, 171

integrated health care; statistics, 1392

Contraindications
acids, fatty; overview, 719

calcium antagonists; heart failure, 1334

Cimicifuga racemosa; overview, 1400

creatine; overview, 1608

drugs; patient outcomes, 699

Echinacea species; overview, 121

ganirelix acetate; overview, 2299

Hypericum perforatum; overview, 329

influenza vaccines, Sep 1 suppl S3

kava; overview, 957

medicinal plants; review, 125

melatonin; overview, 2523

metformin; use, 2535

nonsteroidal anti-inflammatory agents; heart failure, 1334

phosphatidylserine; overview, 2038

pneumococcal vaccines, Sep 1 suppl S3

Silybum marianum; overview, 1195

ubidecarenone; overview, 519

Control
drug distribution systems; home health care, 629

drugs; ASHP guidelines, 1744

Controlled substances; drug diversion; health professions, 1823

Copayments; managed care systems; prescriptions, 507

Coronary artery bypass; amiodarone hydrochloride; atrial fibrillation prophylaxis, 2211

Coronary disease
HMG-CoA reductase inhibitors; cost-benefit analysis, 1726

pravastatin; therapeutic substitution, 1107

prophylaxis; pharmacists' interventions, 2319

simvastatin; therapeutic substitution, 1107

Correction Notices, 384, 1020, 1134, 1460, 1676, 1774, 2142

Annual Meeting '99: Education and Exhibits, Reno, Nevada (Apr 15, 1999, ASHP Reports), 1134

Charting the demand for pharmacists in the managed care era (Jul 1, 1999, Reports), 1676

Dosage adjustment of antiretroviral agents in patients with organ dysfunction (Dec 1, 1998, HIV Update), 384

Drug-related injury visits to hospital emergency departments (Jun 1, 1998, Notes), 1020

Effect of an automated dispensing system on medication administration time (Aug 1, 1999, Notes), 2142

Prophylaxis after nonoccupational exposure to HIV (May 15, 1999, HIV Update), 1460

Second selective COX-2 inhibitor receives marketing approval (Jul 1, 1999, News), 1774

Table of Contents (Aug 1, 1999), 2142

Cosmetics; industry; charity, 208

Cost-benefit, see **Economics**; **cost-benefit analysis**

Cost-effectiveness, see **Economics**; **cost-benefit analysis**

Costs
acyclovir; use, 1102

antibiotics; sinusitis, 853

antidepressants; comparisons, 2242

anti-infective agents; comparisons, 2217; respiratory-tract infections, Nov 15 suppl S25

azathioprine; use, 1102

azithromycin; pneumonia, 1521

cardiac drugs; heart failure, 1339

celecoxib; arthritis, 403

cholesterol; resin; formulations, 80

cimetidine; drug interactions, 1890

ciprofloxacin; comparisons, 2217

clinical studies; academic health centers, 171; pharmacogenomics, 40

computers; hospital pharmacy, 674

discounts; price fixing lawsuits, 113

drugs; control, 887; HMO formularies, 2014; 1999, 31; pharmacists' interventions, 1710; student interventions, 882; therapeutic substitution, 1307; year 2000, 2533

electronic mail; managed care systems, 2391

errors, medication; pharmacists' role, 672

erythromycin; pneumonia, 1521

estrogens, conjugated; therapeutic substitution, 537

estrogens, esterified; therapeutic substitution, 537

fentanyl citrate; comparisons, 551

filgrastim; protocols, 1330

formularies; administration, 467

fosinopril sodium; tablet splitting, 2542

ganciclovir sodium; cytomegalovirus infections, 1831

glipizide; immediate vs. sustained release, 454

globulin immune; cytomegalovirus infections, 1831; shortages, 599; use, 1102

goserelin acetate; wastage, 277

health care; chronic hepatitis B, 232; diabetes, hypertension, 1515; future estimates, 1809; pharmacy benefit, 506

hemostatics; hemophilia, 1303

HMG-CoA reductase inhibitors; therapeutic substitution, 1437

hospital pharmacy; documentation, 2230

hospitals; pharmaceutical services, 2415

hydroxyurea; HIV infections, 1554

ketotifen fumarate; overview, 1926

Medicare; prescription drug benefits, 1503

ofloxacin; comparisons, 2217

parenteral nutrition; home health care, 270

patient care; prospective-pricing system, 2012

perindopril erbumine; overview, 2037

Annual Index

pharmaceutical services; clinical, 1945; operating rooms, 977
 prescription drugs; managed care systems, 313; Medicare, 313
 quality assurance; pharmacist competence, 1549
 rabeprazole sodium; overview, 2300
 remifentanyl hydrochloride; comparisons, 551
 rofecoxib; overview, 1404
 ropinirole hydrochloride; Parkinson's disease, 217
 rosiglitazone maleate; overview, 1925
 serotonin-reuptake inhibitors; comparisons, 23
 somatropin; physicians' prescribing, 51
 sumatriptan; reimbursement, 2193, 2206
 zanamivir; overview, 2190

Cough

lisinopril; toxicity, 914
 losartan potassium; toxicity, 914

Creatine; overview, 1608

Crime; drug diversion; health professions, 1823

Critical illness

enteral nutrition; drug administration, 1441
 proton-pump inhibitors; ulcers, Dec 1 suppl S5
 skeletal muscle relaxants; neuromuscular diseases, 72

Current Literature, 93, 189, 288, 390, 488, 584, 684, 828, 925, 1032, 1160, 1270, 1369, 1467, 1574, 1684, 1788, 1899, 1998, 2164, 2256, 2491, 2564

Curriculum; education, pharmaceutical; interdisciplinary, 12

Cyanocobalamin; hyperlipidemia; alternative medicine, 1668

3-Cyano-2,6-dihydroxypyridine; colorectal neoplasms; review, 2417

Cyclophosphamide; toxicity, environmental; surface contamination, 1427

Cysteine hydrochloride; interactions; trace elements, 1950

L-Cysteine hydrochloride, see **Cysteine hydrochloride**

Cystic fibrosis

antibiotics; protocols, 2271
 clinical pharmacists; patient care, 158

Cytokines; candidiasis; review, 525

Cytomegalovirus infections

ganciclovir sodium; comparisons, 1831
 globulin immune; comparisons, 1831

Cytomegalovirus retinitis

foscarnet; AIDS, 1314
 ganciclovir; AIDS, 1314

Cytotoxic agents, see **Antineoplastic agents**

D

Dalfopristin; combination, quinupristin; FDA approvals, 2174

Dantrolene; pharmacoeconomics; models, Jun 1 suppl S18

Databases

hospitals; administration, 1326
 industry, pharmaceutical; charity, 2181
 International Pharmaceutical Abstracts; content, 1719; pharmacy information, 1719

Data collection

clinical pharmacists; dialysis traineeship, 1623
 clinical studies; fax technology, 2540; investigational drugs, 337
 consumers; advertising, alternative medicine, 307; dietary supplements, 942; generic drugs, 2276; health trend survey, 942
 health-benefit programs; health care costs, 506
 hospital pharmacy; survey, 142
 hospitals; year 2000, 1048
 integrated health care; survey, 1392
 long-term-care facilities; prospective-pricing system, 2012
 managed care systems; membership statistics, 505; quality assurance, 1805
 pharmaceutical services; integrated health care, 2431
 pharmacists; job satisfaction, 1733; poster presentations, 277; practice, 1342
 pharmacists, community; electronic prescriptions, 1351
 pharmacists, hospital; generic substitution attitudes, 615
 pharmacy and therapeutics committee; hospitals, 622
 physicians; managed care systems, 1805; somatropin prescribing, 51

Death

antineoplastic agents; overdose, 707
 drugs; sentinel event policies, 2031

errors, medication; hospital pharmacists, 907
 heart failure; pharmacists' interventions, 1339
 penicillin G benzathine; medication errors, 904
 tolcapone; liver failure, 8

Decision-making

formularies; nonformulary drug requests, 818
 home health care; methodology, 473
 pharmacists; assisted suicides, 1661
 pharmacy and therapeutics committee; meetings, 1132
 protocols; pediatrics, 331

Deficiency diseases; iron; sodium ferric gluconate complex, 706

Degrees

Doctor of Pharmacy; interdisciplinary, 12; student interventions, 882
 pharmacists; job satisfaction, 1733

DEHP, see Diethylhexyl phthalate

Dehydrated alcohol, see Alcohols, ethyl

Denileukin diftitox; approvals; FDA, 502

27-Deoxyactein; *Cimicifuga racemosa*; overview, 1400

Deoxyacetylactol; *Cimicifuga racemosa*; overview, 1400

Department of Health and Human Services

public health; Healthy People 2000, 1479
 reports; JCAHO standards, 1699

Department of Veterans Affairs; drugs; pricing, 313

Dependence

alcohols, ethyl; evidence-based therapy, 501
 drugs; health professions, 1823; protocols, 2276
 nicotine; toxicity, 460

Depression

antidepressants; evidence-based reports, 853
 citalopram hydrobromide; comparisons, 2242
 fluoxetine hydrochloride; comparisons, 2242
 fluvoxamine; comparisons, 2242
Hypericum perforatum; overview, 329
 medicinal plants; evidence-based reports, 853
 serotonin-reuptake inhibitors; pharmacoeconomics, 23
 sertraline hydrochloride; comparisons, 2242

Desensitization; food; medication errors, 907

Developing countries; charity; drug donations, 2016

Devices

drug administration; pediatrics, 1094
 medical; INR monitoring, 1619; unlabeled use, 204
 syringe pumps; home health care, 473

Dexamethasone sodium phosphate; incompatibilities; topotecan injections, 875

Dextrose

concentration; peritoneal dialysis solutions, 246
 diluents; cefepime incompatibilities, 1134; levofloxacin injections, 1458; milrinone injections, 63; tacrolimus incompatibilities, 164; tirofiban incompatibilities, 1627
 hypoglycemia; acetohexamide errors, 2463
 incompatibilities; cefepime, 457
 vehicles; topotecan incompatibilities, 875

Diabetes mellitus

acids, fatty; overview, 719
 antidiabetic agents; patient consultation, 1535
 glipizide; immediate vs. sustained release, 454
 health care; costs, 1515
 insulin; combined therapy, 840
 insulin human; comparisons, 542
 insulin lispro; comparisons, 542
 metformin; use, 2535
 patient education; pharmacists' reimbursement, 603
 pioglitazone hydrochloride; FDA approvals, 1698
 rosiglitazone maleate; FDA approvals, 1292; overview, 1925

Diabetic nephropathies; insulins; comparisons, 542

Diabetic retinopathies; insulins; comparisons, 542

Diagnosis

attention deficit disorder with hyperactivity; NIH protocols, 111
 hepatitis C; review, 961
 onychomycosis, 865

Diagnostic agents; pharmacogenomics; overview, 27, 40

Dialysis

education, pharmaceutical; clinical pharmacists, 1623
 hemo-; kidney failure, 1961

Diarrhea; prophylaxis; traveler's, ASHP protocols, 1201

Diazepam; rational therapy; geriatrics, 433

Dietary Supplement Health and Education Act of 1994; medicinal plants; marketing, 1927

Dietary supplements

acids, fatty; overview, 719
 advertising; FTC guidelines, 308
 creatine; overview, 1608
 Food and Drug Administration; cases, 604
 labeling; laws, 1286
 medicinal plants; laws, 1927
 phosphatidylserine; overview, 2038

Diethylhexyl phthalate; toxicity; reports, 1490

Di(2-ethylhexylphthalate), see **Diethylhexyl phthalate**

Dieticians; attitudes; automated compounding, 25
Digoxin; heart failure; combined therapy, 503; congestive, 1445; geriatrics, 1334

Dihydroergotamine mesylate; incompatibilities; promethazine, 1835

Diluents

dextrose; cefepime incompatibilities, 457, 1134; levofloxacin injections, 1458; milrinone incompatibilities, 63; tacrolimus incompatibilities, 164; tirofiban incompatibilities, 1627
 incompatibilities; valacyclovir, 1957
 juices; nasogastric drug administration, 2327
 Ringer's injection, lactated; milrinone incompatibilities, 63
 sodium bicarbonate; incompatibilities, 81
 sodium chloride; cefepime incompatibilities, 457, 1134; doxorubicin, etoposide, vincristine, 985; fumaillin ophthalmic solutions, 547; milrinone incompatibilities, 63; tacrolimus incompatibilities, 164; tirofiban incompatibilities, 1627; uronase, 2047
 water; nasogastric drug administration, 2327
 water for injection; alteplase, 2056; cefepime incompatibilities, 457, 1134; incompatibilities, 81; uronase incompatibilities, 1350

Dilution; uronase; injections, 1350

Diphenhydramine hydrochloride; dosage; toxicity, 555

Diphtheria and tetanus toxoids and pertussis vaccines; recalls; potency, 504

Dipyridamole; rational therapy; geriatrics, 433

Disaster planning; pharmaceutical services; pharmacists' role, 716

Disasters

pharmaceutical care; drug selection, 236
 pharmaceutical services; ambulatory care, 2554
 pharmacists; role, 716

Disease management

pediatrics; protocols, 331
 pharmacists; collaborative drug therapy management, 1715

Dispensing

abacavir sulfate; hypersensitivity warning card, 304
 ambulatory care; ASHP guidelines, 1744
 automation; acetaminophen overdose, 1774; administration time studies, 1542; hospital pharmacy, 1190; selections, criteria, 1398
 dofenilide; regulations, 2375
 drugs; disasters, 236
 errors, medication; acetohexamide for acetazolamide, 2463; hospital pharmacists, 1319
 hospital pharmacy; technicians' role, 324
 Internet; consumers, 500
 pharmacists; assisted suicides, 260; professional competence, 1981; reimbursement, 1503
 pharmacists, community; role, 1915
 pharmacists, hospital; thalidomide regulations, 1721
 pharmacy; Healthy People 2000, 1479

Dissolution rates

lansoprazole; diluents, 81
 omeprazole; diluents, 81

Diuretics

furosemide; levofloxacin incompatibilities, 1458
 heart failure; combined therapy, 503; congestive, 1445

Documentation

blood derivatives; FDA regulations, 2274
 clinical pharmacists; interventions, 1339; progress note forms, 420
 clinical studies; investigational drug services, 344
 drugs; anesthesiology, surgery, 887
 drugs, adverse reactions; abacavir hypersensitivity, 304
 errors, medication; taxonomy, 314
 home health care; ASHP guidelines, 629; care plans, 1348
 hospital pharmacy; clinical studies, 337; costs, 2230; medication errors, 907
 pharmaceutical care; disasters, 236

- pharmaceutical services; hospitals, 2415
 pharmacists; hospital; medication errors, 2444
Dofetilide; approvals; FDA, 2375
- Dosage**
 acids, fatty; overview, 719
 alitretinoin; Kaposi's sarcoma, 603
 amantadine; influenza prophylaxis, 2303
 amphotericin B; mycoses, 872; urinary tract infections, 1929
 amprevnavir; HIV infections, 1057
 analgesics and antipyretics; sickle-cell pain, 2272
 antidiabetic agents; pharmacists' interventions, 1535
 antineoplastic agents; breast neoplasms, 939
 celecoxib; arthritis, 403
 cimetidine; drug interactions, 1890
Cimicifuga racemosa; overview, 1400
 creatine; overview, 1608
 denileukin diftitox; lymphoma, 502
 dietary supplements; consumer survey, 942
 diphenhydramine hydrochloride; toxicity, 555
 diphtheria and tetanus toxoids and pertussis vaccines; pediatrics, 504
 dofenilide; toxicity, 2375
 drugs; generic substitution, 615
Echinacea species; overview, 121
 entacapone, 2376
 epirubicin hydrochloride; breast neoplasms, 2177
 estrogens conjugated A; menopause, 849
 exemestane, 2378
 filgrastim; neutropenia, 995
 fluconazole; urinary tract infections, 1929
 fluvastatin; therapeutic substitution, 1437
 fosinopril sodium; tablet splitting, 2547
 ganirelix acetate; overview, 1810, 2209
 gentamicin sulfate; neonates, 440
 glipizide; immediate vs. sustained release, 454
Hypericum perforatum; overview, 329
 influenza vaccines; immunization, Sep 1 suppl 53
 kava; overview, 957
 ketotifen fumarate; overview, 1926
 levalbuterol hydrochloride; asthma, 849
 levobupivacaine hydrochloride, 1912
 medicinal plants; review, 125
 melatonin; overview, 2523
 modafinil; overview, 304
 morphine; toxicity, 1009
 neomycin sulfate; hypercholesterolemia, 2227
 olanzapine; Alzheimer's disease, 2245
 oplates; pain management, 1119
 orlistat; obesity, 1058
 oseltamivir phosphate, 2376
 overdose; acetaminophen, 1081, 1774; antineoplastic agents, 707; penicillin G benzathine, 904; skeletal muscle relaxants, 72
 pentoxifylline; sustained-action medications, 1529
 perindopril erbumine; overview, 2037
 phosphatidylserine; overview, 2038
 phytonadione; warfarin toxicity, 2312
 pioglitazone hydrochloride; diabetes mellitus, 1698
 pneumococcal vaccines; immunization, Sep 1 suppl 53
 quinolones; pharmacodynamics, Nov 15 suppl 512; pneumonia models, Nov 15 suppl 521
 quinupristin, combination, dalbapristin, 2174
 rabeprazole sodium, 1910
 rabeprazole sodium; overview, 2300
 rapacuronium bromide, 2178
 rofecoxib; FDA approvals, 1294; overview, 1404
 ropinirole hydrochloride; Parkinson's disease, 217
 rosiglitazone maleate; diabetes mellitus, 1292; overview, 1925
 serotonin-reuptake inhibitors; pharmacoeconomics, 23
 sevelamer hydrochloride; hyperphosphatemia, 11
Silybum marianum; overview, 1195
 simvastatin; therapeutic substitution, 1437
 sirolimus, 2177
 skeletal muscle relaxants; overview, Jun 1 suppl 54
 sodium ferric gluconate complex; overview, 706
 temozolomide, 1910
 tolcapone; Parkinson's disease, 2195
 trichlorfon; Alzheimer's disease, 427
 ubidecarenone; overview, 519
 warfarin; ACCP protocols, 1505; pharmaceutical services, 443
 zaleplon, 1912
 zanamivir; influenza, 1696; overview, 2190
- Dosage forms**
 enteral nutrition; critical illness, 1441
 glipizide; formulary conversions, 454
 lansoprazole; suspensions, Dec 1 suppl 518
 omeprazole; suspensions, Dec 1 suppl 518
- Dosage schedules**
 alitretinoin; Kaposi's sarcoma, 603
 amantadine; influenza prophylaxis, 2303
 amphotericin B; urinary tract infections, 1929
 anti-infective agents; respiratory-tract infections, Nov 15 suppl 525
 diphenhydramine hydrochloride; toxicity, 555
 fluconazole; urinary tract infections, 1929
 gentamicin sulfate; neonates, 440
 infliximab; retreatment, 11
 influenza vaccines; immunization, Sep 1 suppl 53
 Lyme disease vaccines; FDA approvals, 206
 parenteral nutrition; trace elements, 1950
 pneumococcal vaccines; immunization, Sep 1 suppl 53
 polio vaccines; poliomyelitis, 1480
 proton-pump inhibitors; long term, Dec 1 suppl 511
 skeletal muscle relaxants; ICUs, 72
 trichlorfon; Alzheimer's disease, 427
 vaccines; protocols, 303
 warfarin; ACCP protocols, 1505
- Doxazosin**; substitution; therapeutic, 1351
- Doxercalciferol**; overview, 2410
- Doxorubicin hydrochloride**; incompatibilities; etoposide, vincristine, 985
- Drug abuse**
 health professions; diversion, 1823
 protocols; National Institute on Drug Abuse, 2276
- Drug administration**
 amprevnavir; HIV infections, 1057
 antibiotics; home health care, 76
 antineoplastic agents; contamination, 1403; surface contamination, 1427
 crushing; pentoxifylline, 1529
 dofenilide; toxicity, 2375
 enteral nutrition; critical illness, 1441
 hydroxyurea; HIV infections, 1554
 lansoprazole; nasogastric, 2327
 omeprazole; nasogastric, 2327
 pediatrics; devices, 1094
 rotavirus vaccines; delayed distribution, 1589
 self-medication; cystic fibrosis programs, 158
 sevelamer hydrochloride; hyperphosphatemia therapy, 11
 tolcapone; Parkinson's disease, 2195
- Drug administration rate**; antibiotics; i.v. push, 76
- Drug administration routes**
 intravenous; clonidine, 572; filgrastim, 995; magnesium sulfate, 997; sodium ferric gluconate complex, 706
 intravesical; amphotericin, 1929
 oral; antifungals, 865; conversions, pharmacoeconomics, Nov 15 suppl 525; pediatrics, 1094
 rectal; warfarin tablets, 2140
 subcutaneous; goserelin acetate, 277; loxapine, 1259
 topical; antifungals, 865
- Drug administration systems**; errors, medication; quality assurance, 863
- Drug comparisons**
 antipsychotic agents; cost-benefit analysis, 1560
 azithromycin and erythromycin; pneumonia, 1521
 ciprofloxacin and ofloxacin; costs, 2217
 citalopram hydrobromide, fluoxetine hydrochloride, fluvoxamine and sertraline hydrochloride; depression, 2242
 erythromycin and azithromycin; pneumonia, 1521
 fentanyl citrate and remifentanyl hydrochloride; costs, 551
 fluoxetine hydrochloride, citalopram hydrobromide, fluvoxamine and sertraline hydrochloride; depression, 2242
 fluvoxamine, citalopram hydrobromide, fluoxetine hydrochloride and sertraline hydrochloride; depression, 2242
 ganciclovir sodium and globulin immune; cytomegalovirus infections, 1831
 globulin immune and ganciclovir sodium; cytomegalovirus infections, 1831
 glucosamine sulfate and ibuprofen; osteoarthritis, 267
 ibuprofen and glucosamine sulfate; osteoarthritis, 267
 insulin human and insulin lispro; toxicity, 542
 insulin lispro and insulin human; toxicity, 542
 ofloxacin and ciprofloxacin; costs, 2217
 remifentanyl hydrochloride and fentanyl citrate; costs, 551
 ropinirole hydrochloride; Parkinson's disease, 217
 serotonin-reuptake inhibitors; pharmacoeconomics, 23
- sertraline hydrochloride, citalopram hydrobromide, fluoxetine hydrochloride and fluvoxamine; depression, 2242
- Drug distribution**
 ambulatory care; emergency services, 2554
 blood derivatives; documentation, 2274
 computers; year 2000, 1383
 developing countries; charity, 2016
 globulin immune; U.S. shortages, 599
 hospital pharmacy; automation, 1542
 pharmaceutical services; anesthesiology, surgery, 887; year 2000, 2533
 prescription drugs; stability, 2008
 rotavirus vaccines; delayed administration, 1589
 United States; year 2000, 1048; year 2000 problems, 727
- Drug distribution systems**
 ambulatory care; ASHP guidelines, 1744
 automation; dispensing machine, 1398
 clinical pharmacy; cystic fibrosis programs, 158
 home health care; ASHP guidelines, 629
 hospital pharmacy; immune globulin, 1546; medication tracking system, 1190; technicians' role, 324; thalidomide policies, 1721; year 2000, 1048
- Drug diversion**; health professions; hospital pharmacy, 1823
- Drug histories**, see **Patient information; drug histories**
- Drug information**
 consumers; WWW, 2308
 home health care; ASHP guidelines, 629
 Internet; consumer survey, 942
 intranet; hospital pharmacy, 2290
 olanzapine; neuroleptic malignant syndrome, 1558, 1559
 patients; FDA regulations, 107
 pharmacists; professional competence, 1981; professionalism, 613
 pharmacists; hospital; documentation, 2415; investigational drug services, 344
 unlabeled use; FDA regulations, 204
 World Wide Web; guidelines, 212
- Drug interactions**
 acids, fatty; overview, 719
 aminoglycosides and vancomycin; pharmacokinetics, 161
 amprevnavir; FDA approvals, 1057
 carbamazepine and cimetidine; ambulatory care, 1890
 chromium, cysteine hydrochloride and zinc; parenteral nutrition, 1950
 cimetidine and food; FDA approvals, 404
 cimetidine; ambulatory care, 1890
Cimicifuga racemosa; overview, 1400
 creatine; overview, 1608
 cysteine hydrochloride, chromium and zinc; parenteral nutrition, 1950
 dofenilide, 2375
Echinacea species; overview, 121
 entacapone and levodopa; pharmacokinetics, 2376
 enteral nutrition; critical illness, 1441
 food and cimetidine; FDA approvals, 404
 hydroxyurea; HIV infections, 1554
Hypericum perforatum; overview, 329
 juices and warfarin; toxicity, 676
 kava; overview, 957
 ketotifen fumarate; overview, 1926
 levodopa and entacapone; pharmacokinetics, 2376
 medicinal plants; review, 125
 melatonin; overview, 2523
 modafinil; overview, 304
 monitoring; hospital pharmacists, 1524
 perindopril erbumine; overview, 2037
 phenytoin and cimetidine; ambulatory care, 1890
 phosphatidylserine; overview, 2038
 procainamide and cimetidine; cardiac dysrhythmia, 1890
 proton-pump inhibitors; overview, Dec 1 suppl 511
 quinidine and cimetidine; ambulatory care, 1890
 quinupristin, combination, dalbapristin, 2174
 rabeprazole sodium; overview, 2300
 rofecoxib; overview, 1404
 rosiglitazone maleate; overview, 1925
Silybum marianum; overview, 1195
 skeletal muscle relaxants; neuromuscular diseases, 72; overview, Jun 1 suppl 54
 theophylline and cimetidine; nausea and vomiting, 1890
 tolcapone; Parkinson's disease, 2195
 ubidecarenone; overview, 519
 vancomycin and aminoglycosides; pharmacokinetics, 161
 warfarin and cimetidine; intracerebral hemorrhage, 1890

Annual Index

- warfarin and juices; toxicity, 676
 zanamivir; overview, 2190
 zinc, chromium and cysteine hydrochloride; parenteral nutrition, 1950
- Drug product selection**, see **Substitution, generic**
- Drugs**
 approvals; alitretinoin, 603; amprenavir, 1057; celecoxib, 403; clobazam, 404; conjugated estrogens A, 849; denileukin difitox, 502; doletilide, 2375; entacapone, 2376; epirubicin hydrochloride, 2177; exemestane, 2378; FDA, 31, 426; ganirelix, 1810; levalbuterol, 849; levobupivacaine, 1912; Lyme disease vaccines, 206; modafinil, 304; orlistat, 1058; osetamivir phosphate, 2376; pioglitazone, 1698; quinuapristin-dalfopristin, 2174; rabeprazole sodium, 1910; rapacuronium, 2178; rofecoxib, 1294; rosiglitazone, 1292; sevelamer, 11; sirolimus, 2177; sodium ferric gluconate complex, 706; temozolomide, 1910; zaleplon, 1912; zanamivir, 1696
 emergency; antidote carts, 2537
 generic; cholestyramine resin, 80; consumers' attitudes, 2276
 new; FDA approvals, 31, 404; 1998, 408; 1999 approvals, 412; patient information, 426; pediatric, 203; pharmacogenomics, 27, 40; risk management, 1294
 recalls; diphtheria and tetanus toxoids and pertussis vaccines, 504
 selection; antibiotics, 853; antidiabetic agents, 1535; antifungals, 865; antimicrobial prophylaxis, 1839; developing countries, 2016; disasters, 236; formularies, 818; hospital formularies, 622; i.v. push, 76; nonprescription analgesics, 1079, 1126; opiates, 1119; pharmacogenomics, 27; sickle-cell pain, 2272; somatropin, 51; transplantation, 615
 shortage; year 2000, 1383
 unapproved; identification, 2349
 unlabeled use; direct-to-consumer advertising, 1815; FDA regulations, 204, 1695; reimbursement lawsuits, 257
- Drugs, adverse reactions**
 see also **Toxicity**
 abacavir sulfate; warning card, 304
 hospital pharmacy; quality assurance, 1769
 hospitals; admissions, 450
 infliximab; retreatment, 11
 kidney failure; medication errors, 1961
 omeprazole; nasogastric, 2327
 postmarketing surveillance; pharmacists, 426
 reports; health professions, 1558, 1559; Healthy People 2000, 1479
 tolcapone; liver failure, 8
- Drugs, availability**
 lansoprazole; nasogastric, 2327
 omeprazole; nasogastric, 2327
 pentoxifylline; sustained-action medications, 1529
- Drugs, body distribution**
 aminoglycosides; vancomycin interactions, 161
 vancomycin; aminoglycoside interactions, 161
- Drugs, clinical effectiveness**
 lansoprazole; suspensions, Dec 1 suppl S18
 medicinal plants; review, 125
 omeprazole; suspensions, Dec 1 suppl S18
- Drugs, investigational**
 approvals; FDA regulations, 404; 1998, 408, 412
 clinical studies; ASHP guidelines, 344; contract services, 171; pharmaceutical services, 249, 337; regulations, 252
 new drug applications; unlabeled use, 204
- Drugs, nonprescription**
 analgesics and antipyretics; pain, 1126; rational therapy, 1079
 labeling; FDA regulations, 700
 pharmaceutical services; Internet, 1918
- Drug use**
 acyclovir; benchmarking, 1102
 azithromycin; benchmarking, 1102
 cardiac drugs; heart failure, 1334
 ciprofloxacin; comparisons, 2217
 clinical pharmacists; role, 2549
 evaluation; β -blockers, 858; data collection, 2540; geriatrics, 2022; hospital pharmacy, 142; pharmaceutical services, 2415; pharmacists' role, 2270
 geriatrics; rational therapy, 433
 globulin immune; benchmarking, 1102; hospital pharmacy policies, 1546
 managed care systems; drug costs, 313
 metformin; protocols, 2535
 ofloxacin; comparisons, 2217
 pharmacists; future challenges, 123
 review; home health care, 884
 sumatriptan; reimbursement, 2193, 2206
- Drug withdrawal**; alcohols, ethyl; phenobarbital therapy, 175
- Duration of action**; skeletal muscle relaxants; overview, Jun 1 suppl S14
- Dysmenorrhea**; rofecoxib; FDA approvals, 1294; overview, 1404
- E**
- Echinacea augustifolia**; overview, 121
- Echinacea pallida**; overview, 121
- Echinacea purpurea**; overview, 121
- Echinocandins**; candidiasis; review, 525
- Economics**
 cost-benefit analysis; antiemetics, 729; barrier isolators, 1433; cimetidine interactions, 1890; clinical pharmacists, 2230; estrogens, therapeutic substitution, 537; fax technology, 2540; HMG-CoA reductase inhibitors, 1437, 1726; hospital pharmacy, 1945; macrolides, 1521; Medicare drug pricing, 313; olanzapine, 1559, 1560; oral antifungals, 865; pharmacists' interventions, 1710; pharmacoeconomics, 1630; student interventions, 882; ulcer prophylaxis, 347
 health-benefit programs; pharmacy benefit, 506
 hospital pharmacy; clinical studies, 337; transplantation drug costs, 1102
 industry, pharmaceutical; pharmacogenomics, 40
 pharmacy; drug costs, 31
 residencies; pharmacy schools, 1391
- Editorials**, 27, 123, 215, 331, 425, 523, 613, 727, 863, 1079, 1199, 1307, 1403, 1503, 1719, 1829, 1927, 2193, 2415, 2533
 All guidelines are not the same, 1829
 Artificial shortages of drug supplies, 727
 Evidence-based medicine for children, 331
 Exposure to hazardous drugs: time to reevaluate your program? 1403
 Importance of documenting your services, 2415
 Improving ambulatory care through therapeutic interchange, 1307
 Improving antiemetic prophylaxis in ambulatory surgery, 728
 Keeping up with drug information, 613
 Managed migraine, 2193
 Medicare drug benefit, 1503
 Medication misadventures: a policy of openness and learning, 863
 Medicine is changing—so are the bugs, 523
 Mirror to health-system pharmacy, 123
 Nonsurgical antimicrobial prophylaxis: guidelines (and bugs) in evolution, 1199
 Pharmacogenomics: worthy of pharmacy's attention, 27
 Pharmacy practice management in the next century, 2533
 Pharmacy's database—in its 30th year, 1719
 Responsibility for medication errors, 215
 Responsible use of analgesics, 1079
 Serious surveillance, 426
 Should nature be standardized? 1927
 Ways to help patients quit smoking, 425
- Edrophonium**; neuromuscular blockade; reversal, Jun 1 suppl S10
- Education**
 continuing; unlabeled drug use, 1695
 drug diversion; health professions, 1823
 health professions; i.v. push injections, 76
 nurses; acetaminophen overdose, 1774
 pharmaceutical services; documentation, 2415
 physicians; acetaminophen overdose, 1774; dofenilide prescribing, 2375; pain management, 1119
- Education, pharmaceutical**
 American Society of Health-System Pharmacists; meetings, 1991
 clerkships; interdisciplinary, 12
 continuing; AHP articles, 21
 dialysis; clinical pharmacists, 1623
 Internet; telemedicine, telepharmacy, 1405
 pharmaceutical care; students' attitudes, 2330
 pharmacists; care plans, 1348; job satisfaction, 1733; medicinal plants, 125; practice models, 2235; primary care, 1342
 pharmacists; hospital; acetaminophen overdose, 1774
 pharmacy; community; programs, 1912
 quality assurance; institutional pharmacy, 1060
 residencies; ASHP meetings, 2454; cystic fibrosis programs, 158; funding, Texas, 1391
 students; drug interactions, 1524
 technicians; patient-focused care, 324
- Educators**; pharmacy; survey, 1342
- Elements**; trace; parenteral nutrition, 1950
- Elil Lilly**; postmarketing surveillance; olanzapine, 1559
- Elimination**, see **Metabolism**
- Emergencies**
 clonidine; hypertension, 572
 hospital pharmacy; Y2K, 1922
- Emergency services**
 ambulatory care; drug distribution, 2554
 disasters; pharmacists' role, 716
- Employment**
 personnel; health care costs, 506
 personnel; pharmacy; administration, 2518
 pharmacists; hospital; Saudi Arabia, 179
- Endocarditis**; prophylaxis; ASHP protocols, 1201
- Eniluracil**; colorectal neoplasms; review, 2417
- Entacapone**; approvals; FDA, 2376
- Enterococcus faecium**; quinupristin, combination, dalfopristin; FDA approvals, 2174
- Enzyme inhibitors**; hepatitis C; review, 961
- Epidemiology**
 candidiasis; infections, 523; review, 525
 hepatitis C; review, 961
- Epinephrine**; allergies; infliximab, 11
- Epirubicin hydrochloride**; approvals; FDA, 2177
- Equipment**
 aseptic areas; barrier isolators, 1403, 1433
 carts; antidotes, 2537
 dispensing; automation, 1542
 hospital pharmacy; sterile products, 1978
 medical; representatives; team, 473
 pharmacy; institutional; home health care, 629
 telecommunications; prisons, 860
- Equivalency**; glipizide; immediate vs. sustained release, 454
- Equivalency, generic**
 drugs; transplantation, 615
 levthyroxine; clinical studies, 1912
 somatropin; physicians' attitudes, 51
- Equivalency, therapeutic**
 doxazosin; prostatic hyperplasia, 1351
 terazosin; prostatic hyperplasia, 1351
- Errors, medication**
 acetaminophen; overdose, 1774
 acetazolamide; acetohexamide dispensed, 2463
 acetohexamide; dispensed for acetazolamide, 2463
 clinical pharmacists; role, 2549
 dispensing; ambulatory care, 1319
 drug information; pharmacists, 613
 goserelin acetate; implants, 277
 hospital pharmacy; management, 1769; NABP regulations, 699; prevention, 863; sentinel event policies, 2031
 hospitals; personnel management, 1765
 kidney failure; adverse reactions, 1961
 methodology; calculations, 57
 penicillin G benzathine; overdose, 904
 pharmacists; prevention, 672; professional responsibility, 215
 pharmacists; hospital; administration, 907; documentation, 2415; interventions, 2444
 pharmacy; assisted living facilities, 1484
 prescribing; drug interactions, 1524
 taxonomy; NCCMERP guidelines, 314
- Erythema nodosum**; thalidomide; hospital pharmacy policies, 1721
- Erythromycin**; pneumonia; comparisons, 1521
- Estrogens**
 coronary disease; pharmacists' interventions, 2319
 estrogens, conjugated; therapeutic substitution, 537
 estrogens conjugated A; FDA approvals, 849
 estrogens, esterified; therapeutic substitution, 537
- Estrogens, conjugated**; substitution; therapeutic, 537
- Estrogens conjugated A**; approvals; FDA, 849
- Estrogens, esterified**; substitution; therapeutic, 537
- Ethanol**, see **Alcohols, ethyl**
- Ethics**
 pharmacists; assisted suicides, 1661, 1672
 suicides; assisted, 260
- 1-Ethoxymethyl-5-fluorouracil**; colorectal neoplasms; review, 2417
- Etoposide**; incompatibilities; doxorubicin, vincristine, 985
- Examinations**; pharmacists; continuing education, 21
- Excretion**
 aminoglycosides; vancomycin interactions, 161
 vancomycin; aminoglycoside interactions, 161

Exemestane; approvals; FDA, 2378
Exercise; hyperlipidemia; alternative medicine, 1668
Expiration dates; drugs; charity, 2016
Extracts; *Silybum marianum*; overview, 1195

F

Fair Labor Standards Act; employment; pharmacy administration, 2518

Fax
 data collection; clinical studies, 2540
 hospital pharmacy; Y2K, 1922

FDA Medical Products Reporting Form and Instructions, 89, 1367

Federal Trade Commission

attitudes; own-use exemptions, 990
 guidelines; dietary supplement advertising, 308
 legislation; Internet advertising, 1812

Fentanyl; concomitant therapy, 1114

Fentanyl citrate; costs; comparisons, 551

Fertility agents; ganirelix acetate; FDA approvals, 1810; overview, 2299

Fever; analgesics and antipyretics; nonprescription, 1126

Filgrastim

HIV infections; neutrophil apoptosis, Dec 15 suppl 59

neutropenia; ganciclovir toxicity, 257; HIV infections, Dec 15 suppl S17; neonates, 995
 protocols; hospital pharmacy, 1330

Flavonoids; silymarin; *S. marianum*, 1195

Fluconazole; urinary tract infections; mycoses, 1929

Fluorouracil

colorectal neoplasms; review, 2417
 incompatibilities; topotecan injections, 875
 toxicity, environmental; surface contamination, 1427

Fluoxetine

concomitant therapy, 555
 pharmacoeconomics; comparisons, 23

Fluoxetine hydrochloride; depression; comparisons, 2242

Fluvastatin

coronary disease; cost-benefit analysis, 1726
 substitution; therapeutic, 1437

Fluvoxamine; depression; comparisons, 2242

Folic acid; hyperlipidemia; alternative medicine, 1668

Food

allergies; medication errors, 907
 interactions; cimetidine, 404

Food and Drug Administration (U.S.)

approvals; alitretinoin, 603; amprevir marketing, 1057; celecoxib, 403; cimetidine, 404; conjugated estrogens A, 849; denileukin difitox, 502; dofetilide, 2375; drugs, 31; entacapone, 2376; eprubirin, 2177; exemestane, 2378; ganirelix, 1810; levobupivacaine, 849; levobupivacaine, 1912; Lyme disease vaccines, 206; modafinil, 304; new drugs, 408, 426; new drugs 1998, 412; orlistat marketing, 1058; oseltamivir, 2376; pioglitazone marketing, 1698; quinupristin-dalfopristin, 2174; rabeprazole sodium, 1910; rapacuronium, 2178; regulations, 404; reimbursement lawsuits, 257; rofecoxib marketing, 1294; rosiglitazone marketing, 1292; sevelamer, 11; sirolimus marketing, 2177; sodium ferric gluconate complex, 706; temozolomide, 1910; zalciton, 1912; zanamivir marketing, 1696

cases; dietary supplements, 604
 drugs, adverse reactions; Healthy People 2000, 1479
 guidelines; bioequivalence testing, 615
 laws; dietary supplements, 1286
 legislation; Internet, 1812

postmarketing surveillance; olanzapine toxicity, 1558

protocols; immune globulin, 8
 recommendations; troglitazone marketing, 840
 regulations; clinical studies, 252; compounding, 1388; direct-to-consumer advertising, 1815; non-prescription labeling, 700; patient information, 107; pediatric drugs, 203; plasma-derived products, 2274; unlabeled drug use, 1695; unlabeled use information, 204
 reports; DEHP toxicity, 1490; risk management, 1294

Food and Drug Administration Modernization Act of 1997

approvals; new drugs, 426
 laws; labeling, 1286

pharmacists; compounding, 1388
 regulations; unlabeled drug use, 1695

Forms

documentation; pharmacists' progress notes, 420
 medication orders; TPN, 25

Formularies

administration; managed care systems, 467
 drugs; disasters, 236
 emergency services; disasters, 716
 health maintenance organizations; Medicare, 2014
 hospital pharmacy; administration, 818; generic substitution, 615; physician compliance, 596; services, 622; survey, 142
 hospitals; glipizide immediate vs. sustained release, 454; metformin use, 2535
 managed care systems; administration, 1499; pharmacists' role, 2270; restrictions, 507
 pharmaceutical services; anesthesiology, surgery, 887
 pharmacy, institutional; antipsychotic agents, 1559; cholestyramine resin, 80
 somatropin; generic equivalency, 51
 standards; managed care systems, 846
 United States; legislation, 2338

Formulations

cholestyramine resin; taste, 80
 ganciclovir sodium; oral liquids, 1738
 infliximab; allergies, 11
 rifabutin; suspensions, 333
 vaccines; thimerosal, 1589

Foscarnet

cytomegalovirus retinitis; AIDS, 1314
 toxicity; neutropenia, Dec 15 suppl 55

Fosinopril sodium; tablets; patient compliance, 2542

Freezing

alteplase; stability, 2056
 urokinase; stability, 1350, 2047

Frontline Pharmacist, 25, 212, 420, 610, 860, 1074, 1715, 2398

Changing the routine to suit an automated compounding, 25

Counseling the deaf and hearing-impaired, 610

Developing an immunization program, 2398

Developing a protocol for collaborative drug therapy management, 1715

Guiding patients through the maze of drug information on the Internet, 212

Providing timely discharge counseling, 1074

Televised technology for patient counseling and education, 860

Using a pharmacist's progress-note form to manage HIV pharmacotherapy, 420

Fumagillin bicyclohexylammonium; stability; ophthalmic solutions, 547

Furosemide; incompatibilities; levofloxacin, 1458

G

Gabapentin; bipolar disorder; overview, 1939

Ganciclovir

cytomegalovirus retinitis; AIDS, 1314

toxicity; neutropenia, 257, Dec 15 suppl 55

Ganciclovir sodium

cytomegalovirus infections; comparisons, 1831

stability; compounding, 1738

Ganirelix acetate

approvals; FDA, 1810

overview, 2299

Garlic; hyperlipidemia; alternative medicine, 1668

Gastric lavage; acetaminophen; overdose, 1081

Gastroesophageal reflux; rabeprazole sodium; FDA approvals, 1910; overview, 2300

Gastroesophageal reflux disease; proton-pump inhibitors; overview, Dec 1 suppl 53

Gastrointestinal drugs

proton-pump inhibitors; ulcers, gastroesophageal reflux disease, Dec 1 suppl 53

cimetidine; drug interactions, 1890

histamine H₂ antagonists; ulcer prophylaxis, 347

lanoprazole; incompatibilities, 81; nasogastric, 2327; suspensions, Dec 1 suppl 518

omeprazole; incompatibilities, 81; nasogastric, 2327; suspensions, Dec 1 suppl 518

proton-pump inhibitors; overview, Dec 1 suppl 55; toxicity, Dec 1 suppl 511; ulcer prophylaxis, 347

rabeprazole sodium; FDA approvals, 1910; overview, 2300

Gastrointestinal hemorrhage; nonsteroidal anti-inflammatory agents; toxicity, Dec 1 suppl 55

Gatifloxacin; respiratory-tract infections; pharmacodynamics, pharmacokinetics, Nov 15 suppl 517

General Accounting Office; reports; assisted living facilities, 1484

Generic substitution, see **Substitution, generic**

Genetics; role; pharmacogenomics, 40

Gentamicin; blood levels; collection tubes, 1457

Gentamicin sulfate; dosage; neonates, 440

Geography; physicians; prescribing, 433

Geriatrics

analgesics and antipyretics; nonprescription, 1126
 angiotensin-converting-enzyme inhibitors; heart failure, 1334

antiparkinson agents; risperidone use, 2139

β -blockers; contraindications, 1334

diabetes mellitus; pharmacists' consultation, 1535

drug use; ambulatory care, 2022

hearing loss; consultation, 610

lisinopril; toxicity, 914

losartan potassium; toxicity, 914

nonsteroidal anti-inflammatory agents; contraindications, 1334

prescription drugs; Healthy People 2000, 1479

rational therapy; physicians' prescribing, 433

risperidone; antiparkinson prescribing, 2139

Glass; incompatibilities; valacyclovir suspensions, 1957

Glipizide; formularies; immediate vs. sustained release, 454

Globulin immune

cytomegalovirus infections; comparisons, 1831

distribution; U.S. shortages, 599

protocols; shortages, 1546

toxicity; kidney failure, 8

use; benchmarking, 1102

Gloves; permeation; antineoplastics, 2450

Glucosamine sulfate; osteoarthritis; comparisons, 267

Glucose, see **Dextrose**

Glycopyrrolate; paralysis; rocuronium toxicity, 1114

Gonadorelin agonists; goserelin acetate; implants, 277

Good Clinical Practice; clinical studies; investigational drugs, 252

Goserelin acetate; implants; wastage, 277

Government; United States; year 2000, 1048

Group purchasing, see **Purchasing**

Gugulipid; hyperlipidemia; alternative medicine, 1668

Guidelines

ambulatory care; ASHP, 1744

American Society of Health-System Pharmacists; assisted suicides, 1661; development process, 1829;

patient confidentiality, 1664; primary care, 1665

clinical studies; ASHP, 344

drug administration; enteral nutrition, 1441

Federal Trade Commission; dietary supplement advertising, 308

Food and Drug Administration; bioequivalence testing, 615

home health care; ASHP standards, 629

National Association of Boards of Pharmacy; patient compliance, 1486

National Coordinating Council for Medication Error Reporting and Prevention; medication error reports, 314

parenteral nutrition; home health care, 815

patient information; WWW, 212

pharmaceutical services; anesthesiology, surgery, 887

World Health Organization; drug donations, 2016

Guidelines Update, 190, 490, 829, 1165, 1370, 1790

Guidelines, treatment, see **Protocols**

H

Haemophilus influenzae; resistance; anti-infective agents, Nov 15 suppl 54

Harvey A. K. Whitney Lecture Award; pharmacy; 21st century, 1613

Hazardous substances; compounding; barrier isolators, 1433; contamination, 1403

Health-benefit programs

costs; pharmacy benefit, 506

Medicaid; HMO membership, 505; home health care, 884; hospital admissions, 450; hospital databases, 1326

Medicare; antidepressant costs, 23; cost projections, 1809; drug pricing, 313; HMO formularies, 2014; HMO membership, 505; pharmacists' interventions, 1710; pharmacists' reimbursement, 603; prescription drug benefits, 1503; prospective-pricing system, 2012
reimbursement; somatropin, 51
third party; reimbursement lawsuits, 257
transplantation; bone marrow, 939

Health care
clinical pharmacists; role, 2549
costs; diabetes, hypertension, 1515; drug purchasing, 31; future estimates, 1809; pharmacy benefit, 506
hepatitis B; costs, 232
home; ASHP guidelines, 629; care plans, 1348; i.v. push injections, 76; parenteral nutrition, 270, 815; pharmaceutical services, 884; pharmacist competence, 1549; quality assurance, 473, 911; regulations, 603
hospital pharmacy; quality assurance, 909
migraine; costs, 2193, 2206
patient care; collaborative drug therapy management, 2018
patients; managed care systems, 1805
pharmaceutical care; technicians' role, 1602
pharmacists; 21st century, 1613; role, 1342
pharmacy; practice models, 1758
quality assurance; methodology, 2336
smoking; ASHP protocols, 460

Health Care Financing Administration
health care; cost projections, 1809
regulations; home health care, 603; pharmacists' reimbursement, 603

Health maintenance organizations
see also **Managed care systems**
costs; diabetes, hypertension, 1515
estrogens; therapeutic substitution, 537
formularies; Medicare, 2014; restrictions, 507
membership; statistics, 505
pharmacy, institutional; pharmacists' interventions, 1710
reimbursement; sumatriptan, 2193, 2206

Health Plan Employer Data and Information Set; managed care systems, 2270; quality assurance; survey, 942; standards, 846

Health professions
drug diversion; hospital pharmacy, 1823
drug information; unlabeled use, 204; WWW, 212
education; i.v. push injections, 76; pharmacists' interventions, Sep 1 suppl S3
errors, medication; prevention, 863
gastrointestinal drugs; ulcer prophylaxis, 347
identification; foreign drugs, 2349
prescribing; hospital admissions, 450
reports; adverse reactions, 1558, 1559
role; drug risk management, 1294
team; cystic fibrosis programs, 158

Hearing loss
azithromycin; toxicity, 380
patients; consultation, 610

Heart disease; prophylaxis; AHA protocols, 503

Heart failure
angiotensin-converting-enzyme inhibitors; geriatrics, 1334
digoxin; geriatrics, 1334
pharmaceutical services; hospital admissions, 1339
protocols, 503
ubidecarenone; overview, 519

Helicobacter infections
anti-infective agents; combined therapy, Dec 1 suppl S5
proton-pump inhibitors; combined therapy, Dec 1 suppl S5

Hematopoietic agents
filgrastim; HIV infections, Dec 15 suppl S17; neutropenia, 257, 995, Dec 15 suppl S3; protocols, 1330
sargramostim; neutropenia, 257, Dec 15 suppl S17

Hemophilia; hemostatics; costs, 1303

Hemorrhage; warfarin; toxicity, 1505, 1540

Hemorrhologic agents; pentoxifylline; availability, 1529

Hemostatics; hemophilia; disease management, 1303

Heparin sodium; incompatibilities; levofloxacin, 1458

Hepatitis A vaccines; protocols; pediatrics, 2275

Hepatitis B; health care; costs, 232

Hepatitis C
interferon alfa-2a; review, 961
interferon alfa-2b; review, 961
interferon alfa-2b, combination, ribavirin; review, 961

interferon alfacon-1; review, 961

Herpes virus infections; prophylaxis; ASHP protocols, 1201

History
pharmacists; specialties, 1342
pharmacy; future challenges, 123; practice, 2000, 2533; practice models, 1758

HIV infections
see also **Human immunodeficiency virus**
amprenavir; FDA approvals, 1057
antiretroviral agents; ambulatory care, 420
azithromycin; hearing loss, 380
cidofovir; neutropenia, Dec 15 suppl S5
filgrastim; neutropenia, Dec 15 suppl S17; neutrophil apoptosis, Dec 15 suppl S17
foscarnet; neutropenia, Dec 15 suppl S5
ganciclovir; neutropenia, Dec 15 suppl S5
hematopoietic agents; reimbursement lawsuits, 257
prophylaxis; antiretroviral agents, 1011; ASHP protocols, 1201
protease inhibitors; combined therapy, 273; lipomatosis toxicity, 2343
sargramostim; neutropenia, Dec 15 suppl S17
sulfamethoxazole, combination, trimethoprim; neutropenia, Dec 15 suppl S5
therapy; neutropenia, Dec 15 suppl S3
zidovudine; neutropenia, Dec 15 suppl S5, S17

HIV Update, 273, 1011, 1554, 2343

HMOs, see **Health maintenance organizations**

Home Care Exchange, 76, 270, 473, 815, 911, 1009, 1348, 1549

Hormones
melatonin; overview, 2523
somatropin; physicians' prescribing, 51

Hospital pharmacy, see **Pharmacy, institutional, hospital**

Hospitals
administration; medication errors, 1765; year 2000, 1048; Y2K, 1922
admissions; adverse reactions, 450; heart failure, 1339
computers; Y2K, 2181
costs; diabetes, hypertension, 1515; pharmaceutical services, 2415; quinolone comparisons, 2217
databases; administration, 1326
discharge; patient consultation, 1074
drug distribution; automation, 1542
emergency rooms; antidote carts, 2537
inpatients; physicians, 596
intensive care units; skeletal muscle relaxants, 72
length of stay; health maintenance organizations, 505
operating rooms; pharmaceutical services, 977
pharmacy and therapeutics committee; administration, 622
prescriptions drugs; price fixing, 113

Human growth hormone, see **Somatropin**

Human immunodeficiency virus; resistance; protease inhibitors, 273

Hydralazine; heart failure; congestive, 1445

Hydrocortisone sodium succinate; therapy; promethazine extravasation, 1742

Hydrogen ion concentration
cefepime hydrochloride; incompatibilities, 1134
fumagillin bicyclohexylammonium; ophthalmic solutions, 547
peritoneal dialysis solutions; incompatibilities, 246

Hydromorphone; hyperalgesia; morphine toxicity, 1009

Hydromorphone hydrochloride; incompatibilities; tacrolimus, 164

Hydroxyurea; HIV infections; review, 1554

Hyperalgesia; morphine; toxicity, 1009

Hyperalimentation, see **Nutrition; parenteral**

Hypercholesterolemia
neomycin sulfate, 2227
pravastatin; therapeutic substitution, 1107
simvastatin; therapeutic substitution, 1107

Hypericum perforatum; overview, 329

Hyperlipidemia
alternative medicine, 1668
HMG-CoA reductase inhibitors; therapeutic substitution, 1437
protocols; postmenopause, 1179

Hyperphosphatemia; sevelamer hydrochloride; FDA approvals, 11

Hypertension
clonidine; emergencies, 572
health care; costs, 1515
perindopril erbumine; overview, 2037

Hypalbuminemia; albumin; rational therapy, 1451

Hypoglycemia; acetohexamide; toxicity, 2463

Hypotensive agents
clonidine; hypertensive emergencies, 572
fosinopril sodium; tablet splitting, 2542
lisinopril; toxicity, 914, 1773
losartan potassium; toxicity, 914

Hypovolemia; albumin; rational therapy, 1451

I

Ibuprofen; osteoarthritis; comparisons, 267

Identification
cards; abacavir hypersensitivity warning, 304
drugs; foreign, 2349

Ifosfamide; toxicity, environmental; surface contamination, 1427

IGIV Safety Net Program; globulin immune; administration, 599

Immune Deficiency Foundation; globulin immune; distribution, 599

Immunization
diphtheria and tetanus toxoids and pertussis; vaccine recalls, 504
diseases; ambulatory care, 2398
hepatitis A; protocols, 2275
influenza; pharmacists' interventions, Sep 1 suppl S3
pediatrics; combination vaccines, 1179
pneumococcal infections; pharmacists' interventions, Sep 1 suppl S3
poliomyelitis; protocols, 303, 1480
rotavirus; protocols, 303; vaccines, toxicity, 1589

Immunologic diseases; globulin immune; shortages, 599

Immunomodulating agents; hepatitis C; review, 961

Immunostimulant agents; *Echinacea* species; overview, 121

Immunosuppressive agents
azathioprine; use, 1102
mycophenolate mofetil; incompatibilities, 2224
sirolimus; FDA approvals, 2177
tacrolimus; incompatibilities, 164

Immunotherapy; allergies; food, 907

Implants; goserelin acetate; wastage, 277

Incompatibilities
acyclovir sodium and levofloxacin; Y-site injections, 1458
alprostadil and levofloxacin; Y-site injections, 1458
cefepime hydrochloride and diluents; stability, 457
cefepime hydrochloride, diluents and polypropylene; stability, 1134
ceftazidime sodium and tacrolimus; injections, 164
ceftazidime, peritoneal dialysis solutions and vancomycin hydrochloride; temperature, 246
containers and tirofiban hydrochloride; stability, 1627
dexamethasone sodium phosphate and topotecan hydrochloride; i.v. injections, 875
dihydroergotamine mesylate and promethazine hydrochloride; stability, 1835
diluents and cefepime hydrochloride; stability, 457
diluents and gastrointestinal drugs; nasogastric administration, 2327
diluents and milrinone lactate; Y-site injections, 63
diluents and tirofiban hydrochloride; stability, 1627
diluents, cefepime hydrochloride and polypropylene; stability, 1134
diluents, mycophenolate mofetil and polyethylene terephthalate; compounding, 2224
doxorubicin hydrochloride, etoposide and vincristine sulfate; stability, 985
drugs and enteral nutrition; critical illness, 1441
enteral nutrition and drugs; critical illness, 1441
etoposide, doxorubicin hydrochloride and vincristine sulfate; stability, 985
fluorouracil and topotecan hydrochloride; i.v. injections, 875
furosemide and levofloxacin; Y-site injections, 1458
ganciclovir sodium; oral liquids, 1738
heparin sodium and levofloxacin; Y-site injections, 1458
hydromorphone hydrochloride and tacrolimus; injections, 164
indomethacin sodium and levofloxacin; Y-site injections, 1458
insulin and levofloxacin; Y-site injections, 1458
lamotrigine; stability, 240
lansoprazole and diluents; nasogastric administration, 2327; suspensions, 81

- levofloxacin; oral liquid, 2316; Y-site injections, 1458
- milrinone lactate and diluents; Y-site injections, 63
- mitomycin and topotecan hydrochloride; i.v. injections, 875
- morphine sulfate and tacrolimus; injections, 164
- mycophenolate mofetil, diluents and polyethylene terephthalate; compounding, 2224
- nitroglycerin and levofloxacin; Y-site injections, 1458
- omeprazole and diluents; nasogastric administration, 2327; suspensions, 81
- parenteral nutrition; compounding, 815
- peritoneal dialysis solutions, cefazidime and vancomycin hydrochloride; temperature, 246
- plastics and lamotrigine; stability, 240
- plastics and terbinafine hydrochloride; stability, 243
- polyethylene terephthalate, diluents and mycophenolate mofetil; compounding, 2224
- polypropylene and sumatriptan succinate; syringes, 983
- polypropylene, cefepime hydrochloride and diluents; stability, 1134
- promethazine hydrochloride and dihydroergotamine mesylate; stability, 1835
- rifabutin; suspension compounding, 333
- sodium bicarbonate and gastrointestinal drugs; suspensions, 81
- sodium nitropruside and levofloxacin; Y-site injections, 1458
- sumatriptan succinate and polypropylene; syringes, 983
- suspending agents and lamotrigine; stability, 240
- suspending agents and terbinafine hydrochloride; stability, 243
- suspending agents, syrups and valacyclovir hydrochloride; storage, 1957
- syringes, urokinase and water for injection; stability, 1350
- syrups, suspending agents and valacyclovir hydrochloride; storage, 1957
- tacrolimus; injections, 164
- terbinafine hydrochloride; stability, 243
- ticarcillin disodium, combination, clavulanate potassium and topotecan hydrochloride; i.v. injections, 875
- tirofiban hydrochloride and containers or diluents; stability, 1627
- topotecan hydrochloride; i.v. injections, 875
- urokinase, syringes and water for injection; stability, 1350
- valacyclovir hydrochloride, suspending agents and syrups; storage, 1957
- vancomycin hydrochloride, cefazidime and peritoneal dialysis solutions; temperature, 246
- vincristine sulfate, doxorubicin hydrochloride and etoposide; stability, 985
- water for injection and gastrointestinal drugs; suspensions, 81
- water for injection, syringes and urokinase; stability, 1350
- Indomethacin sodium**; incompatibilities; levofloxacin, 1458
- Industry**
- cosmetics; charity, 208
 - medical devices; unlabeled use, 204
- Industry, pharmaceutical**
- administration; year 2000, 1048
 - cases; lawsuits, 1912
 - charity; drug donations, 2016
 - clinical studies; competition trends, 171; pediatrics, 203
 - computers; Y2K, 2181
 - databases; charity, 2181
 - drug distribution; year 2000, 1383
 - drug information; unlabeled use, 204
 - new drugs; risk management, 1294
 - pharmacogenomics; overview, 40
 - pricing; lawsuits, 113
 - profits; Medicare reform, 1503
 - regulations; patient information, 107; unlabeled drug use, 1695
- Infection control**; influenza; amantadine prophylaxis, 2303
- Infections**
- candidiasis; antifungals, 523
 - prophylaxis; ASHP protocols, 1199
- Infertility**; ganirelix acetate; FDA approvals, 1810; overview, 2299
- Infliximab**; adverse reactions; retreatment, 11
- Influenza**
- amantadine; prophylaxis, 2303
 - oseltamivir phosphate; FDA approvals, 2376
 - zanamivir; FDA approvals, 1696; overview, 2190
- Influenza A**; prophylaxis; ASHP protocols, 1201
- Influenza vaccines**; immunization; pharmacists' interventions, Sep 1 suppl 53
- Information**
- hospital pharmacy; Intranet, 2290
 - pharmacy; International Pharmaceutical Abstracts, 1719
 - unlabeled use; U.S. regulations, 1695
- Inhalation therapy**; zanamivir; Influenza, 1696
- Inhalers**, see **Aerosols**
- Injections**
- ambulatory care; infusion services, 1974
 - azithromycin; pneumonia, 1521
 - cefepime hydrochloride; incompatibilities, 457, 1134
 - cefazidime; incompatibilities, 246
 - dihydroergotamine mesylate; incompatibilities, 1835
 - doxorubicin hydrochloride; incompatibilities, 985
 - erythromycin; pneumonia, 1521
 - etoposide; incompatibilities, 985
 - intravenous; administration rate, 76; home health care, 473; immune globulin, 8; topotecan incompatibilities, 875
 - levofloxacin; incompatibilities, 1458
 - milrinone lactate; incompatibilities, 63
 - morphine; toxicity, 1009
 - parenteral nutrition; home health care, 270
 - promethazine hydrochloride; extravasation, 1742; incompatibilities, 1835
 - sumatriptan succinate; incompatibilities, 983
 - tacrolimus; incompatibilities, 164
 - tirofiban hydrochloride; incompatibilities, 1627
 - urokinase; dilution, 1350; stability, 2047
 - vancomycin hydrochloride; incompatibilities, 246
 - vincristine sulfate; incompatibilities, 985
- Insomnia**; zaleplon; FDA approvals, 1912
- Insulin**
- diabetes mellitus; combined therapy, 840
 - incompatibilities; levofloxacin, 1458
- Insulin human**; toxicity; comparisons, 542
- Insulin lispro**; toxicity; comparisons, 542
- Insulins**
- insulin; combined therapy, 840; levofloxacin incompatibilities, 1458
 - insulin human; toxicity, 542
 - insulin lispro; toxicity, 542
- Insurance**; health care; community pharmacy, 1915
- Integrated health care**
- pharmaceutical services; survey, 2431
 - statistics; survey, 1392
- Interferon alfa-2a**; hepatitis C; overview, 961
- Interferon alfa-2b**; combination, ribavirin; hepatitis C, 961
- Interferon alfacon-1**; hepatitis C; overview, 961
- Intermittent claudication**; cilostazol; FDA approvals, 404
- International Normalized Ratio**; warfarin; ACCP protocols, 1505
- International Pharmaceutical Abstracts**; databases; pharmacy, 1719
- Internet**
- advertising; legislation, 1812
 - drug information; accuracy, 2308; consumer survey, 942
 - patient information; telemedicine, telepharmacy, 1405; WWW, 212
 - pharmaceutical services; pharmacy benefit management companies, 1918
 - prescribing; consumers, 500
 - prescriptions; consumers, 1174
- Interventions**
- clinical pharmacists; coronary disease, 2319; cost-benefit analysis, 2230; heart failure, 1339; medication use, 2549; nutrition support clinic, 2324; operating rooms, 977; progress note forms, 420
 - hospital pharmacy; students, 882
 - pharmacists; diabetes mellitus, 1535; immunization, Sep 1 suppl 53; patient counseling, 576; pharmaceutical care, 672
 - pharmacists, hospital; computer protocols, 225; documentation, 2415; influenza prophylaxis, 2303; inpatient physicians, 596; kidney failure, 1961; medication errors, 2444
 - pharmacists, institutional; drug costs, 1710
- Intussusception**; rotavirus vaccines; toxicity, 1589
- Inventory**
- antidotes; carts, 2537
 - controlled substances; anesthesiology, surgery, 887
 - hospital pharmacy; technicians' role, 324
 - pharmaceutical services; disasters, 716
- Ipratropium bromide**; toxicity; vision disorders, 914
- Iron preparations**; sodium ferric gluconate complex; FDA approvals, 706
- Isoorbide dinitrate**; heart failure; congestive, 1445
- Issues in Clinical Research**, 170, 249, 337
- Itraconazole**; onychomycosis; review, 865
- IVIG**, see **Globulin immune**
- I.V. Services of America**; cases; reimbursement lawsuits, 257
- I.V. Services of America v. American Consulting Engineers Council Insurance Fund**; health-benefit programs; reimbursement lawsuits, 257
- J**
- Job description**
- pharmacists; job satisfaction, 1733; practice change, 2458; survey, 1342
 - pharmacists, hospital; computer protocols, 225
- Job performance**; personnel, pharmacy; adverse drug reactions, 1769
- Job satisfaction**
- pharmacists; survey, 1733
 - pharmacists, hospital; planning and design, 1978
- Joint Commission on Accreditation of Health-care Organizations**
- home health care; accreditation, 911
 - policies and procedures; sentinel events, 2031
 - standards; clinical studies, 252; compliance, 887; home health care, 1348; hospital accreditation, 1699
- Journal References**, 93, 189, 288, 390, 488, 584, 684, 828, 925, 1032, 1160, 1270, 1369, 1467, 1574, 1684, 1788, 1899, 1998, 2164, 2256, 2491, 2564
- Journals**
- American Journal of Health-System Pharmacy; continuing education, 21
 - medical; writing, 1353
 - pharmacy; writing, 1353
- Juices**; interactions; warfarin, 676
- K**
- Kava**; *Piper methysticum*; overview, 957
- Ketotifen fumarate**; overview, 1926
- Kidney failure**
- globulin immune; toxicity, 8
 - prescribing; medication errors, 1961
 - rocuronium bromide; paralysis, 1114
 - sevelamer hydrochloride; hyperphosphatemia, 11
- Knoll Pharmaceutical**; cases; levothyroxine equivalency, 1912
- L**
- Labeling**
- dietary supplements; laws, 1286
 - drugs, nonprescription; FDA regulations, 700
 - goserelin acetate; implants, 277
 - new drugs; pediatrics, 203
 - parenteral nutrition; home health care, 815
 - polyvinyl chloride; diethylhexyl phthalate contamination, 1490
 - prescription drugs; direct-to-consumer advertising, 1815
- Lamotrigine**
- bipolar disorder; overview, 1939
 - stability; suspensions, 240
- Lansoprazole**
- dosage forms; suspensions, Dec 1 suppl 518
 - incompatibilities; diluents, 81; nasogastric administration, 2327
- Latex**; gloves; antineoplastics permeation, 2450
- Law Notes**, 990
- Laws**
- cases; FDA, 604; medication errors, 215; pharmaceutical industry, 1912; price fixing, 113; unlabeled use, 257
 - Civil Rights Act of 1964; sexual harassment, 117
 - pharmacists' compounding, 1388
 - Fair Labor Standards Act; employment, 2518
 - Food and Drug Administration Modernization Act of 1997; dietary supplements, 1286; pharmacists' compounding, 1388

Annual Index

- hospital pharmacy; documentation, 907; year 2000, 1066
- Minnesota; collaborative drug therapy, 943
- patient information; confidentiality, 1664
- pharmacists; collaborative drug therapy management, 1715
- Robinson-Patman Act; own-use exemptions, 990
- suicides; assisted, 260
- Virginia; collaborative drug therapy, 943
- Leaching;** diethylhexyl phthalate; polyvinyl chloride, 1490
- Legislation**
- advertising; Internet, 1812
- Food and Drug Administration; risk management, 1294
- formularies; U.S., 2338
- managed care systems; formularies, 467
- pharmaceutical care; collaborative drug therapy management, 2018
- Letters,** 80, 179, 277, 384, 477, 575, 674, 818, 914, 1019, 1132, 1262, 1350, 1457, 1558, 1674, 1773, 1890, 1988, 2139, 2245, 2349, 2463, 2553
- Acetohexamide-acetazolamide mix-up during emergency treatment, 2463
- Alternative method for administering proton-pump inhibitors through nasogastric tubes, 1020
- Antiparkinsonian drug prescribing in elderly inpatients receiving risperidone therapy, 2139
- Bad medical writing as a barrier to communication, 1353
- Benefits of olanzapine as first-line schizophrenia therapy, 1559
- Be wary of computer interfaces and Y2K, 674
- Blurred vision from ipratropium bromide inhalation, 914
- Clinical usefulness of urokinase after dilution and freezing, 1350
- Compatibility of levofloxacin with 34 medications during simulated Y-site administration, 1458
- Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium, 1891
- Confidence about an odds ratio, 1989
- Distinct drug-interaction profiles for statins, 1019
- Doxazosin-to-terazosin switch for benign prostatic hyperplasia, 1351
- Effect of collection tube on measured gentamicin and vancomycin concentrations, 1457
- Electronic prescriptions in pharmacy, 1351
- Evidence-based pharmacy versus opinion on generic product selection of warfarin, 2246
- Expensive lesson in administration of goserelin implant, 277
- FDA's guidelines on educational programs, 1775
- Finding drug link to reaction, 1558
- Formularies and therapeutic interchange in managed care, 1776
- Grapefruit juice might still be factor in warfarin response, 676
- Heart failure management program in a group-model HMO, 2553
- Helping patients plan for emergencies, 2554
- High-dose amoxicillin in new guidelines for treatment of otitis media in children, 2351
- Importance of identifying foreign drugs, 2349
- Incompatibility of ceftriaxone sodium with lactated Ringer's injection, 384
- Labeling on parenteral nutrient admixtures, 1460
- Lipophilic nature of atorvastatin, 1988
- Losartan-induced cough after lisinopril therapy, 914
- A matter of taste, 80
- Medication errors: integrating individual and system accountability, 1262
- More citizen-soldier pharmacists needed, 2351
- Negative outcomes from drug interactions involving cimetidine in older ambulatory care patients, 1890
- Nonformulary drug requests as a guide in formulary system management, 818
- Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia, 2245
- Omeprazole and lansoprazole suspensions for nasogastric administration, 81
- Other sources of stability research, 179
- Paronychia of the great toes associated with protease inhibitors, 1674
- Penile angioedema possibly related to lisinopril, 1773
- The pharmacist as healer, 576
- Pharmacist positions in Saudi Arabia, 179
- Pharmacy and therapeutics committee 'virtual' meetings, 1132
- Pharmacy-buzzword bingo, 2464
- Plasticizers in perspective, 2141
- Potential danger from too much acetaminophen in opiate agonist combination products, 1774
- Preliminary survey of pharmacists' use of the Internet, 1675
- Rectal administration of warfarin, 2140
- Removal of pyrogens by filtration? 477
- Request for donations of *Mirror to Hospital Pharmacy*, 2464
- Response rates from poster presenters at ASHP meetings, 277
- Splitting bupropion extended-release tablets, 575
- Stability of cefepime hydrochloride in polypropylene syringes, 1134
- Students' reactions to ASHP MCM, 1991
- Useful prescription drug information, 477
- Wanted: ambulatory care pharmacists for cardiovascular task force, 1775
- Levalbuterol hydrochloride**
- approvals; FDA, 849
- overview, 1191
- Levobupivacaine hydrochloride;** approvals; FDA, 1912
- Levodopa;** combination, carbidopa; combined therapy, 2376
- Levofloxacin**
- incompatibilities; Y-site injections, 1458
- stability; compounding, 2316
- Levorphanol;** hyperalgesia; morphine toxicity, 1009
- Levothyroxine;** equivalency, generic; lawsuits, 1912
- Liability**
- drugs, adverse reactions; hospital pharmacy, 1769
- hospital pharmacy; year 2000, 1066
- Lidocaine hydrochloride;** therapy; promethazine extravasation, 1742
- Lipomatosis;** protease inhibitors; toxicity, 2343
- Liposomes;** amphotericin B; candidiasis, 525
- Liquids**
- acetaminophen; pediatrics, 1094
- ganciclovir sodium; stability, 1738
- levofloxacin; stability, 2316
- Lisinopril;** toxicity; angioneurotic edema, 1773; cough, 914
- Liver diseases;** *Silybum marianum*; overview, 1195
- Liver failure**
- alatrofloxacin; toxicity, 1388
- tolcapone; adverse reactions, 8
- troglitazone; toxicity, 840
- trovafloxacin mesylate; toxicity, 1388
- Long-term care facilities**
- influenza; amantadine prophylaxis, 2303
- reimbursement; prospective-pricing system, 2012
- Losartan potassium;** toxicity; cough, 914
- Louisiana;** clinical pharmacists; collaborative drug therapy management, 2018
- Lovastatin**
- coronary disease; cost-benefit analysis, 1726
- dietary supplements; cases, 604
- substitution; therapeutic, 1437
- Loxapine hydrochloride;** subcutaneous; protocols, 1259
- Lung diseases;** cannabis; smoking, 940
- Lyme disease vaccines;** approvals; FDA, 206
- Lymphoma;** denileukin difitox; T-cell, cutaneous, 502
- M**
- Macrolides**
- azithromycin; hearing loss, 380; pneumonia, 1521
- erythromycin; pneumonia, 1521
- Magnesium sulfate;** status asthmaticus; pediatrics, 997
- Malaria;** prophylaxis; ASHP protocols, 1201
- Managed Care Forum,** 23, 858, 1303, 1499, 1710, 2391
- Communicating with plan members by e-mail, 2391
- Determining the most economical SSRI for a Medicare risk contract, 23
- Improving the care of hemophiliacs by managing the drug benefit, 1303
- Improving the prior-authorization process to the satisfaction of customers, 1499
- Promoting optimal use of β -blockers after myocardial infarction, 858
- Reducing drug costs of a Medicare-risk population, 1710
- Managed care systems**
- see also **Health maintenance organizations**
- administration; formularies, 467
- drugs; own-use exemptions, 990
- electronic mail; telecommunications, 2391
- estrogens; therapeutic substitution, 537
- formularies; administration, 1499; restrictions, 507
- health care; survey, 1805
- membership; statistics, 505
- pharmaceutical services; hemophilia disease management, 1303; pharmacist manpower, 1309
- pharmacists, community; benchmarking, 566
- pharmacists, institutional; smoking cessation, 425
- pharmacy, institutional; drug costs, 31, 313, 1710
- physicians; inpatients, 596
- prescriptions drugs; price fixing, 113
- quality assurance; β -blocker use, 858; report, 1805; standards, 846
- standards; NCQA accreditation, 2270
- Management, see Administration**
- Management Case Studies,** 1119, 1546, 1974, 2230
- Management Consultation,** 117, 324, 516, 716, 952, 1190, 1398, 1602, 1823, 1922, 2031, 2290, 2518
- Benchmarking the allocation of pharmacists' time, 516
- Choosing an automated dispensing machine, 1398
- Choosing what to post on a pharmacy intranet web page, 2290
- Facing up to drug diversion, 1823
- Getting to the bottom of a sentinel event, 2031
- Integrating pharmacy technicians into the health care team, 1602
- Labor law and salaried employees, 2518
- The need for legal compliance plans in health institutions, 952
- New sexual harassment rules under Title VII of the Civil Rights Act of 1964, 117
- Planning for Y2K, 1922
- Preparing pharmacy technicians for patient-focused care, 324
- Role of pharmacists on disaster response teams, 716
- Tracking medication dispensed from a hospital pharmacy, 1190
- Manpower**
- hospital pharmacy; cost-benefit analysis, 2230
- pharmacists; ambulatory care, 443
- pharmacists, institutional; managed care, 1309
- pharmacy; pharmacists' job satisfaction, 1733
- Manufacturers**
- computers; hospital pharmacy, 675
- globulin immune; distribution, 599
- Manufacturing**
- drugs; pharmacy practice models, 1758; year 2000 problems, 727
- vaccines; thimerosal toxicity, 1589
- Marijuana, see Cannabis**
- Marketing**
- alitreinoin; FDA approvals, 603
- ambulatory care; infusion services, 1974
- amprenavir; FDA approvals, 1057
- celecoxib; FDA approvals, 403; rheumatoid arthritis, 106
- cilostazol; FDA approvals, 404
- denileukin difitox; FDA approvals, 502
- dofetilide; FDA approvals, 2375
- entacapone; FDA approvals, 2376
- epirubicin hydrochloride; FDA approvals, 2177
- estrogens conjugated A; FDA approvals, 849
- exemestane; FDA approvals, 2378
- ganirelix acetate; FDA approvals, 1810
- levobupivacaine hydrochloride; FDA approvals, 849
- levobupivacaine hydrochloride; FDA approvals, 1912
- Lyme disease vaccines; FDA approvals, 206
- medicinal plants; dietary supplements, 1927
- modafinil; FDA approvals, 304
- new drugs; risk management, 1294
- orlistat; FDA approvals, 1058
- oseltamivir phosphate; FDA approvals, 2376
- pharmaceutical services; clinical studies, 337
- pharmacogenomics; overview, 40
- pioglitazone hydrochloride; FDA approvals, 1698
- quinupristin, combination, dalbapristin; FDA approvals, 2174
- rabeprazole sodium; FDA approvals, 1910
- rapacuronium bromide; FDA approvals, 2178
- rofecoxib; FDA approvals, 1294; rheumatoid arthritis, 106
- rosiglitazone maleate; FDA approvals, 1292
- sevelamer hydrochloride; FDA approvals, 11
- silimulim; FDA approvals, 2177
- sodium ferric gluconate complex; FDA approvals, 706
- temozolomide; FDA approvals, 1910
- troglitazone; FDA recommendations, 840

- zaleplon; FDA approvals, 1912
 zanamivir; FDA approvals, 1696
- Massachusetts;** nursing; state boards, 707
- Materials management;** home health care; team, 473
- Mechanism of action**
 acids, fatty; overview, 719
 celecoxib; toxicity, 403
Echinacea species; overview, 121
 entacapone; Parkinson's disease, 2376
 exemestane; breast neoplasms, 2378
 hydroxyurea; HIV infections, 1554
 kava; overview, 957
 levalbuterol hydrochloride; asthma, 849
 medicinal plants; review, 125
 orlistat; obesity, 1058
 pioglitazone hydrochloride; diabetes mellitus, 1698
 proton-pump inhibitors; overview, Dec 1 suppl S3
 rofecoxib; FDA approvals, 1294
 rosiglitazone maleate; diabetes mellitus, 1292
 skeletal muscle relaxants; overview, Jun 1 suppl S4
 tolcapone; Parkinson's disease, 2195
 warfarin; interactions, 676
 zaleplon, 1912
- Medication errors, see Errors, medication**
- Medication orders**
 hospital pharmacy; survey, 142; technicians' role, 324
 parenteral nutrition; pharmacy compounding, 25
- Meetings**
 American Pharmaceutical Association; 1999 annual, 706
 American Society of Health-System Pharmacists; poster presentations, 277; residency preceptors, 2454; students' reactions, 1991
 Pharmacy and therapeutics committee; administration, 1132
- Melatonin;** overview, 2523
- Membership**
 managed care systems; statistics, 505
 National Pharmacists Cardiovascular Task Force; pharmacists, 1775
- Men**
 drugs, adverse reactions; hospital admissions, 450
 mortality; AIDS, 1314
- Meningitis;** prophylaxis; ASHP protocols, 1201
- Menopause**
Climicifuga racemosa; overview, 1400
 estrogens conjugated A; FDA approvals, 849
- Meperidine hydrochloride;** therapy; promethazine extravasation, 1742
- Mercury;** toxicity; vaccine preservatives, 1589
- Metabolic diseases;** protease inhibitors; toxicity, 2343
- Metabolism**
 cilostazol; FDA approvals, 404
 rabeprazole sodium, 1910
 rofecoxib, 1294
- Metformin;** use; prescribing, 2535
- Methicillin;** resistance; *S. aureus*, 2174
- Methodology**
 decision-making; home health care, 473
 formularies; hospital pharmacy, 818
 meta-analysis; albumin, rational therapy, 1451
 pharmacoeconomics; hospital pharmacy, 1630
 quality assurance; health care, 2336; institutional pharmacy, 1060
 quality of life; instrument evaluation, 1965
 quinolones; pharmacodynamics, Nov 15 suppl S12; pneumonia, Nov 15 suppl S21
 validation; medication delivery system, 1094; medication error calculations, 57
- Metrifonate, see Trichlorfon**
- Midazolam**
 concomitant therapy, 1114
 myoclonus; morphine toxicity, 1009
- Migraine;** sumatriptan; pharmacy benefit limits, 2193, 2206
- Military;** personnel, pharmacy; role, 568
- Milrinone lactate;** incompatibilities; Y-site injections, 63
- Minnesota;** pharmacists; collaborative drug therapy, 943
- Mitomycin;** incompatibilities; topotecan injections, 875
- Mivacurium;** overview, Jun 1 suppl S4
- Modafinil;** approvals; FDA, 304
- Models**
 pharmacoeconomics; skeletal muscle relaxants, Jun 1 suppl S18
 pharmacy; interdisciplinary, 12; practice, 1758, 1981, 2235
 quinolones; pharmacodynamics, Nov 15 suppl S12; pneumonia, Nov 15 suppl S21
- Moisture;** prescription drugs; stability, 2008
- Moraxella catarrhalis;** resistance; anti-infective agents, Nov 15 suppl S4
- Morphine;** toxicity; hyperalgesia, myoclonus, 1009
- Morphine sulfate;** incompatibilities; tacrolimus, 164
- Mortality**
 acquired immunodeficiency syndrome; antivirals, 1314
 breast neoplasms; antineoplastics—bone marrow transplantation, 939
 coronary disease; HMG-CoA reductase inhibitors, 1726
- Motivation;** pharmacists; practice changes, 2235
- Multiple sclerosis;** acids, fatty; overview, 719
- Mycophenolate mofetil;** incompatibilities; diluents, containers, 2224
- Mycoses**
 amphotericin B; dosage, 872; urinary tract infections, 1929
 fluconazole; urinary tract infections, 1929
- Myocardial infarction**
 β -blockers; protocols, 858
 HMG-CoA reductase inhibitors; cost-benefit analysis, 1726
- Myoclonus;** morphine; toxicity, 1009
- N**
- Narcolepsy;** modafinil; FDA approvals, 304
- National Association of Boards of Pharmacy**
 attitudes; Internet prescribing, 1174; Internet prescribing, dispensing, 500
 legislation; Internet advertising, 1812
 regulations; patient outcomes, 699
 reports; task force, 1486
 standards; prescription drug storage, 2008
- National Association of Chain Drug Stores**
 education, pharmaceutical; programs, 1912
 strategic planning; pharmacy practice, 1915
- National Cancer Institute;** protocols; cervix neoplasms, 702
- National Committee for Quality Assurance**
 managed care systems; quality assurance, 1805
 standards; managed care accreditation, 2270; managed care systems, 846;
- National Community Pharmacists Association**
 education, pharmaceutical; programs, 1912
 strategic planning; pharmacy planning, 1915
- National Coordinating Council for Medication Error Reporting and Prevention;** guidelines; medication error reports, 314
- National Cosmetology Association;** charity; cosmetology services, 208
- National Institute on Drug Abuse;** protocols; drug addiction, 2276
- National Institutes of Health;** protocols; attention deficit disorder, 111
- National Pharmacists Cardiovascular Task Force;** pharmacists; membership, 1775
- Nausea**
 antiemetics; ASHP protocols, 729; pharmacists' role, 728
 cannabis; smoking, 940
- Neomycin sulfate;** hypercholesterolemia, 2227
- Neoplasm metastasis;** antineoplastic agents; combined therapy, 2417
- Neoplasms**
 acids, fatty; overview, 719
 filgrastim; protocols, 1330
 melatonin; overview, 2523
- Neoprene;** gloves; antineoplastics permeation, 2450
- Neostigmine;** neuromuscular blockade; reversal, Jun 1 suppl S10
- Neostigmine methylsulfate;** paralysis; rocuronium toxicity, 1114
- Neuroleptic malignant syndrome;** olanzapine; toxicity, 1558, 1559
- Neuromuscular blockade;** skeletal muscle relaxants; reversal, Jun 1 suppl S10
- Neuromuscular diseases;** skeletal muscle relaxants; toxicity, 72
- Neutropenia**
 cidofovir; toxicity, Dec 15 suppl S5
 filgrastim; HIV infections, Dec 15 suppl S17
 filgrastim; neonates, 995; protocols, 1330
 foscarnet; toxicity, Dec 15 suppl S5
 ganciclovir; toxicity, Dec 15 suppl S5
 sargamostim; HIV infections, Dec 15 suppl S17
 sulfamethoxazole, combination, trimethoprim; toxicity, Dec 15 suppl S5
- therapy; HIV infections, Dec 15 suppl S3
 zidovudine; toxicity, Dec 15 suppl S5, S17
- News,** 8, 106, 203, 303, 403, 500, 596, 699, 840, 937, 1048, 1174, 1286, 1383, 1479, 1589, 1695, 1805, 1910, 2008, 2174, 2270, 2372, 2504
 Abbott names winners of hospital pharmacy quality awards, 318
 Actions for pharmaceutical safety outlined, 2504
 Active isomer of albuterol approved for marketing, 849
 Advisory panel hears contradictory evidence, backs keeping troglitazone on market, 840
 Advocacy group targets PVC i.v. equipment, 937
 AHCPR announces new evidence report topics; ASHP selected as partner, 314
 AHCPR charts health differences by race and ethnicity, 1480
 All-IPV schedule proposed for polio immunization in 2000, 1480
 Amprenavir approved for HIV treatment, 1057
 Antidepressants, rhinosinusitis are topics of new AHCPR evidence reports, 853
 APhA sets policy on telepharmacy, DTC ads, unions, 706
 Appointments and Promotions, 113, 506, 702, 947, 1185, 1388, 1594, 1806, 2272, 2508
 Ban on Cholestol sales overruled, 604
 Book correction notice, 938
 BPS certifies 118 in oncology, 419
 Breast cancer studies yield mixed results on high-dose chemotherapy with stem cell support, 939
 Broad-based efforts needed to rein in outpatient antimicrobial use, study suggests, 1183
 Build information framework for measuring health care quality, says NCQA report, 2187
 CDC broadens recommendations for hepatitis A vaccination, 2275
 CDC issues recommendations on use of Lyme disease vaccine, 1484
 CDC releases rotavirus vaccine recommendations, 854
 CDC says upcoming doses of rotavirus vaccine should be delayed, 1589
 Celecoxib approved as NSAID with some concessions on class warning, 403
 Changes found in nursing home admission practices since advent of PPS, 2012
 Cilostazol approved for use in intermittent claudication, 404
 Coalition continues work on medication-use performance measures, 2022
 Combined chemotherapy—radiation therapy recommended for invasive cervical cancer, 702
 Commonly used herbs adversely affect fertility measures in vitro, 710
 Community pharmacy pricing suit dismissed, 113
 Companies cooperate in emergency supply program for IGIV, 599
 Computerized drug cost information fails to sway physician prescribing, 1183
 Congress explores limits on Internet pharmacy, 1812
 Consumer group touts generics, 2276
 Consumers want details about prescription drugs; many use 'alternative' medicines, 307
 Cost savings by pharmacists documented, 2378
 Cytotoxic protein approved for cutaneous T-cell lymphoma, 502
 Database on patient-assistance programs available, 2181
 Decisions loom on selective COX-2 inhibitors, 106
 Diabetes training proposal says Medicare can pay pharmacists, 603
 1998 drug and biological approvals, 412
 Disparities in HIV care have narrowed but not disappeared, 1593
 Dofetilide approved for serious atrial arrhythmias, 2375
 Drug addiction treatment guide released, 2276
 Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA, 1294
 Elimination of thimerosal from vaccines set as goal, 1589
 Emphasize diet—not antioxidant supplements, says AHA, 503
 Employers report 6% jump in 1998 health care costs, 506
 Employment, wages of nurses perform poorly during 1994-97, 609
 Entacapone marketed as adjunct to levodopa—carbidopa, 2376
 Eprubirin approved for breast cancer treatment, 2177

Annual Index

- Exemestane receives breast cancer indication, 2378
Express Scripts, PlanetRx.com forge agreement, 1918
Fatal liver injury reported with tolcapone, 8
FDA approves oral treatment for influenza A and B, 2376
FDA approves pioglitazone for diabetes, 1698
FDA approves quinupristin-dalfopristin for some vancomycin-resistant infections, 2174
FDA approves single enantiomer of bupivacaine, 1912
FDA approves topical treatment for cutaneous lesions of Kaposi's sarcoma, 603
FDA culls nominations for compounding list, 1388
FDA drug-review, surveillance processes under scrutiny, 404
FDA finalizes guidance on DTC broadcast ads, 1815
FDA plan highlights drug safety efforts, 408
FDA to propose tracking, notification system for plasma-derived products, 2274
FDA to require pediatric studies for drugs commonly used in children, 203
Former MCP president Gosselin dies, 2513
For second year, teen drug-use survey shows declines, 419
Foundation names Allen, 1184
Four deaths from community-acquired MRSA reported, 1916
Four-drug regimen recommended for most heart failure patients, 503
FTC reminds supplement makers of standards for advertising, 308
FTC zeroes in on Internet health fraud, 1489
Ganirelix approved for use in fertility treatment, 1810
Government finds fault with hospital quality review by Joint Commission and states, 1699
Growing popularity of alternative medicine documented in new survey, 112
Growth hormone found effective in short, healthy children, 607
Growth of integrated systems continues, 1392
Guideline offers help in managing sickle-cell pain, 2272
Guidelines address role of aerosolized antibiotics in cystic fibrosis, 2271
Guidelines address use of protectants in oncology practice, 2378
Guidelines for angina management released, 1482
Guidelines recognize greater role for antileptic agents in postmenopausal women, 1179
HCFA lowers national health spending projections, 1809
Health literacy rated low in one third of Medicare managed care enrollees, 709
Health trend survey: consumers like Internet, alternative medicine; employers lukewarm on quality measurement, 942
Healthy People report: progress toward year 2000 objectives, but some growing gaps, 1479
Henney takes helm at FDA, 17
Higher approval standards, consistent practice policies needed for safe use of generic immunosuppressants, say transplant experts, 604
Hospitalists offer prospect for increased efficiencies, 596
Infliximab retreatment: caution advised, 11
Inhaled zanamivir approved for influenza treatment, 1696
Internet-based prescribing and dispensing trouble medical and pharmacy boards, 500
January 2000 drug supply will be adequate if all act responsibly, industry group assures public, 1383
Judge strikes down FDA policies on industry dissemination of off-label information, 1695
Kenneth A. Davis dies; 'wrote the book' on injectable drug quality, 507
Key findings of evidence-based reports announced, 501
King steps down as ASHP Foundation exec, 2510
Limits placed on trovafloxacin, alatrofloxacin following reports of liver failure, 1388
Lyme disease vaccine cleared for marketing, 206
Managed care plans spent \$8.5 billion on prescriptions in 1997, 313
Medicare costs found higher where for-profit hospitals prevail, 1809
Medicare drug benefit based on private-sector model proposed, 2182
Medicare pays twice the VA cost for drugs, report says, 313
Medication error taxonomy available, 314
Medications a problem in assisted-living facilities, 1484
Minnesota researchers find few differences in HMO, fee-for-service care of acute myocardial infarction, 2272
Modafinil approved for narcolepsy, 304
More health plans restricting drug use, setting three-tier copayments, 507
More states endorse medical marijuana use; researchers note ill effects, 11
Most U.S. overseas drug donations are useful; attention needed to donor requests and product age and relevance, 2016
Movement to temperature monitoring loses steam, 2008
NABP addresses pain management, confidentiality, Y2K preparedness, 1486
NCQA accreditation 2000 standards note pharmacist's role, need for DUE, 2270
NCQA draft accreditation standards for 2000 address formularies, 846
NCQA report shows health plan performance flat on most measures, 1805
New cases of vancomycin-intermediate MRSA infection reported, 705
New community pharmacy foundation to benefit from lawsuits against drug companies, 1912
New i.v. iron product to be introduced, 706
Newly approved abacavir to carry hypersensitivity warning, 304
New members appointed to A/HP's editorial board, 508
News Briefs, 18, 111, 211, 320, 418, 509, 608, 708, 854, 944, 1062, 1184, 1298, 1393, 1490, 1594, 1705, 1815, 1921, 2026, 2187, 2284, 2386, 2513
New short-acting neuromuscular blocker released, 2178
1999 Regional Resident-Preceptor Conferences, 18
1997 saw HMO membership up, hospital days down, 505
Nonabsorbable polymer marketed as phosphate binder, 11
Nonmalignant pain goes untreated in one fourth of nursing home residents, study shows, 2024
Nonprescription labeling requirements issued, 700
North Carolina, Louisiana legislate collaborative drug therapy management, 2019
North Carolina vaccine program linked to improved childhood immunization rates, 2019
Offer smokers a choice of drug therapy, physicians recommend, 415
Oral antimicrobials seen as an option for some cancer patients with fever and neutropenia, 1810
Oral temozolomide approved for refractory brain tumor, 1910
Organization releases osteoporosis guide, 206
Organizations outline challenges, actions for community pharmacy, 1915
Orlistat approved for obesity management, 1058
Panel finds inconsistencies in ADHD care, 111
Panel recommends strategies for 'wired' health communication, 2181
Panel sees medical potential in standardized cannabinoids but not in smoked marijuana, 940
Patients need more information about HMO formularies, says report on Medicare plans, 2014
Pharmaceutical costs higher at system hospitals, but rising faster at nonsystem facilities, 1702
Pharmacist on care team contributes to better outcomes in patients with heart failure, 2274
Pharmacists excluded from home care patient assessment, 603
Pharmacists in all countries should join wider efforts to improve health, says FIP president, 2284
Pharmacists on ICU team cuts ordering errors by 66%, 1700
Pharmacy benefit costs continue upward trend, 1702
Pharmacy technician helps cancer patients look good, 208
Pharm.D. student takes interdisciplinary path to career goals, 12
Physicians, nurses say patients' plans often deny coverage, 1805
Physicians report impact of managed care financial incentives, 113
Precautions advised for IGIV, 8
Priority drugs well represented among 1998 approvals, 408
Rabeprazole is latest entrant in proton-pump-inhibitor class, 1910
Ramipril study suggests drug may benefit broad group of patients, 2504
Report examines strategies for reducing breast cancer risk, 1298
Report examines use of combination childhood vaccines, 1179
Report explores insurer policies and clinical trial access, 2507
Report says elderly can benefit from cholesterol-lowering therapy, 1812
Report shows decline in health plan pharmacy coverage, steady prescription use, rising costs, 2510
Requirements for FDA-approved patient information spelled out in final rule, 107
Research fails to support TPN use in critically ill patients, 310
Resources on quality measurement available, 1060
Rite Aid, GNC link to drugstore.com, 1490
Rosiglitazone approved for treatment of type 2 diabetes, 1292
Rotavirus, poliovirus top 1999 immunization changes, 303
Rules set for dissemination of off-label-use information, 204
Scientific and trade groups clash over 'authoritative' statements for health claims, 1286
Second selective COX-2 inhibitor receives marketing approval, 1294
Sirolimus approved with renal transplant indication, 2177
Site survey, FDA editorial note hazards of prescription drug availability on Internet, 2178
Smoking-cessation programs need to target college students, 416
Spirinolactone an important addition to heart-failure treatment, study shows, 1695
State board disciplines nurses for Dana-Farber overdoses, 707
State boards consider outcomes-based regulation, 699
Study documents cost reduction with outpatient enoxaparin therapy, 2508
Study notes lower HEDIS scores in investor-owned HMOs, 1806
Study quantifies impact of resistant *Pseudomonas* on outcomes, 1392
Suboptimal vaccine lot recalled, recommendations on supplemental doses issued, 504
Survey explores consumer views on government regulation of supplements, 942
Synthetic conjugated estrogens product approved, 849
Syringe sales by pharmacies reviewed as HIV-prevention strategy, 16
Task force 'grades' strategies for boosting vaccination rates, 1480
Technician-pharmacist teams receive PTCB awards, 318
Texas creates state funding source for residency training, 1391
Therapeutics research centers named by AHCPR, 2283
Upcoming Meetings, 415, 607, 849, 1060, 1294, 1489, 1698, 2381
Updated exam to reflect current work of technicians, 1918
Update of guidelines on myocardial infarction released, 1916
Use of meningococcal vaccine in college freshmen reconsidered, 2372
U.S. TB trends reflect global influence, 1915
Virginia, Minnesota expand pharmacists' role in drug therapy, 943
Virtual pharmacies boast easy access, privacy safeguards, 1174
Warnings needed about PVC, group tells FDA, 1490
William H. Briner, 'father of radiopharmacy,' dies, 206
With 100 days to Y2K, some health care settings remained vulnerable, 2181
Y2K activities, 1696
Y2K repairs unfinished in health care sector, 1048
Zaleplon marketed for insomnia, 1912
News media: communication; adverse drug reactions, 1769
Nicotine: smoking; cessation, 460
Nitrile rubber: gloves; antineoplastics permeation, 2450
Nitroglycerin: incompatibilities; levofloxacin, 1458
Nitrous oxide: combination, oxygen; concomitant therapy, 551
Nomenclature: drugs; foreign, 2349
pharmacy; humor, 2464
similarities; medication errors, 2463
North Carolina: clinical pharmacists; collaborative drug therapy management, 2018

Nuclear pharmacy, see Radiopharmacy**Nurse practitioners:** prescribing; geriatrics, 1479**Nurses**

ambulatory care; administration, 1974
attitudes; managed care systems, 1805
communication; hospital pharmacists, 225, 1546
drug information; pharmacists, 613
errors, medication; methodology, 57; penicillin overdose, 904
home health care; regulations, 603; team, 473

Nursing: state boards; antineoplastic overdose, 707**Nursing homes:** reimbursement; prospective-pricing system, 2012**Nutrition**

diet; heart diseases, 503; heart failure, 1339; hyperlipidemia, 1668
enteral; drug administration, 1441; pharmacists' interventions, 2324
parenteral; automated compounding, 25; home health care, 270, 815; pediatrics, 1950; pharmacists' interventions, 2324
specialties; certification examinations, 419

O**Obesity:** orlistat; FDA approvals, 1058**Ofloxacin:** use; comparisons, 2217**Olanzapine**

psychotic disorders; Alzheimer's disease, 2245
schizophrenia; cost-benefit analysis, 1559, 1560
toxicity; neuroleptic malignant syndrome, 1558, 1559

Oligonucleotides: hepatitis C; antisense, 961**Omeprazole**

dosage forms; suspensions, Dec 1 suppl 518
incompatibilities; diluents, 81; nasogastric administration, 2327

Oncology: specialties; certification examinations, 419**Ophthalmology**

itraconazole; review, 865
terbinafine hydrochloride; review, 865

Ophthalmic preparations: ketotifen fumarate; allergic conjunctivitis, 1926**Opiates**

codeine phosphate, combination, acetaminophen; overdose, 1774
fentanyl citrate; cost comparisons, 551
hydrocodone bitartrate, combination, acetaminophen; overdose, 1774
hydromorphone; morphine toxicity, 1009
hydromorphone hydrochloride; tacrolimus incompatibilities, 164
meperidine hydrochloride; promethazine extravasation, 1742
morphine; toxicity, 1009
morphine sulfate; tacrolimus incompatibilities, 164
oxycodone hydrochloride; promethazine extravasation, 1742
oxycodone, combination, acetaminophen; overdose, 1774
pain; hospital pharmacy services, 1119; sickle-cell trait, 2272
propoxyphene napsylate, combination, acetaminophen; overdose, 1774
remifentanyl hydrochloride; cost comparisons, 551

Opportunistic infections: prophylaxis; ASHP protocols, 1201**Organizations**

American Pharmaceutical Association; policies and procedures, 706; strategic planning, 1915
American Society of Health-System Pharmacists; ambulatory care guidelines, 1744; antimicrobial prophylaxis, 1199, 1201, 1839; assisted suicide guidelines, 1661; assisted suicides, 1672; continuing education, 21; home care guidelines, 629; investigational services guidelines, 344; meetings, 277, 1991; national survey, 142; nonprescription analgesics, 1126; patient confidentiality guidelines, 1664; pharmaceutical services survey, 2431; protocols, 460; publications, 1301; residency preceptors, 2454; standards, 846; ulcer prophylaxis, 347
drug information; unlabeled use, 204
Joint Commission on Accreditation of Healthcare Organizations; standards, 1348
National Association of Boards of Pharmacy; reports, 1486
National Association of Chain Drug Stores; education programs, 1912; strategic planning, 1915
National Committee for Quality Assurance; standards, 846

National Community Pharmacists Association; education programs, 1912; strategic planning, 1915
National Pharmacists Cardiovascular Task Force; membership, 1775
pharmacy; year 2000, 1048
Pharmacy Quality Council; quality assurance, 1060
Volunteers in Health Care; databases, 2181

Oritat

approvals; FDA, 1058
overview, 1364

Osetamivir phosphate: approvals; FDA, 2376**Osteoarthritis**

celecoxib; FDA approvals, 403; marketing, 106
glucosamine sulfate; comparisons, 267
ibuprofen; comparisons, 267
rofecoxib; FDA approvals, 1294; marketing, 106; overview, 1404

Osteoporosis: protocols; postmenopause, 206**Outcomes**

clinical; data collection, 2540; HMG-CoA reductase inhibitors, 1437; home health care, 911; pharmacists' role, 2549
economics; cimetidine interactions, 1890
patient care; NABP regulations, 699
therapeutic; congestive heart failure, 1445; glipizide conversions, 454

Outpatients, see Patients; outpatients**Oxycodone hydrochloride:** therapy; promethazine extravasation, 1742**P****Package inserts:** patient information; troglitazone toxicity, 840**Packaging:** drugs; medication errors, 2463**Pacitaxel:** permeation; gloves, 2450**Pain**

analgesics; sickle-cell trait, 2272
analgesics and antipyretics; nonprescription, 1126
cannabis; smoking, 940
opiates; hospital pharmacy services, 1119
rofecoxib; FDA approvals, 1294; overview, 1404

Palliative care: loxapine hydrochloride; subcutaneous, 1259**Pancuronium**

concomitant therapy, 551
overview, Jun 1 suppl 54

Papaverine hydrochloride: therapy; promethazine extravasation, 1742**Paralysis:** rocuronium bromide; toxicity, 1114**Parasympatholytic agents:** glycopyrrolate; paralysis, 1114**Parasympathomimetic agents**

edrophonium; reversing neuromuscular block, Jun 1 suppl 510
neostigmine; reversing neuromuscular block, Jun 1 suppl 510
neostigmine methylsulfate; paralysis, 1114
pyridostigmine; reversing neuromuscular block, Jun 1 suppl 510
rapacuronium; reversing neuromuscular block, Jun 1 suppl 510
trichlorfon; Alzheimer's disease, 427

Parenterals, see Injections**Parkinson's disease**

carbidopa, combination, levodopa; combined therapy, 2376

entacapone; FDA approvals, 2376

ropinirole hydrochloride; review, 217

tolcapone; liver failure, 8; review, 2195

Paroxetine: pharmacoeconomics; comparisons, 23**Patients:** new drugs; FDA regulations, 203**Patient care**

clinical pharmacists; pain management, 1119
costs; prospective-pricing system, 2012
cystic fibrosis; clinical pharmacists, 158
home health care; care plans, 1348
hospital pharmacy; year 2000, 1066
managed care systems, 1805
pharmaceutical care; collaborative drug therapy management, 2018
pharmacists, community; strategic planning, 1915

Patient education

diabetes mellitus; pharmacists' reimbursement, 603
pain; sickle-cell trait, 2272
smoking; cessation programs, 460
warfarin; ambulatory care, 443

Patient-focused care: technicians; role, 324**Patient Information:** 1159**Patient information**

computers; Y2K, 2181

confidentiality; ASHP guidelines, 1664; electronic mail, 2391; Internet, 1174; NABP reports, 1486; telecommunications, 1351; telemedicine, telepharmacy, 1405

consultation; ambulatory care, 1744; anticoagulation clinics, 443; antiretroviral agents, 420; diabetes mellitus, 1535; discharge prescriptions, 1074; hearing loss, 610; home health care, 629; hospital pharmacists, 225; immunization, Sep 1 suppl 53; influenza prophylaxis, 2303; investigational drug services, 344; Medicare benefits, 1503; medicinal plants, 125; nonprescription analgesics, 1079; pharmacists' role, 576; smoking cessation, 425; telecommunications, 860; thalidomide, 1721; troglitazone toxicity, 840

drug histories; abacavir warning card, 304
drugs; FDA, 107

formularies; HMO Medicare, 2014
pharmacists; new drugs, 426; professionalism, 613
prescription drugs; Healthy People 2000, 1479
prescriptions; consumers' attitudes, 307
World Wide Web; guidelines, 212

Patients

attitudes; estrogens, therapeutic substitution, 537;

managed care services, 1499

communication; managed care systems, 2391

consultation; disasters, 236

discharge; consultation, 1074

home health care; parenteral nutrition, 270

inpatients; dofetilide administration, 2375; health

care team, 158; thalidomide dispensing, 1721

outpatients; Medicare drug pricing, 313; Medicare

prescription benefits, 1503; thalidomide dispensing, 1721; warfarin protocols, 1505

role; drug risk management, 1294

World Wide Web; information, 212

Pediatrics

acetaminophen; liquids, 1094; overdose, 1081

amprenavir; HIV infections, 1057

analgesics and antipyretics; nonprescription, 1126

antibiotics; ASHP protocols, 1839

antimetotics; ASHP protocols, 729; pharmacists' role, 728

anti-infective agents; ASHP protocols, 1199, 1201

attention deficit disorder with hyperactivity; NIH

protocols, 111

diphtheria and tetanus toxoids and pertussis vac-

cines; recalls, 504

hepatitis A vaccines; protocols, 2275

home health care; quality assurance, 473

immunization; protocols, 303

magnesium sulfate; status asthmaticus, 997

neonates; filgrastim, 995; gentamicin protocols,

440; medication errors, 904

new drugs; FDA regulations, 203

parenteral nutrition; trace elements, 1950

polio vaccines; protocols, 1480

protocols; disease management, 331

somatotropin; physicians' prescribing, 51

thimerosal; vaccine toxicity, 1589

vaccines; protocols, 1179

Penicillin G benzathine: errors, medication; over-

dose, 904

Penicillins

injections; i.v. push, 76

methicillin; *S. aureus*, 2174

penicillin G benzathine; medication errors, 904

ticarcillin disodium, combination, clavulanate po-

tassium; topotecan incompatibilities, 875

Pentoxifylline: sustained-action medications;

availability, 1529

Perindopril erbumine: overview, 2037**Peritoneal dialysis solutions:** incompatibilities;

cefazidime, vancomycin, 246

Permeability: gloves; antineoplastics, 2450**Permeation:** antineoplastic agents; gloves, 2450**Personnel:** benefits; health care costs, 506**Personnel, pharmacy**

employment; administration, 2518

errors, medication; administration, 1765

home health care; team, 473

hospitals; ADR reports, 1769; clinical studies, 337;

communication, 225; medication errors, 2463

services; clinical, 1945

sexual harassment; administration, 117

supportive; anesthesia services, 887; health care

team, 1602; military, 568; patient-focused care,

324; patient outcomes, 699; technicians, 208,

1319, 1549

Annual Index

Pharmaceutical care

ambulatory care: ASHP guidelines, 1744
collaborative drug therapy management; laws, 943;
pharmacists, 1715; pharmacists' role, 2018; pri-
mary care, 1665
disasters: drug selection, 236; pharmacists' role, 716
immunization; pharmacists' interventions, Sep 1
suppl S3
interventions; operating rooms, 977
personnel, pharmacy; military, 568
pharmacists; future challenges, 123; medication er-
rors, 215; potential, 672; professional compe-
tence, 1981
pharmacy; practice models, 1758
students; attitudes, 2330
technicians; role, 1602

Pharmaceutical education, see Education, pharmaceutical

Pharmaceutical services

ambulatory care: anticoagulation clinics, 443; com-
puter protocols, 225; emergencies, 2554; guide-
lines, 1744; therapeutic substitution, 1307
clinical; cystic fibrosis, 158; operating rooms, 977;
progress note forms, 420
clinical pharmacists; benchmarking, 516
cognitive; documentation, 2415; home health care,
884; reimbursement, 603
community; strategic planning, 1915
disasters; pharmacists' role, 716
drug information; pharmacists, 613
drugs, investigational; ASHP guidelines, 344; clini-
cal studies, 252, 337
guidelines; anesthesiology, surgery, 887
home health care; ASHP guidelines, 629; regula-
tions, 603
hospital pharmacy; dialysis traineeship, 1623
hospitals; ambulatory care, 1974; antibiotics, 675;
clinical, 1945; computers, 674; formularies, 622;
heart failure, 1339; interventions, 2444; investi-
gational drugs, 249; kidney failure, 1961; medica-
tion errors, 1319; pain management, 1119; quali-
ty assurance, 909, 1542; survey, 142; warfarin
clinics, 1540; year 2000, 1066
integrated health care; ambulatory care, 2431
Internet; pharmacy benefit management compa-
nies, 1918
managed care systems; administration, 1499; he-
mophilia, 1303; pharmacist manpower, 1309
pharmacists; pharmacogenomics, 27
prisons; patient counseling, 860
quality assurance; antidote carts, 2537
telepharmacy; APhA policies, 706
transplantation; generic substitution, 615

Pharmacists

administration; immune globulin shortages, 599
ambulatory care; organizations, 1775; therapeutic
substitution, 1307; warfarin monitoring, 443
certification; examinations, 419
collaborative drug therapy management; physi-
cians, 1715
compounding; laws, 1388
consultation; diabetes mellitus, 1535; hearing loss,
610; reimbursement, 1503; smoking cessation,
425; telecommunications, 860
dispensing; assisted suicide, 260
drug information; professionalism, 613; WWW,
212
education, pharmaceutical; continuing, 21; medi-
cal plants, 125
errors, medication; methodology, 57; professional
responsibility, 215
ethics; assisted suicides, 1661, 1672
home health care; care plans, 1348; professional
competence, 1549; regulations, 603
information; poster presentations, 277
job description; survey, 1342
military; pharmaceutical care, 568
patient information; new drugs, 426
pharmaceutical care; potential, 672
preceptors; development, 2454
primary care; ASHP guidelines, 1665
reimbursement; Medicare, 603
role; antiemetic prophylaxis, 728; clinical studies,
252; collaborative drug therapy, 943; dietary sup-
plements, 1927; disaster planning, 716; disasters,
236; immunization, 2398; nonprescription anal-
gesics, 1126; patient confidentiality, 1664; pa-
tient counseling, 576; pharmaceutical care, 123;
pharmacogenomics, 27; pharmacy benefit limits,
2193; product development, 171; smoking ces-
sation, 460; therapeutic substitution, 1351; 21st
century, 1613
sociology; practice change, 2458

Pharmacists, clinical, see Clinical pharma- cists

Pharmacists, community

attitudes; electronic prescriptions, 1351
consultation; nonprescription analgesics, 1079
education, pharmaceutical; practice models, 2235
managed care systems; benchmarking, 566
professional competence; practice models, 1981
role; strategic planning, 1915

Pharmacists, hospital

administration; P&T committee, 1132
ambulatory care; administration, 1974; ASHP
guidelines, 1744; computer protocols, 225; war-
farin clinics, 1540
attitudes; automated compounding, 25; generic
substitution, 615; goserelin labeling, 277
clinical studies; ASHP guidelines, 344; investiga-
tional drugs, 337
communication; immune globulin shortages, 1546
consultation; discharge prescriptions, 1074
dispensing; dofenitide, 2375; thalidomide regula-
tions, 1721
drug interactions; monitoring, 1524
education, pharmaceutical; acetaminophen over-
dose, 1774
errors, medication; administration, 907, 1765; pen-
icillin overdose, 904
interventions; documentation, 2415; inpatient
physicians, 596; kidney failure, 1961; medication
errors, 2444
job satisfaction; planning and design, 1978
postmarketing surveillance; olanzapine toxicity,
1558
practice; survey, 142
professionalism; quality assurance, 909
role; filgrastim protocols, 1330; formularies, 818;
influenza prophylaxis, 2303; pharmacy and ther-
apeutics committee, 622
salaries; Saudi Arabia, 179
telecommunications; metformin use, 2535

Pharmacists, institutional

ambulatory care; integrated health care, 2431
consultation; nonprescription analgesics, 1079
education, pharmaceutical; practice models, 2235
formularies; managed care systems, 2270
interventions; HMOs, 1710; immunization, Sep 1
suppl S3
job satisfaction; survey, 1733
managed care systems; smoking cessation, 425
manpower; managed care systems, 1309
role; drug distribution, 727; managed care systems,
858
services; cognitive, 884

Pharmacists, institutional, hospital; errors, medication; dispensing, 1319

Pharmacodynamics

quinolones; models, Nov 15 suppl S12; pneumonia
models, Nov 15 suppl S21; respiratory-tract infec-
tions, Nov 15 suppl S17, S25
ropinirole hydrochloride; review, 217
skeletal muscle relaxants; overview, Jun 1 suppl S14

Pharmacoeconomics

anti-infective agents; respiratory-tract infections,
Nov 15 suppl S25
cost-benefit analysis; amiodarone prophylaxis,
2211
methodology; hospital pharmacy, 1630
serotonin-reuptake inhibitors; comparisons, 23
skeletal muscle relaxants; models, Jun 1 suppl S18

Pharmacogenetics; pharmacogenomics; overview, 27

Pharmacogenomics; overview, 40

Pharmacokinetics

aminoglycosides; vancomycin interactions, 161
anti-infective agents; respiratory-tract infections,
Nov 15 suppl S25
Cimicifuga racemosa; overview, 1400
dofenitide, 2375
entacapone, 2376
gentamicin sulfate; neonates, 440
levodopa; entacapone interactions, 2376
melatonin; overview, 2523
oseltamivir phosphate, 2376
pentoxifylline; sustained-action medications, 1529
quinolones; in vitro models, Nov 15 suppl S12;
pneumonia models, Nov 15 suppl S21; respira-
tory-tract infections, Nov 15 suppl S17
rapacuronium bromide, 2178
ropinirole hydrochloride; review, 217
Silybum marianum; overview, 1195
skeletal muscle relaxants; overview, Jun 1 suppl S4,
S14
tolcapone; Parkinson's disease, 2195

trichlorfon; review, 427
ubidecarenone; overview, 519
vancomycin; aminoglycoside interactions, 161
zaleplon, 1912

Pharmacotheapy; specialties; certification exami- nations, 419

Pharmacy

administration; immune globulin shortages, 599;
sexual harassment, 117
ambulatory care; pharmacists' organizations, 1775
clinical studies; competition trends, 171
errors, medication; assisted-living facilities, 1484
history; practice models, 1758
information; International Pharmaceutical Ab-
stracts, 1719
patient information; Healthy People 2000, 1479
practice; change, 2458; future challenges, 123; hu-
mor, 2464; interdisciplinary education, 12; phar-
macogenomics, 27; survey, 1342; 21st century,
1613; year 2000, 2533
regulations; NABP reports, 1486
students; ASHP meetings, 1991; cystic fibrosis pro-
grams, 158; drug interactions, 1524; interdisciplinary
education, 12; interventions, 882; pharma-
ceutical care, 2330

Pharmacy and therapeutics committee

administration; survey, 622
hospital pharmacy; survey, 142
hospitals; administration, 1132
policies and procedures; immune globulin pro-
tocols, 1546
formularies; managed care systems, 467

Pharmacy benefit management companies

contracts; Internet pharmacy services, 1918
formularies; restrictions, 507
managed care systems; hemophilia disease manage-
ment, 1303

Pharmacy, clinical, see Clinical pharmacy

Pharmacy, community

chain stores; industry lawsuits, 1912
Independent; industry lawsuits, 1912
patients; hospital admissions, 450
pharmacists; professional competence, 1981
practice; models, 1758, 2235
pricing; lawsuits, 113
strategic planning; pharmacists' role, 1915
telecommunications; electronic prescriptions, 1351

Pharmacy, education, see Education, pharma- ceutical

Pharmacy, institutional

administration; formularies, 467; parenteral nutri-
tion, 815
costs; diabetes, hypertension, 1515; pharmacists'
interventions, 1710; 1999 projections, 31
formularies; antipsychotic agents, 1559;
cholestyramine resin, 80
health maintenance organizations; sumatriptan re-
imbursement, 2193, 2206
Integrated health care; ambulatory care, 2431
job description; pharmacists' satisfaction, 1733
managed care systems; drug costs, 313; electronic
mail, 2391; pharmacist manpower, 1309; quality
assurance, 858
practice; models, 2235
quality assurance; Pharmacy Quality Council, 1060
services; home health care, 629; immunization, Sep
1 suppl S3

Pharmacy, institutional, hospital

administration; ambulatory care, 225; automated
dispensing machine, 1398; clinical studies, 252,
337; computers, 674, 675; discharge consulta-
tion, 1074; dofenitide dispensing, 2375; employ-
ment, 2518; formularies, 818; generic substi-
tution, 615; inpatient physicians, 596; investiga-
tional drug services, 344; medication errors,
1765; medication tracking system, 1190; P&T
committee, 1132; pharmacists' interventions,
2444; pharmacoeconomics, 1630; sterile prod-
ucts, 1978; student interventions, 882; Y2K, 1922
clinical pharmacists; cost-benefit analysis, 2230;
operating rooms, 977
compounding; TPN, 25
computers; intranet, 2290
costs; transplantation, 1102
dispensing; automation, 1542
drug distribution systems; immune globulin, 1546;
year 2000, 1048
drug diversion; health professions, 1823
drug information; postmarketing surveillance,
1558
drug interactions; monitoring, 1524
drugs, adverse reactions; quality assurance, 1769

- errors, medication; acetaminophen overdose, 1774; administrator's role, 907; dispensing, 2463; goserelin wastage, 277; penicillin overdose, 904; prevention, 863; sentinel event policies, 2031
- filtration; protocols, 1330**
- formuleries; glipizide, immediate vs. sustained release, 454**
- home health care; quality assurance, 911**
- liability; year 2000, 1066**
- pharmacists, hospital; professional competence, 1981**
- policies and procedures; thalidomide dispensing, 1721**
- practice; models, 1758**
- publications; ASHP production, 1301**
- quality assurance; administration, 909; antidote carts, 2537**
- regulations; compliance, 952**
- services; ambulatory care, 1744, 1974; anesthesiology, surgery, 887; clinical, 1945; dialysis traineeship, 1623; documentation, 2415; heart failure, 1339; home health care, 629; investigational drugs, 249; kidney failure, 1961; pain management, 1119; pharmacy and therapeutics committee, 622; survey, 142; warfarin therapy, 1540**
- technicians; patient-focused care, 324**
- telecommunications; metformin use, 2535**
- toxicity, environmental; antineoplastic agents, 1403, 1427**
- Pharmacy Manpower Project; managed care systems; pharmaceutical services, 1309**
- Pharmacy personnel, see Personnel, pharmacy**
- Pharmacy Quality Council; quality assurance; institutional pharmacy, 1060**
- Pharmacy services, see Pharmaceutical services**
- Phenobarbital; alcohol withdrawal delirium, 175**
- Phenothiazines**
- hyperalgesia; morphine toxicity, 1009**
- protocols; nausea and vomiting, 729**
- Phenytin; interactions; cimetidine, 1890**
- Phosphate binders; sevelamer hydrochloride; FDA approvals, 11**
- Phosphatidylserine; overview, 2038**
- Phospholipids; phosphatidylserine; overview, 2038**
- Photodecomposition; fumagillin bicyclohexylammonium; ophthalmic solutions, 547**
- Physicians**
- attitudes; automated compounding, 25; managed care systems, 1805**
- collaborative drug therapy management; pharmacists, 1715**
- communication; hospital pharmacists, 225, 1546**
- computers; Y2K, 2181**
- dispensing; medication errors, 2463**
- drug information; pharmacists, 613**
- errors, medication; methodology, 57; penicillin overdose, 904**
- home health care; team, 473**
- hospitals; inpatients, 596**
- prescribing; assisted suicide, 260; diabetes mellitus, 1535; dofetilide, 2375; formularies, 818; geriatrics, 433; managed care formularies, 1499; metformin, 2535; pain management, 1119; patient information, 1479; pharmacists' interventions, 1710; somatropin, 51; thalidomide regulations, 1721; therapeutic substitution, 1307**
- role; pharmacy and therapeutics committee, 622**
- Phytonadione; dosage; warfarin toxicity, 2312**
- Pioglitazone hydrochloride; approvals; FDA, 1698**
- Piper methysticum; overview, 957**
- Planning and design**
- hospital pharmacy; ambulatory care, 1744; sterile products, 1978**
- pharmacy, institutional; home health care, 629**
- Plants; medicinal; *Cimicifuga racemosa*, 1400; depression, 853; dietary supplements, 1927; *Echinacea* species, 121; *H. perforatum*, 329; kava, 957; toxicity, 125**
- Plasticizers; diethylhexyl phthalate; toxicity, 1490**
- Plastics**
- containers; lamotrigine incompatibilities, 240; terbinafine incompatibilities, 243**
- polyvinyl chloride; stability, 1490**
- Platelet aggregation inhibitors**
- aspirin; pharmacists' interventions, 2319**
- tirofiban hydrochloride; incompatibilities, 1627**
- Pneumococcal vaccines; immunization; pharmacists' interventions, Sep 1 suppl S3**
- Pneumonia**
- azithromycin; comparisons, 1521**
- erythromycin; comparisons, 1521**
- prophylaxis; ASHP protocols, 1201**
- quinolones; models, Nov 15 suppl S21**
- Poisoning**
- acetaminophen; overdose, 1081**
- antidotes; carts, 2537**
- Policies and procedures, see Administration**
- Poliomyelitis**
- immunization; protocols, 303**
- polio vaccines; toxicity, 1480**
- Pollo vaccines; protocols; pediatrics, 303, 1480**
- Polyethylene terephthalate; containers; ganciclovir stability, 1738; mycophenolate incompatibilities, 2224**
- Polypropylene**
- containers; alteplase, 2056; doxorubicin, etoposide, vincristine, 985; promethazine-dihydroergotamine incompatibilities, 1835**
- incompatibilities; sumatriptan, 983**
- syringes; cefepime incompatibilities, 457; cefepime injections, 1134**
- Polyurethane; gloves; antineoplastics permeation, 2450**
- Polyvinyl chloride; containers; stability, 1490; tirofiban incompatibilities, 1627**
- Postmarketing surveillance**
- new drugs; FDA approvals, 404; pharmacists, 426; risk management, 1294**
- olanzapine; neuroleptic malignant syndrome, 1559; toxicity, 1558**
- Postmenopause**
- exemestane; breast neoplasms, 2378**
- HMG-CoA reductase inhibitors; protocols, 1179**
- women; osteoporosis, 206**
- Potassium oxalate; colorectal neoplasms; review, 2417**
- Potency**
- diphtheria and tetanus toxoids and pertussis vaccines; recalls, 504**
- skeletal muscle relaxants; overview, Jun 1 suppl S14**
- Pravastatin**
- coronary disease; cost-benefit analysis, 1726**
- substitution; therapeutic, 1107, 1437**
- Preceptors; residencies; ASHP meetings, 2454**
- Precipitation; levofloxacin; incompatibilities, 1458**
- Pregnancy; acetaminophen; overdose, 1081**
- Prescribing**
- alfloxacin; rational therapy, 1388**
- antiparkinson agents; risperidone use, 2139**
- drugs; disasters, 236**
- errors, medication; drug interactions, 1524**
- globulin immune; shortages, 1546**
- health professions; hospital admissions, 450**
- hospital pharmacy; survey, 142**
- Internet; consumers, 500**
- pharmacists; collaborative drug therapy management, 1715; warfarin, 443**
- physicians; assisted suicide, 260; diabetes mellitus, 1535; dofetilide, 2375; formularies, 818; geriatrics, 433; kidney failure, 1961; managed care formularies, 1499; metformin, 2535; pain management, 1119; patient information, 1479; pharmacists' interventions, 1710; somatropin, 51; thalidomide regulations, 1721; therapeutic substitution, 1307; unlabeled use, 257**
- trovafloxacin mesylate; rational therapy, 1388**
- Prescriptions**
- advertising; Internet, 1812**
- copayments; managed care systems, 507**
- costs; diabetes, hypertension, 1515**
- discharge; patient consultation, 1074**
- dispensing; community pharmacists, 1915; computer protocols, 225**
- drugs; direct-to-consumer advertising, 1815; formularies, 2338; industry lawsuits, 1912; managed care systems, 313; Medicare costs, 313; patient information, 1479; price fixing, 113**
- errors, medication; dispensing, 1319**
- Internet; consumers, 1174**
- mail order; stability, 2008**
- managed care systems; pharmacist manpower, 1309**
- Medicare; benefits, 1503**
- patient information; FDA regulations, 107**
- pharmaceutical services; Internet, 1918**
- pharmacy, community; telecommunications, 1351**
- refills; abacavir hypersensitivity warning, 304; disasters, 236; Y2K, 2181**
- Preservatives; thimerosal; vaccine toxicity, 1589**
- Pricing**
- drugs; lawsuits, 113; managed care systems, 990; Medicare vs. VA, 313**
- prescription drugs; industry lawsuits, 1912**
- Primary care; pharmacists; ASHP guidelines, 1665; survey, 1342**
- Primers, 1630, 1965**
- Prisons; pharmaceutical services; pharmacists' consultation, 860**
- Proclonidine; interactions; cimetidine, 1890**
- Prochlorperazine hydrochloride; therapy; promethazine extravasation, 1742**
- Product development**
- pharmacists; role, 171**
- pharmacogenomics; overview, 27, 40**
- Product withdrawal; new drugs; FDA approvals, 404**
- Professional competence**
- assessment; anesthesia services, 887**
- pharmacists; home health care, 1348, 1549; practice models, 1981**
- Professionalism**
- pharmacists; drug information, 613**
- pharmacists, hospital; quality assurance, 909**
- pharmacy; future challenges, 123**
- Promethazine hydrochloride**
- incompatibilities; dihydroergotamine, 1835**
- toxicity; extravasation, 1742**
- Propoxyphene; rational therapy; geriatrics, 433**
- Prostaglandin derivatives; ulcers; prophylaxis, 347**
- Prostatic hyperplasia**
- doxazosin; therapeutic substitution, 1351**
- terazosin; therapeutic substitution, 1351**
- Prostatic neoplasms; antiandrogens; AHCPR protocols, 501**
- Protocols**
- Advisory Committee on Immunization Practices; combination childhood vaccines, 1179**
- Agency for Health Care Policy and Research; evidence-based therapy, 501**
- algorithms; antiemetics prophylaxis, 728**
- American Academy of Family Physicians; combination childhood vaccines, 1179**
- American Academy of Pediatrics; combination childhood vaccines, 1179**
- American College of Cardiology; HMG-CoA reductase inhibitors, 1179**
- American Heart Association; HMG-CoA reductase inhibitors, 1179**
- American Society of Health-System Pharmacists; antiemetics, 728, 729; antimicrobial prophylaxis, 1199, 1201, 1839; ulcer prophylaxis, 347**
- analgesics; sickle-cell pain, 2272**
- analgesics and antipyretics; nonprescription, 1126**
- antibiotics; cystic fibrosis, 2271; i.v. push, 76**
- antileptic agents; therapeutic substitution, 1107**
- antivirals; hepatitis C, 961**
- anxiolytics, sedatives and hypnotics; operating rooms, 977**
- β -blockers; myocardial infarction, 858**
- cannabinoids, 940**
- clinical studies; investigational drugs, 249**
- collaborative drug therapy management; pharmacists' prescribing, 1715**
- computers; ambulatory care, 225**
- drug abuse; publication, 2276**
- filgrastim; hospital pharmacy, 1330**
- gentamicin sulfate; neonates, 440**
- globulin immune; FDA, 8; shortages, 1546**
- heart diseases; American Heart Association, 503**
- heart failure; Advisory Council To Improve Outcomes Nationwide in Heart Failure, 503**
- hepatitis A vaccines; pediatrics, 2275**
- hospital pharmacy; physician compliance, 596**
- hyperalgesia; morphine toxicity, 1009**
- loxapine hydrochloride; subcutaneous, 1259**
- managed care systems; patient care, 1805**
- metformin; electronic mail, 2535**
- myoclonus; morphine toxicity, 1009**
- National Cancer Institute; cervix neoplasms, 702**
- National Institutes of Health; attention deficit disorder, 111**
- osteoporosis; women, 206**
- pediatrics; disease management, 331**
- polio vaccines; pediatrics, 1480**
- skeletal muscle relaxants; critical illness, 72; operating rooms, 977**
- sympatholytic agents; therapeutic substitution, 1351**
- vaccines; immunization, 303**
- warfarin; ACCP protocols, 1505**
- Pruritus; ketotifen fumarate; allergic conjunctivitis, 1926**

Annual Index

Pseudomonas infections; antibiotics; cystic fibrosis, 2271

Psychology

administration; medication errors, 1765
pharmacists; practice change, 2458

Psychopharmacology; specialties; certification examinations, 419

Psychotic disorders

loxapine hydrochloride; subcutaneous, 1259
olanzapine; Alzheimer's disease, 2245
risperidone; geriatric psychiatric facility, 2139

Publications

American Society of Health-System Pharmacists; production, 1301
drug abuse; protocols, 2276
drugs; unlabeled use, 1695
International Pharmaceutical Abstracts; databases, 1719

Public health; United States; Healthy People 2000, 1479

Public relations; hospital pharmacy; adverse drug reactions, 1769

Purchasing; hospital pharmacy; computers, 674;
globulin immune shortages, 1546

Purity; dietary supplements; consumer survey, 942

PVC, see Polyvinyl chloride

Pyridostigmine; neuromuscular blockade; reversal, Jun 1 suppl S10

Pyridoxine hydrochloride; hyperlipidemia; alternative medicine, 1668

Q

Quality assurance

ambulatory care; ASHP guidelines, 1744
antimetotics; prophylaxis, 728
clinical studies; academic health centers, 171

drug use; geriatrics, 2022
health care; methodology, 2336; pharmacists' role, 1613

Health Plan Employer Data and Information Set; survey, 942

home health care; ASHP guidelines, 629; care plans, 1348; clinical outcomes, 911; decision-making, 473; i.v. push injections, 76; pharmacist competence, 1549

hospital pharmacy; administration, 909; adverse drug reactions, 1769; antidote carts, 2537; drug distribution, 1542; medication error prevention, 863; medication errors, 907, 1765; nonformulary drug requests, 818; sterile products, 1978

hospitals; JCAHO, 1699
managed care systems; β -blockers, 858; hemophilia, 1303; NCQA standards, 2270; report, 1805

parenteral nutrition; home health care, 815
pharmaceutical services; administration, 2533; anesthesiology, surgery, 887; clinical studies, 337

pharmacists; pharmaceutical care, 672
pharmacy, institutional; Pharmacy Quality Council, 1060

Quality improvement, see Quality assurance

Quality of life

methodology; instrument evaluation, 1965
pharmaceutical care; pharmacists, 672

Questions and Answers, 21, 1066, 1301

Are you ready for January 1, 2000? 1066
Continuing education in *AJHP*, 21

Translating an idea into a product at ASHP, 1301

Quinidine; interactions; cimetidine, 1890

Quinolones

alatrofloxacin; toxicity, 1388
ciprofloxacin; cost comparisons, 2217
gatifloxacin; respiratory-tract infections, Nov 15 suppl S17

levofloxacin; incompatibilities, 1458; stability, 2316
ofloxacin; cost comparisons, 2217
pharmacodynamics; in vitro models, Nov 15 suppl S12

pneumonia; models, Nov 15 suppl S21
respiratory-tract infections; anti-infective agent resistance, Nov 15 suppl S4; pharmacodynamics, Nov 15 suppl S25

trovafloxacin mesylate; toxicity, 1388

Quinupristin; combination, dalfopristin; FDA approvals, 2174

Quinupristin and dalfopristin; overview, 2530

R

Rabeprazole sodium
approvals; FDA, 1910
overview, 2300

Radiation

cervix neoplasms; combined therapy, 702
toxicity; nausea and vomiting, 728, 729

Radiopharmacy; specialties; certification examinations, 419

Rapacuronium

clinical studies; pharmacokinetics, pharmacodynamics, Jun 1 suppl S14

neuromuscular blockade; reversal, Jun 1 suppl S10

Rapacuronium bromide; approvals; FDA, 2178

Rational therapy

alatrofloxacin; toxicity, 1388
albumin; meta-analysis, 1451

analgesics and antipyretics; nonprescription, 1079
antibiotics; sinusitis, 853; surgical prophylaxis, 1839

β -blockers; myocardial infarction, 858
cardiac drugs; heart failure, 1334

colloids; meta-analysis, 1451
disasters; drug selection, 236

filgrastim; protocols, 1330
geriatrics; ambulatory care, 2022; physicians' prescribing, 433

globulin immune; shortages, 1546
metformin; use, 2535

prescribing; therapeutic substitution, 1307
prescription drugs; U.S. legislation, 2338

trovafloxacin mesylate; toxicity, 1388

Readability; data collection; clinical studies, 2540

Recombinant t-PA, see Alteplase

Records

filling; NABP regulations, 699
Medicaid; hospital databases, 1326

medical; ambulatory care, 443
pharmaceutical services; clinical pharmacists, 516;

interventions, 2444

References; drug information; pharmacists, 613

Regulations

clinical studies; investigational drugs, 252
dietary supplements; consumer survey, 942

Food and Drug Administration; compounding, 1388; direct-to-consumer advertising, 1815; drug approvals, 31, 408, 426; new drug approvals, 404; new drugs, 1294; nonprescription labeling, 700;

pediatric drugs, 203; plasma-derived products, 2274; unlabeled drug use, 1695; unlabeled use information, 204

Health Care Financing Administration; home health care, 603; pharmacists' reimbursement, 603

hospital pharmacy; compliance, 952; dofenitide dispensing, 2375; sterile products, 1978

National Association of Boards of Pharmacy; patient outcomes, 699

patient information; FDA, 107

pharmacists; collaborative drug therapy, 943
pharmacy; NABP reports, 1486

thalidomide; hospital pharmacy policies, 1721

Reimbursement

health-benefit programs; somatropin, 51; unlabeled use, 257

health maintenance organizations; sumatriptan, 2193, 2206

hospital pharmacy; clinical studies, 249

Medicare; prescription drugs, 1503; prospective-pricing system, 2012

pharmacists; HCFA regulations, 603; immunization programs, 2398

telemedicine; pharmaceutical services, 1405

Release; glipizide; immediate vs. sustained action, 454

Remifentanyl hydrochloride; costs; comparisons, 551

Replacement solutions

albumin; rational therapy, 1451
colloids; rational therapy, 1451

Reports

Agency for Health Care Policy and Research; antidepressants, sinusitis, 853

drugs; adverse reactions; health professions, 1558, 1559; Healthy People 2000, 1479; hospital pharmacy, 1769

errors, medication; personnel management, 1765; taxonomy, 314

Food and Drug Administration; risk management, 1294

hospital pharmacy; sentinel events, 2031

integrated health care; statistics, 1392

National Association of Boards of Pharmacy; task force, 1486

Research; pharmacists; smoking cessation, 425

Residencies, see Education, pharmaceutical; residencies

Resistance

antifungals; *Candida* species, 523, 525
anti-infective agents; respiratory-tract infections, Nov 15 suppl S4

ciprofloxacin; *P. aeruginosa*, 2217
protease inhibitors; HIV infections, 273

vancomycin; *E. faecium*, 2174

Respiratory smooth muscle relaxants; theophylline; cimetidine interactions, 1890

Respiratory tract infections

Echinacea species; overview, 121
anti-infective agents; pharmacoeconomics, Nov 15 suppl S25; pharmacodynamics, pharmacokinetics, Nov 15 suppl S17; resistance, Nov 15 suppl S4

9-cis-Retinoic acid, see All-trans-retinoic acid

Ribavirin; combination, interferon α -2b; hepatitis C, 961

Ribozymes; hepatitis C; review, 961

Rifabutin; stability; compounding, 333

Ringer's injection, lactated; diluents; milrinone injections, 63

Risperidone

concomitant therapy, 555
psychotic disorders; geriatric psychiatric facility, 2139

Robinson-Patman Act; laws; own-use exemptions, 990

Rocuronium bromide; toxicity; paralysis, 1114

Rofecoxib

approvals; FDA, 1294
arthritis; rheumatoid, 106

overview, 1404

Ropinrole hydrochloride; Parkinson's disease; review, 217

Rosiglitazone maleate

approvals; FDA, 1292
overview, 1925

Rotavirus vaccines

protocols; pediatrics, 303
toxicity; intussusception, 1589

S

Salaries; pharmacists; hospital; Saudi Arabia, 179

Sales; dietary supplements; laws, 604

Sarcoma; alitretinoin; Kaposi, 603

Sargramostim; neutropenia; ganciclovir toxicity, 257; HIV infections, Dec 15 suppl S17

Saudi Arabia; pharmacists; hospital; salaries, 179

SCH56592; candidiasis; review, 525

Schizophrenia

diphenhydramine hydrochloride; toxicity, 555
olanzapine; cost-benefit analysis, 1559, 1560

Schools; pharmacy; residencies, funding, 1391

Self-study Materials, 491, 1273, 2256

Concepts in Oncology Therapeutics, Second Edition, 1273

Manual for Pharmacy Technicians, Second Edition, 2256

Pharmacoeconomics and Outcomes: Applications for Patient Care, Module 3: Assessment of Humanistic Outcomes, 491

The Pharmacy Technician, 2258

Pharmacy Technician Certification Review and Practice Exam, 2256

Pharmacy Technician Workbook & Certification Review, 2258

Serotonin agonists

sumatriptan; reimbursement, 2193, 2206
sumatriptan succinate; incompatibilities, 983

protocols; nausea and vomiting, 729

Sertraline; pharmacoeconomics; comparisons, 23

Sertraline hydrochloride; depression; comparisons, 2242

Serums; globulin immune; cytomegalovirus infections, 1831; distribution systems, 1546; shortages, 599; toxicity, 8; use, 1102

Sevelamer hydrochloride; approvals; FDA, 11

Sex; students; pharmaceutical care attitudes, 2330

Sexual harassment; personnel, pharmacy; administration, 117

Sickle-cell trait; analgesics; protocols, 2272

Silybum marianum; overview, 1195

Silymarin; *Silybum marianum*; overview, 1195

Simvastatin

coronary disease; cost-benefit analysis, 1726
substitution; therapeutic, 1107, 1437

Sinusitis; antibiotics; evidence-based reports, 853
Sirolimus; approvals; FDA, 2177

Skeletal muscle relaxants

atracurium; overview, Jun 1 suppl S4
dantrolene; pharmacoeconomic models, Jun 1 suppl S18
magnesium sulfate; status asthmaticus, 997
mivacurium, Jun 1 suppl S4
operating rooms; pharmaceutical services, 977
pancuronium; overview
pharmacoeconomics; models, Jun 1 suppl S18
rapacuronium; pharmacokinetics, pharmacodynamics, Jun 1 suppl S14
rapacuronium bromide; FDA approvals, 2178
rocuronium bromide; toxicity, 1114
succinylcholine; overview, Jun 1 suppl S4; pharmacoeconomic models, Jun 1 suppl S18
toxicity; monitoring, Jun 1 suppl S10; neuromuscular diseases, 72

Skilled-nursing facilities; reimbursement; prospective-pricing system, 2012

Sleep disorders

Hypericum perforatum; overview, 329
melatonin; overview, 2523

Smoking

cannabis; medical use, 940
cessation; ASHP protocols, 460; pharmacists' role, 425

Social workers; home health care; team, 473

Sociology

hospital pharmacy; quality assurance, 909
low income; coronary disease prophylaxis, 2319;
immunization, 2398
parenteral nutrition; home health care, 270
pharmacists; practice change, 2458

Sodium bicarbonate; diluents; gastrointestinal drugs, 81

Sodium chloride

diluents; cefepime incompatibilities, 1134; doxorubicin, etoposide, vincristine, 985; fumagillin ophthalmic solutions, 547; milrinone injections, 63; tacrolimus incompatibilities, 164; tirofiban incompatibilities, 1627; urokinase, 2047
incompatibilities; cefepime, 457
vehicles; topotecan incompatibilities, 875

Sodium ferric gluconate complex; approvals; FDA, 706

Sodium nitroprusside; incompatibilities; levofloxacin, 1458

Solutions; alteplase; stability, 2056

Solutions, ophthalmic; fumagillin bicyclohexylammonium; stability, 547

Sumatriptan; prescribing; physicians, 51

Specialties

pharmacy; certification examinations, 419; survey, 1342

physicians; inpatients, 596

Stability

alteplase; cryopreserved, 2056
cefepime hydrochloride; incompatibilities, 457, 1134

ceftazidime; incompatibilities, 246
dihydroergotamine mesylate; incompatibilities, 1835

doxorubicin hydrochloride; incompatibilities, 985
etoposide; incompatibilities, 985

fumagillin bicyclohexylammonium; ophthalmic solutions, 547

ganciclovir sodium; compounding, 1738

gentamicin; laboratory tests, 1457

lamotrigine; suspensions, 240

levofloxacin; compounding, 2316; Y-site injections, 1458

milrinone lactate; Y-site injections, 63
mycophenolate mofetil; suspensions, 2224

olanzapine; tablets, 2245

parenteral nutrition; compounding, 815
polyvinyl chloride; DEHP leaching, 1490

prescription drugs; mail order, 2008
promethazine hydrochloride; incompatibilities, 1835

rifabutin; compounding, 333
sumatriptan succinate; incompatibilities, 983

tacrolimus; incompatibilities, 164

terbinafine hydrochloride; suspensions, 243

tirofiban hydrochloride; incompatibilities, 1627
topotecan hydrochloride; incompatibilities, 875

urokinase; storage, 1350; temperature, 2047

vaccines; temperature, 2052
valacyclovir hydrochloride; incompatibilities, 1957

vancomycin; laboratory tests, 1457

vancomycin hydrochloride; incompatibilities, 246
vincristine sulfate; incompatibilities, 985

Standards

American Society of Health-System Pharmacists; guidelines, 1829

Food and Drug Administration; new drug approvals, 404

home health care; ASHP guidelines, 629; JCAHO, 1348

Joint Commission on Accreditation of Healthcare Organizations; clinical studies, 252; home health care, 911; compliance, 887; hospitals, 1699

medicinal plants; U.S., 1927

National Committee for Quality Assurance; managed care accreditation, 2270; managed care systems, 846

pharmacists, community; managed care systems, 566

storage; prescription drugs, 2008

Staphylococcal skin infections; quinupristin, combination, dalbapristin; FDA approvals, 2174

Statistics

Food and Drug Administration; drug approvals, 408

integrated health care; survey, 1392
managed care systems; membership, 505

pharmacogenomics; overview, 27

Status asthmaticus; magnesium sulfate; pediatric, 997

Sterile products; hospital pharmacy; planning and design, 1978

Steroids, corticosteroids

allergies; infliximab adverse reactions, 11
dexamethasone sodium phosphate; topotecan incompatibilities, 875

hydrocortisone sodium succinate; promethazine extravasation, 1742

protocols; nausea and vomiting, 729

Storage

alteplase; cryopreserved, 2056
cefepime hydrochloride; incompatibilities, 457, 1134

ceftazidime; incompatibilities, 246
dihydroergotamine mesylate; incompatibilities, 1835

doxorubicin hydrochloride; incompatibilities, 985
drugs; donations, 2016

etoposide; incompatibilities, 985
fumagillin bicyclohexylammonium; stability, 547

ganciclovir sodium; oral liquids, 1738
lamotrigine; suspensions, 240

levofloxacin; incompatibilities, 1458; oral liquid, 2316

milrinone lactate; injections, 63
mycophenolate mofetil; suspensions, 2224

prescription drugs; mail order, 2008
promethazine hydrochloride; incompatibilities, 1835

rifabutin; suspensions, 333
sumatriptan succinate; incompatibilities, 983

tacrolimus; incompatibilities, 164
terbinafine hydrochloride; suspensions, 243

tirofiban hydrochloride; incompatibilities, 1627
topotecan hydrochloride; incompatibilities, 875

urokinase; stability, 1350, 2047
vaccines; temperature, 2052

valacyclovir hydrochloride; incompatibilities, 1957
vancomycin hydrochloride; incompatibilities, 246

vincristine sulfate; incompatibilities, 985

Strategic planning

pharmaceutical services; administration, 2533
pharmacy, community; organizations, 1915

Strawberry syrup; sweetening agents; levofloxacin stability, 2316

Streptococcal infections; quinupristin, combination, dalbapristin; FDA approvals, 2174

Streptococcus pneumoniae; resistance; anti-infective agents, Nov 15 suppl S4

Substitution

generic; transplantation pharmacists' attitudes, 615
therapeutic; ambulatory care, 1307; antileptic agents, 1107; antimicrobial pharmacoeconomics, Nov 15 suppl S25; doxazosin-terazosin, 1351;

esterified vs. conjugated estrogens, 537; HMG-CoA reductase inhibitors, 1437; managed care systems, 467

Succinylcholine

overview, Jun 1 suppl S4
pharmacoeconomics; models, Jun 1 suppl S18

Suicides

ethics; assisted, 1661, 1672
laws; assisted, 260

Sulfamethoxazole; combination, trimethoprim; toxicity, Dec 15 suppl S5

Sulfonamides; sulfamethoxazole, combination, trimethoprim; toxicity, Dec 15 suppl S5

Sumatriptan; use; reimbursement, 2193, 2206

Sumatriptan succinate; incompatibilities; polypropylene, 983

Surgery

antibiotics; ASHP protocols, 1839
fentanyl citrate; cost comparisons, 551

onychomycosis; review, 865
operating rooms; pharmaceutical services, 977

pharmaceutical services; ASHP guidelines, 887
remifentanyl hydrochloride; cost comparisons, 551

toxicity; nausea and vomiting, 729
warfarin; ACCP protocols, 1505

Surgical supplies

administration sets; tirofiban incompatibilities, 1627

gloves; antineoplastics permeation, 2450

Suspending agents; incompatibilities; lamotrigine, 240; mycophenolate suspensions, 2224; rifabutin suspensions, 333; terbinafine, 243; valacyclovir, 1957

Suspensions

lamotrigine; incompatibilities, 240
lansoprazole; clinical studies, Dec 1 suppl S18; compounding, 81

mycophenolate mofetil; incompatibilities, 2224
omeprazole; clinical studies, Dec 1 suppl S18; compounding, 81

rifabutin; stability, 333
terbinafine hydrochloride; incompatibilities, 243

valacyclovir hydrochloride; compounding, 1957

Sustained-action medications

acetaminophen; overdose, 1081
glipizide; formulary conversions, 454

pentoxifylline; tablets, 1529

Sweetening agents

cherry syrup; rifabutin stability, 333
incompatibilities; ganciclovir, 1738; mycophenolate suspensions, 2224

strawberry syrup; levofloxacin stability, 2316

Sympatholytic agents

β -blockers; alcohol withdrawal syndrome, 175;
congestive heart failure, 1445; contraindications, 1334; heart failure, 503; myocardial infarction, 858

dihydroergotamine mesylate; incompatibilities, 1835

doxazosin; therapeutic substitution, 1351
terazosin; therapeutic substitution, 1351

Sympathomimetic agents

clonidine; alcohol withdrawal delirium, 175
epinephrine; infliximab adverse reactions, 11

ipratropium bromide; toxicity, 914
levalbuterol hydrochloride; FDA approvals, 849

Syringes

polypropylene; cefepime incompatibilities, 457, 1134; promethazine-dihydroergotamine incompatibilities, 1835; sumatriptan incompatibilities, 983

urokinase; incompatibilities, 1350

Syrups; incompatibilities; valacyclovir, 1957

T**Tablets**

crushing; enteral nutrition, 1441; pentoxifylline, 1529

fosinopril sodium; splitting, 2542
olanzapine; stability, 2245

serotonin-reuptake inhibitors; costs, 23
valacyclovir hydrochloride; suspension compounding, 1957

warfarin sodium; rectal administration, 2140

Tacrolimus; incompatibilities; injections, 164
Taste; cholestyramine resin; formulations, 80

Taxonomy; errors, medication; NCCMERP guidelines, 314

Team

ambulatory care; pharmaceutical services, 2431
health care; technicians' role, 1602

health professions; cystic fibrosis programs, 158
home health care; decision-making, 473

hospital pharmacy; patient-focused care, 324
pharmacists; disasters, 716

pharmacy; interdisciplinary, 12

Technicians, pharmacy, see **Personnel, pharmacy**; supportive

Annual Index

Technology

fax; data collection, 2540
pharmaceutical services; year 2000, 2533
pharmacogenomics; pharmacy practice, 27
telemedicine; pharmaceutical services, 1405
United States; Y2K, 2181

Tegafur; colorectal neoplasms; review, 2417

Telecommunications

managed care systems; patient information, 2391
pharmacists; patient counseling, 860
pharmacists, community; electronic prescriptions, 1351
pharmacy, community; electronic prescriptions, 1351
physicians; metformin use, 2535

Telemedicine; technology; pharmaceutical services, 1405

Telepharmacy; pharmaceutical services; APHA policies, 706; pharmaceutical care, 1405

Telephone; ambulatory care; warfarin clinics, 1540

Telephones; hospital pharmacy; Y2K, 1922

Temozolomide

approvals; FDA, 1910

overview, 2529

Temperature

alteplase; stability, 2056
cefepime hydrochloride; incompatibilities, 457, 1134

ceftazidime; incompatibilities, 246

dihydroergotamine mesylate; stability, 1835

doxorubicin hydrochloride; incompatibilities, 985

etoposide; incompatibilities, 985

fumagillin bicyclohexylammonium; stability, 547

lamotrigine; stability, 240

levofloxacin; stability, 2316

mycophenolate mofetil; storage, 2224

prescription drugs; stability, 2008

promethazine hydrochloride; stability, 1835

ribavirin; stability, 333

sumatriptan succinate; incompatibilities, 983

terbinafine hydrochloride; stability, 243

urokinase; stability, 2047; storage, 1350

vaccines; stability, 2052

valacyclovir hydrochloride; incompatibilities, 1957

vancomycin hydrochloride; incompatibilities, 246

vincristine sulfate; incompatibilities, 985

Terazosin; substitution; therapeutic, 1351

Terbinafine hydrochloride

onychomycosis; review, 865

stability; suspensions, 243

Tests

documentation; clinical pharmacists, 420

equivalency; generic; transplantation pharmacists' attitudes, 615

gentamicin; blood levels, 145s7

International Normalized Ratio; warfarin, 1619

vancomycin; blood levels, 1457

warfarin; pharmaceutical services, 443

Texas; education, pharmaceutical; residencies, funding, 1391

Thalidomide; prescribing; hospital pharmacy policies, 1721

Thawing

alteplase; stability, 2056

urokinase; stability, 2047

Theophylline; interactions; cimetidine, 1890

Therapeutic interchange, see **Substitution**;

therapeutic

Therapy Consultation, 175, 267, 380, 572, 1259, 1668, 2242

Thickness; gloves; antineoplastics permeation, 2450

Thimerosal; preservatives; vaccines reformulation, 1589

Thiopental; concomitant therapy, 551

Thrombocytopenia; melatonin; overview, 2523

Thrombolytic agents

alteplase; stability, 2056

urokinase; incompatibilities, 1350; stability, 2047

Thrombophlebitis; warfarin; protocols, 1505

Thrombosis

catheters; toxicity, 1350

urokinase; catheters, 1350

warfarin; protocols, 1505; toxicity, 1540

Thyroid drugs; levothyroxine; generic equivalency, 1912

Ticarcillin disodium; combination, clavulanate

potassium; topotecan incompatibilities, 875

Time studies

clinical pharmacists; benchmarking, 516

drug distribution; automation, 1542

pharmacists, hospital; ambulatory care, 225

Tinnitus; melatonin; overview, 2523

Tirofiban hydrochloride; incompatibilities; stability, 1627

Tobacco

nicotine; cessation protocols, 460

patient education; smoking cessation, 460

Tolcapone

adverse reactions; liver failure, 8

Parkinson's disease; review, 2195

Topical preparations

allretinoin; FDA approvals, 603

antifungals; onychomycosis, 865

Topotecan hydrochloride; incompatibilities; i.v. injections, 875

Toxicity

acetaminophen; overdose, 1081, 1774

acetohexamide; medication errors, 2463

acids, fatty; overview, 719

alatrofloxacin; liver failure, 1388

alcohols, ethyl; alcoholism, 175

allretinoin, 603

amantadine; influenza prophylaxis, 2303

amprenavir, 1057

analgesics and antipyretics; nonprescription, 1126;

rational therapy, 1079

antibiotics; home health care, 76

antidiabetic agents; patient consultation, 1535

antineoplastic agents; cosmetics, 208; nausea and vomiting, 728, 729; neutropenia, 1330; state nursing boards, 707

antiretroviral agents; overview, 1011

azithromycin; comparisons, 1521; hearing loss, 380

blood derivatives; documentation, FDA regulations, 2274

cannabis; lung diseases, 940

celecoxib; gastrointestinal, 106; mechanism of action, 403

cidofovir; neutropenia, Dec 15 suppl S5

clotazol, 404

cimetidine; interactions, 1890

Cimicifuga racemosa; overview, 1400

citalopram hydrobromide; comparisons, 2242

creatine; overview, 1608

denileukin difitox; overview, 502

dietary supplements; consumer survey, 942

diethylhexyl phthalate; reports, 1490

diphenhydramine hydrochloride; lack, 555

dofetilide; dosage, 2375

doxazosin, 1351

drugs; foreign, identification, 2349; kidney failure, 1961; new FDA approvals, 404; pharmaceutical care, 672; pharmacogenomics, 405; sentinel event policies, 2031; student interventions, 882

Echinacea species; overview, 121

entacapone, 2376

epirubicin hydrochloride, 2177

errors, medication; pharmacists' responsibility, 215

erythromycin; comparisons, 1521

exemestane, 2378

foscarnet; neutropenia, Dec 15 suppl S5

fluoxetine hydrochloride; comparisons, 2242

fluvastatin; comparisons, 2242

ganirelix acetate; overview, 2299

glipizide; immediate vs. sustained release, 454

globulin immune; kidney failure, 8

hydroxyurea, 1554

Hypericum perforatum; overview, 329

influenza vaccines, Sep 1 suppl S3

insulin human; comparisons, 542

insulin lispro; comparisons, 542

ipratropium bromide; vision disorders, 914

kava; overview, 957

ketotifen fumarate; overview, 1926

levobupivacaine hydrochloride, 849

lisinopril; angioneurotic edema, 1773; cough, 914

losartan potassium; cough, 914

medicinal plants; review, 125

melatonin; overview, 2523

mercury; vaccine preservatives, 1589

modafinil; overview, 304

morphine; hyperalgesia, myoclonus, 1009

new drugs; pediatrics, 203; risk management, 1294

nicotine; dependence, 460

nonsteroidal anti-inflammatory agents; gastrointestinal hemorrhage, Dec 1 suppl S5

olanzapine; clinical studies, 2245; cost-benefit analysis, 1559, 1560; neuroleptic malignant syndrome, 1558, 1559

orlistat, 1058

oseltamivir phosphate, 2376

penicillin G benzathine; overdose, 904

pentoxifylline; tablet crushing, 1529

perindopril erbumine; overview, 2037

phosphatidylserine; overview, 2038

pneumococcal vaccines, Sep 1 suppl S3

polio vaccines; poliomyelitis, 1480

promethazine hydrochloride; extravasation, 1742

protease inhibitors; lipomatosis, 2343

proton-pump inhibitors; overview, Dec 1 suppl S3, 511

quinupristin, combination, dalofopristin, 2174

raheprazole sodium; overview, 2300

radiation; nausea and vomiting, 728, 729

rapacuronium bromide, 2178

rocuronium bromide; paralysis, 1114

rofecoxib, 1294; gastrointestinal, 106; overview, 1404

ropinirole hydrochloride, 217

rosiglitazone maleate, 1292; overview, 1925

rotavirus vaccines; intussusception, 1589

sertraline hydrochloride; comparisons, 2242

Silybum marianum; overview, 1195

stimulus, 2177

skeletal muscle relaxants; monitoring, Jun 1 suppl S10; neuromuscular diseases, 72; overview, Jun 1 suppl S4; pharmacokinetics, pharmacodynamics, Jun 1 suppl S14

sulfamethoxazole, combination, trimethoprim; neutropenia, Dec 15 suppl S5

surgery; nausea and vomiting, 729

temozolomide, 1910

terazosin, 1351

tolcapone, 2195

trichlorfon; review, 427

troglitazone; liver failure, 840

trovafoxacin mesylate; liver failure, 1388

ubidecarenone; overview, 519

warfarin; ambulatory care, 1540; hemorrhage, 1505; interactions, 676; phytonadione therapy, 2312

zaleplon, 1912

zanamivir; overview, 2190

zidovudine; neutropenia, Dec 15 suppl S5

Toxicity, environmental

antineoplastic agents; contamination, 1403; gloves permeation, 2450; surface contamination, 1427

aseptic areas; barrier isolators, 1433

olanzapine; tablet splitting, 2245

Transplantation

bone marrow; antimicrobial prophylaxis, 1201;

breast neoplasms, 939

liver; drug costs, 1102

organs; antimicrobial prophylaxis, 1839; generic drug selection, 615

renal; antiviral comparisons, 1831; drug costs, 1102; sirolimus, 2177

stem cells; antibiotic pharmacokinetics, 161

Transportation

prescription drugs; mail order, 2008

vaccines; temperature, 2052

Trichlorfon; Alzheimer's disease; review, 427

Trimethoprim; combination, sulfamethoxazole; toxicity, Dec 15 suppl S5

Triterpenes; *Cimicifuga racemosa*; overview, 1400

Troglitazone; toxicity; liver failure, 840

Trovafoxacin mesylate; toxicity; liver failure, 1388

Tuberculosis; prophylaxis; ASHP protocols, 1201

Tubes; collection; gentamicin and vancomycin, 1457

U

Ubidecarenone; heart failure; overview, 519

Ulcers

prophylaxis; ASHP protocols, 347

proton-pump inhibitors; overview, Dec 1 suppl S3, Dec 1 suppl S5

raheprazole sodium; FDA approvals, 1910

Unions; collective bargaining; APHA policies, 706

United States

computers; Y2K, 2181

formalities; legislation, 2338

globulin immune; shortages, 599

government; year 2000, 1048

laws; medicinal plants, 1927

pharmacy; history, 1758

smoking; prevalence, 460

United States Pharmacopeia; standards; prescription drug storage, 2008

Universities; administration; clinical studies, 171

Uroclil; colorectal neoplasms; review, 2417

Urinary anti-infectives; urinary tract infections; evidence-based therapy, 501

Urinary tract infections

amphotericin B; mycoses, 1929
fluconazole; mycoses, 1929

Urine levels

chromium; parenteral nutrition, 1950
zinc; parenteral nutrition, 1950

Urokinase; stability; storage, 1350; temperature, 2047

V**Vaccines**

diphtheria and tetanus toxoids and pertussis; recalls, 504
hepatitis A; protocols, 2275
influenza; pharmacists' interventions, Sep 1 suppl 53

Lyme disease; FDA approvals, 206
pediatrics; protocols, 1179
pneumococcal; pharmacists' interventions, Sep 1 suppl 53

polio; protocols, 1480
preservatives; mercury toxicity, 1589
protocols; immunization, 303
rotavirus; toxicity, 1589
storage; temperature, 2052

Valacyclovir hydrochloride; incompatibilities; suspending agents, syrups, 1957

Vancomycin

blood levels; collection tubes, 1457
interactions; aminoglycosides, 161
resistance; *E. faecium*, 2174

Vancomycin hydrochloride; incompatibilities; peritoneal dialysis solutions, 246

Vasodilating agents

alprostadil; levofloxacin incompatibilities, 1458
cilostazol; FDA approvals, 404
hydralazine; congestive heart failure, 1445
papaverine hydrochloride; promethazine extravasation, 1742

Vehicles

dextrose; topotecan incompatibilities, 875
sodium chloride; topotecan incompatibilities, 875

Vincristine sulfate; incompatibilities; doxorubicin, etoposide, 985

Virginia; pharmacists; collaborative drug therapy, 943

Vision disorders; ipratropium bromide; toxicity, 914

Vitamin B₁₂; see **Pyridoxine hydrochloride**

Vitamin B₁₂; see **Cyanocobalamin**

Vitamin C; see **Ascorbic acid**

Vitamin E

heart diseases; protocols, 503
hyperlipidemia; alternative medicine, 1668

Vitamins

multiple; hyperlipidemia, 1668
phytonadione; warfarin toxicity, 2312

Volunteers in Health Care; databases; industry charity, 2181

Vomiting; antiemetics; ASHP protocols, 729; pharmacists' role, 728

Voriconazole; candidiasis; review, 525

W**Warfarin**

interactions; cimetidine, 1890; grapefruit juice, 676
monitoring; ambulatory care, 443

tests; laboratory; INR, 1619
thrombosis; protocols, 1505

toxicity; ambulatory care, 1540; phytonadione therapy, 2312

Warfarin sodium; tablets; rectal administration, 2140

Wastage

drugs; control, 887
goserelin acetate; implants, 277

Water for injection

diluents; alteplase, 2056; cefepime incompatibilities, 1134; gastrointestinal drugs, 81
incompatibilities; cefepime, 457; urokinase, 1350

Wholesalers; pricing; lawsuits, 113

Withdrawal, see **Drug withdrawal**

Women

drugs; adverse reactions; hospital admissions, 450
osteoporosis; postmenopause, 206

Workload

hospital pharmacy; clinical studies, 337
pharmacists; ambulatory care, 443
pharmacy; community; electronic prescriptions, 1351

World Health Organization; guidelines; drug donations, 2016

World Wide Web

American Society of Health-System Pharmacists; continuing education, 21
drug information; accuracy, 2308

hospital pharmacy; information, 2290

patient information; guidelines, 212

Writing; journals; pharmacy, 1353

Z

Zaleplon; approvals; FDA, 1912

Zanamivir

approvals; FDA, 1696
overview, 2190

Zidovudine

acquired immunodeficiency syndrome; cytomegalovirus retinitis, 1314

toxicity; neutropenia, Dec 15 suppl 55, 517

Zinc; parenteral nutrition; pediatrics, 1950

Zollinger-Ellison syndrome; rabeprazole sodium; FDA approvals, 1910

Author Index

A

Aamot, Steve M. Expensive lesson in administration of goserelin implant (letter), 277

Abdel-Rahman, Susan M. Stability of fumagillin in an extemporaneously prepared ophthalmic solution, 547

Abdel-Rahman, Susan M. Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 °C, 243

Abel, Steven R. see Brockmiller, Heather, 882

Abell, Thomas L. see Brown, Rex O., 2324

Abraham, Lovely see Henson, Elonia B., 1773

Achusim, Louis E. see Pettit, Herbert E., 2537

Akkerman, Shawn R. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions, 63

Alexis, George see Conlin, Paul R., 2535

Allen, James C. see Sabb, Patricia C., 2463

Allen, Pamela see Berndt, Elizabeth M., 995

Ames, Timothy W. Role of pharmacists on disaster response teams (Management Consultation), 716

Ames, Timothy see also Montello, Michael J., 236

Amin, Sejal P. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO, 1515

Anaizi, Nasr H. Stability of ganciclovir in extemporaneously compounded oral liquids, 1738

Anaizi, Nasr H. see also Swenson, Chad F., 2224

Anderson, James H. Jr. see Glazer, N. Brady, 542

Anderson, Kelly J. Electronic prescriptions in pharmacy (letter), 1351

Anderson, Roger W. see Connor, Thomas H., 1427

Andria, Michael see Leader, W. Greg, 161

Angaran, David M. Telemedicine and telepharmacy: current status and future implications, 1405

Anon Pharmacist positions in Saudi Arabia (letter), 179

Aparasu, Rajender R. Inappropriate prescribing for elderly outpatients, 433

Arenberg, Steven see Ringold, Debra Jones, 142

Armstrong, Todd A. Potential danger from too much acetaminophen in opiate agonist combination products (letter), 1774

Asclone, Frank J. see Mannebach, Mark A., 622

ASHP Executive Office Request for donations of *Mirror to Hospital Pharmacy* (letter), 2464

B

Bach, David S. see Higgins, Barbara, 977

Bagozzi, Richard P. see Mannebach, Mark A., 622

Bailey, Michael see Rayner, Craig R., 1457

Baillie, George R. see Mason, Nancy A., 1623

Baillie, George R. see also Possidente, Carl J., 1961

Bair, Teri L. see Cato, Martha A., 1672

Balthasar, Joseph P. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium (letter), 1891

Baluch, William M. Therapeutic interchange of conjugated and esterified estrogens in a managed care organization, 537

Baran, Robert W. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling, 1535

Barber, Gerard R. Book review, 2164

Barber, Gerard R. Medicine is changing—so are the bugs (editorial), 523

Barber, Nicholas D. see Dean, Bryony S., 57

Barcta, Joseph see Wutoh, Anthony K., 1314

Barker, Kenneth N. see Flynn, Elizabeth Allan, 1319

Barnadas, Gisela Preparing for parenteral nutrition therapy at home, 270

Baron, Melvin F. The pharmacist as a healer (letter), 576

Bartkowski, Richard R. Evaluating neuromuscular blocking agents. Recent advances in neuromuscular blocking agents, Jun 1 suppl 514

Bartle, W. R. Grapefruit juice might still be factor in warfarin response (letter), 676

Bastyr, Edward J. III see Glazer, N. Brady, 542

Bedford, Nancy K. see Kizer, Kristin M., 914

Benda, William see Grant, Kathryn L., 1927

Bender, Thurza W. see Johnson, Kathy A., 473

Berger, Bruce A. see Flynn, Elizabeth Allan, 1319

Bergquist, Paul A. Stability of tirofiban hydrochloride in three commonly used i.v. solutions and polyvinyl chloride administration sets, 1627

Berndt, Elizabeth M. Filgrastim for treatment of neutropenia in a neonate, 995

Bernstein, Bridget J. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients, 1330

Bernstein, Ira H. see Weideman, Rick A., 1524

Bess, David T. see Henson, Elonia B., 1773

Bess, David Todd see also Kizer, Kristin M., 914

Bevan, David R. Evaluating neuromuscular blocking agents. Monitoring and reversal of neuromuscular block, Jun 1 suppl 510

Bhavnani, Sujata M. see Rifenburg, Robert P., 2217

Birk, Carol W. see Brockmiller, Heather, 882

Blalock, Susan J. see Knapp, Katherine K., 2431

Blanchard, Lourdes M. Bernstein, Bridget J., 1330

Bland, Sarah E. Self-study material review, 491

Blandford, Larry see Amin, Sejal P., 1515

Blumenschein, Karen see Howard, Kimberly B., 1521

Blumenschein, Karen see also Ranz, Thomas T., 1334

Bockheim-McGee, Christine see Rockwell, Kenneth Jr., 337

Bonasso, Josephine see Grabenstein, John D. Sep 1 suppl

Bottom, Michael B. Distinct drug-interaction profiles for statins (letter), 1019

Botts, Sheila R. Gabapentin and lamotrigine in bipolar disorder, 1939

Bowles, Susan K. Influenza outbreak in a long-term-care facility: considerations for pharmacy, 2303

Bozovich, Michelle Wanted: ambulatory care pharmacists for cardiovascular task force (letter), 1775

Brackowski, James P. see Henson, Elonia B., 1773

Bradberry, J. Chris see Murphy, John E., 1342

Brish, Linda K. see Rhoney, Denise H., 2047

Broadfield, Larry see Connor, Thomas H., 1427

Brockmiller, Heather Cost impact of Pharm.D. candidates' drug therapy recommendations, 882

Broussard, Malcolm J. see Cato, Martha A., 1672

Brown, Nathaniel see Metcalf, Marilyn, 232

Brown, Rex O. One-year experience with a pharmacist-coordinated nutritional support clinic, 2324

Annual Index

- Brushwood, David B.** Reimbursement for unlabeled medication use, 257
Bryant-Wimp, Jay Partnerships for establishing a hospital-based ambulatory care infusion center, 1974
Bublin, Janice G. Response rates from poster presenters at ASHP meetings (letter), 277
Burke, John Facing up to drug diversion (Management Consultation), 1823
Burkiewicz, Jill S. Incompatibility of ceftriaxone sodium with lactated Ringer's injection (letter), 384
Byrd, Debbie C. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio, 2312

C

- Cahill, Judith A.** Formularies and therapeutic interchange in managed care (letter), 1776
Cain, Debbie A. Experience of a home infusion organization with a performance measurement company, 911
Calis, Karim Anton Bioactivity of cryopreserved platelet solutions, 2056
Canaday, Bruce R. Taking a bold approach to advancing the profession, 1644
Cano, Steven B. Promoting optimal use of β -blockers after myocardial infarction (Managed Care Forum), 858
Cao, Trang M. see Nii, Leslie J., 983
Carlson, Dawn L. Improving the care of hemophiliacs by managing the drug benefit (Managed Care Forum), 1303
Carlstedt, Bruce C. see Mueller, Bruce A., 2464
Carroll, Norman V. Formularies and therapeutic interchange in managed care (letter), 1777
Carroll, Norman V. Formularies and therapeutic interchange: the health care setting makes a difference, 467
Carson, John J. Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults, 2319
Catania, Patrick N. Other sources of stability research (letter), 180
Cates, Marshall Antiparkinsonian drug prescribing in elderly inpatients receiving risperidone therapy (letter), 2139
Cato, Martha A. Perspective on ASHP's assisted-suicide policy, 1672
Cawood, Christi Book review, 1901
Chaffee, Betty J. Book review, 190
Chamberlain, Marvin A. see Edwards, Jennifer, 1350
Chapman, Stanley W. see Cleary, John D., 1529
Chellam, Kezia Choosing what to post on a pharmacy intranet web page (Management Consultation), 2290
Chen, Yingxue see Haslam, John L., 333
Chin, Alfred see Nii, Leslie J., 983
Chio, Christine C. see Johnson, Cary E., 164
Chisholm, Marie A. Factors influencing students' attitudes toward pharmaceutical care, 2330
Chow, Moses S. S. see Dunn, Alisha, 2327
Chow, Moses S. S. see Reddy, Prabashni, 2211
Christensen, Michael L. see Mouser, Jay F., 1950
Cingle, Colleen M. see Malesker, Mark A., 1742
Clark, Steven T. see Wong, Bruce J., 1398
Cleary, John D. Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects, 1529
Clifton, G. Dennis see Ranz, Thomas T., 1334
Cline, Julie Chaffin Intravenous clonidine for hypertensive emergencies, 572
Cochran, Robert M. II see Malesker, Mark A., 1742
Cochren, Brad E. Splitting bupropion extended-release tablets (letter), 575
Cohen, Ira A. see Mannebach, Mark A., 622
Cohen, Lawrence J. see Edgell, Eric T., 1559
Cohen, Michael R. see Smetzer, Judy L., 1263
Colbert James Jr. More citizen-soldier pharmacists needed (letter), 2351
Collins, Robert see Cates, Marshall, 2139
Collins, Veronica see Bowles, Susan K., 2303
Conigliaro, Rosemarie L. Losartan-induced cough after lisinopril therapy (letter), 914
Conlin, Paul R. Use of e-mail for obtaining approval to use a restricted agent, 2535
Connelly, Julie F. Distribution plan for immune globulin intravenous during a shortage, 1546
Connelly, Julie see also Cline, Julie Chaffin, 572

- Connor, Thomas H.** Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs, 2450
Connor, Thomas H. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States, 1427
Cookson, Thomas L. see Fawell, Nabeel G., 2542
Coplin, William M. see Rhoney, Denise H., 2047
Côté, Isabelle see Moisan, Jocelyne, 1437
Couldry, Rick Book review, 490
Couldry, Richard J. see also Knoer, Scott J., 1102
Cox, Emily R. Pharmacists' job satisfaction and perceived utilization of skills, 1733
Crouch, Michael A. see Rodgers, Jo E., 175
Crovo, Robert J. see Piccoro, Lance T., 1326
Crumlish, Kevin see Baran, Robert W., 1535
Cullinane, Ann M. see Calis, Karim Anton, 2056
Cupp, Melanie Johns see Runkel, David R., 267
Curry, Clarence E. Jr. see Murphy, John E., 1342

D

- da Camara, Carlos C.** see Peek, Brian T., 1835
D'Agostino, Joe see Rayner, Craig R., 1457
Daniels, Charles E. see Keravich, Daniel P., 1721
Dans, Peter E. see Goldfarb, Scott D., 2206
Dean, Bryony S. A validated, reliable method of scoring the severity of medication errors, 57
Dees, Debra N. see Cato, Martha A., 1672
Deeter, Robert G. see Fish, Douglas N., 1957
Dejong, Douglas J. see McDaniel, Michael R., 2230
Dentinger, Paul J. see Anaizi, Nasr H., 1738
Dentinger, Paul J. see also Swenson, Chad F., 2224
Devenport, Craig Pharmacy and therapeutics committee "virtual" meetings (letter), 1132
Devereaux, Debra S. see Cato, Martha A., 1672
Dib, Jean G. Intravenous magnesium sulfate treatment in a child with status asthmaticus, 997
Dickerson, Roland N. see Brown, Rex O., 2324
Diener, Kathy see Rorstad, Amy, 1273
Dillon, Michael J. Formularies and therapeutic interchange in managed care (letter), 1776
Dix, Jackie see Patel, Avni, 1991
Dixon, Wanda S. see Piccoro, Lance T., 1326
Dolovich, Lisa Book review, 1282
Dong, Betty J. Prophylaxis after nonoccupational exposure to HIV, 1011
Donley, Kathleen D. see Cato, Martha A., 1672
Dorko, Craig see Byrd, Debbie C., 2312
Du, Chengan see Wolfe, Janet L., 985
Duncan, Babette S. see Amin, Sejal P., 1515
Duncan, Babette S. see also Goldfarb, Scott D., 2206
Dunn, Alisha Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro, 2327
Dunn, Alisha see also Reddy, Prabashni, 2211
Duong, Phong see Baran, Robert W., 1535

E

- Eastham, John H.** see McAndrews, Kenneth L. Jr., 81
Eckert, George J. see Murray, Michael D., 225
Edgell, Eric T. Benefits of olanzapine as first-line schizophrenia therapy (letter), 1559
Edwards, Jennifer Clinical usefulness of urokinase after dilution and freezing (letter), 1350
Egodage, Kamal L. see Haslam, John L., 333
Eley, John G. Book review, 926
Elliott, William J. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction, 1726
Engle, Kelley K. Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition, 1441
Engstrom, Fayette M. see Dib, Jean G., 997
Ereshefsky, Larry All guidelines are not the same (editorial), 1829
Ernst, Michael E. see Micek, Scott T., 2195
Erstad, Brian L. Concerns with defining appropriate uses of albumin by meta-analysis, 1451
Erwin, W. Gary see Baran, Robert W., 1535
Evans, Pamela C. see Cleary, John D., 1529

F

- Fan, Jian-Hua** see Saltzman, Connie L., 1458
Fawell, Nabeel G. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance, 2542
Federico, Frank Importance of documenting your services (editorial), 2415
Feld, Andrew see Metcalf, Marilyn, 232
Fera, Toni Book review, 1034
Ferris, David J. Controlling myoclonus after high-dosage morphine infusions, 1009
Fillbeck, Donald J. Developing a care plan, 1348
Firsov, Alexander A. see Zinner, Stephen H., Nov 15 suppl S12
Fish, Douglas N. Nonsurgical antimicrobial prophylaxis: guidelines (and bugs) in evolution (editorial), 1199
Fish, Douglas N. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids, 1957
Fisher, Dennis M. Evaluating neuromuscular blocking agents. Clinical pharmacology of neuromuscular blocking agents, Jun 1 suppl S4
Fitchett, Linda see Golz, Barbara, 904
Fitzpatrick, Valerie see Cox, Emily R., 1733
Flake, Lisa J. Developing an immunization program (Frontline Pharmacist), 2398
Flynn, Elizabeth Allan Impact of interruptions and distractions on dispensing errors in an ambulatory care pharmacy, 1319
Folker, Tanya see Knoer, Scott J., 1102
Folstad, Jon see Hritcko, Philip, 2227
Fontana, Eleonora M. see VandenBussche, Heather L., 2316
Foss, Melissa T. Efficient operation of a high-volume anticoagulation clinic, 443
Fotis, Michael A. see Lothian, Scott T., 1119
Frank, Kirk J. Monitoring temperature-sensitive vaccines and immunologic drugs, including anthrax vaccine, 2052
Frear, Raulo S. see Nelson, Winnie W., 51
Freeman-Bosco, Linda see Reddy, Prabashni, 2211

G

- Gailey, Ronald A.** see Saltzman, Connie L., 1458
Gaither, Caroline A. see Mannebach, Mark A., 622
Gale, Fred see Metcalf, Marilyn, 232
Gales, Barry J. see Bublin, Janice G., 277
Gales, Mark A. see Bublin, Janice G., 277
Gallagher, Marianne Home care pharmacist competency assessment program, 1549
Gallelli, Joseph F. see Wolfe, Janet L., 985
Gardner, Jacqueline S. see Baluch, William M., 537
Gates, Dennis M. Self-study material review, 2258
Gaudet, Michel see Moisan, Jocelyne, 1437
Gauen Suzanne Ways to help patients quit smoking (editorial), 425
Geletko, Sandra Using a pharmacist's progress-note form to manage HIV pharmacotherapy (Frontline Pharmacist), 420
Gelone, Steven P. Hydroxyurea in the treatment of human immunodeficiency virus infection, 1554
Gennaro, Alfonso R. see Mayron, David, 875
Gibson, J. Tyrone see Flynn, Elizabeth Allan, 1319
Gill, Mark A. see Nii, Leslie J., 983
Glaizer, N. Bradley Safety of insulin lispro: pooled data from clinical trials, 542
Gleason, Patrick P. see Conigliaro, Rosemarie L., 914
Goldfarb, Scott D. HMO direct costs and health care resource use after implementation of a monthly limit on sumatriptan, 2206
Goldspiel, Barry R. see Wolfe, Janet L., 985
Golembiewski, Julie A. Improving antiemetic prophylaxis in ambulatory surgery (editorial), 728
Golz, Barbara Nurses' perspective on a serious adverse drug event, 904
Gouvêa, William A. At center stage: pharmacy in the next century, 1613
Gouvêa, William A. Pharmacy practice management in the next century (editorial), 2533
Grabenstein, John D. Health-system pharmacists' role in immunizing adults against pneumococcal disease and influenza, Sep 1 suppl
Grant, Kathryn L. Should nature be standardized? (editorial), 1927
Greengold, Nancy L. Can science measure art? 2336

Grégoire, Jean-Pierre see Moisan, Jocelyne, 1437
Gresham, Colleen Helping patients plan for emergencies (letter), 2554
Grier, Donna see Valdez, Connie, 23
Grimes, George J. see Wolfe, Janet L., 985
Gubbins, Paul O. Current management of funguria, 1929
Guenette, Amy J. see Schumock, Glen T., 1945
Gupchup, Gireesh V. see Sen Shuvayu S., 1965

H

Haese, Diane Den see Rifenburg, Robert P., 2217
Hagen, Joanne C. see Johnson, Kathy A., 473
Hailemeskel, Bisrat Nonformulary drug requests as a guide in formulary system management (letter), 818
Hak, Emily B. see Mouser, Jay F., 1950
Hak, Lawrence J. see Brown, Rex O., 2324
Hamann, Gale L. see Byrd, Debbie C., 2312
Hamilton, Cindy W. Bad medical writing as a barrier to communication (letter), 1353
Hamilton, Robert A. see Saltsman, Connie L., 450, 1990
Hammond, Connie Finding drug link to reaction (letter), 1558
Hammond, Raymond W. see Reichert, Shay L., 1715
Hammonds, Barbara see Schultheis, Naomi, 21
Han, Ron Yieng-Hau see Bergquist, Paul A., 1627
Hanna, Mona see Berndt, Elizabeth M., 995
Hannawa, Tana E. see Engle, Kelley K., 1441
Hannon, Patricia R. see Kraus, Donna M., 1094
Harrison, Bruce R. Exposure to hazardous drugs: time to reevaluate your program? (editorial), 1403
Hasegawa, Elizabeth Managed migraine (editorial), 2193
Hasegawa, Guy R. Medication errors: Integrating individual and system accountability (letter), 1264
Hasegawa, Guy R. Responsibility for medication errors (editorial), 215
Haslam, John L. Stability of rifabutin in two extemporaneously compounded oral liquids, 333
Hatfield, Catherine L. Quality of consumer drug information provided by four Web sites, 2308
Heaton, Alan see Carlson, Dawn L., 1303
Helms, Richard A. see Mouser, Jay F., 1950
Henson, Elionia B. Penile angioedema possibly related to lisinopril (letter), 1773
Hetey, Stephen K. Translating an idea into a product at ASHP (Questions and Answers), 1301
Hidalgo, Julia see Wutoh, Anthony K., 1314
Higgins, Barbara Effect of pharmaceutical services on adherence to criteria-for-use guidelines in the operating room, 977
Hikali, Ahmed H. see Cleary, John D., 1529
Hipple, Thomas F. see Nahata, Milap C., 240
Hisel, Tina Improving outcomes in congestive heart failure, 1445
Hoffman, Richard M. see Jansen, David J., Jr., 1351
Hogue, Susan Cost analysis of remifentanyl and fentanyl for neurosurgical anesthesia, 551
Hollimon, Teresa D. see Thomas, Kimberly V., 2242
Holland, Ross W. Transitions, part 1: beyond pharmaceutical care, 1758
Holland, Ross W. Transitions in pharmacy practice, part 3: effecting change—the three-ring circus, 2235
Holland, Ross W. see also Nimmo, Christine M., 1981, 2458
Holtzer, Christopher D. see Varav, Harry, 273
Hood, Virginia L. see Possidente, Carl J., 1961
Hopeff, Alan Medication errors: Integrating individual and system accountability (letter), 1262
Hopeff, Alan Plasticizers in perspective (letter), 2141
Horne McDonald K. III see Calis, Karim Anton, 2056
Hostettler, Charles F. see Normark, James W., 568
Howard, Kimberly B. Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis, 1521
Howden, Colin W. Update on the use of proton-pump inhibitors in the hospital setting. Introduction, Dec 1 suppl 53
Howden, Colin W. Update on the use of proton-pump inhibitors in the hospital setting. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding, Dec 1 suppl 55
Hritckio, Philip Treatment of hypercholesterolemia with oral neomycin, 2227

Hunke, William A. see Bergquist, Paul A., 1627
Hunter, Barney H. Be wary of computer interfaces and Y2K (letter), 674
Hutchinson, Doreen Getting to the bottom of a sentinel event (Management Consultation), 2031
Hysaw, Amanda Pitts Self-study material review, 2256
Huff, Patricia see McNicholl, Joan Jovero, 2553

I

Ignoffo, Robert J. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer, 2417
Ioannides-Demos, Lisa L. see Rayner, Craig R., 1457
Isabelle, Carol Long-term heavy use of diphenhydramine without anticholinergic delirium, 555
Ito, Matthew K. A matter of taste (letter), 80
Ito, Matthew K. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP), 1107
Ito, Matthew K. see also Stolley, Stephen N., 1988

J

Jacobson, Jody Counseling the deaf and hearing-impaired (Frontline Pharmacist), 610
Jacobson, Pamela A. see Johnson, Cary E., 164
Jagers, Leslie Dotson Pharmacogenomics: worth of pharmacy's attention (editorial), 27
Jansen, David J., Jr. Doxazosin-to-terazosin switch for benign prostatic hyperplasia (letter), 1351
Jaresko, George Update on the treatment of neutropenia in HIV-infected patients. Etiology of neutropenia in HIV-infected patients, Dec 15 suppl 55
Johnson, Carrie L. see Sachdev, Gloria P., 1505
Johnson, Cary E. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous co-administration, 164
Johnson, Cary E. see also VandenBussche, Heather L., 2316
Johnson, Curtis A. see Mason, Nancy A., 1623
Johnson, Kathy A. Multidisciplinary approach to improving pediatric home infusion, 473
Johnstone, Bryan M. see Edgell, Eric T., 1559
Jones, Edward see Rockwell, Kenneth Jr., 337
Jones, Rick Evidence-based medicine for children (editorial), 331
Jones, Ronald N. Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections, Nov 15 suppl 54
Jungnickel, Paul W. see Murphy, John E., 1342

K

Kalash, Leslie D. Book review, 2565
Kane, Michael P. see Tom, Catherine M., 865
Kang-Birken, S. Lena Paronychia of the great toes associated with protease inhibitors (letter), 1674
Kapadia, Vaishali K. see Hritckio, Philip, 2227
Katz, Lynn E. see Nesbit, Suzanne A., 872
Kaufman, Michele B. Book review, 1034
Keith, Matthew R. Televideo technology for patient counseling and education (Frontline Pharmacist), 860
Kelvas, Martin see Hailemeskel, Bisrat, 818
Kenney, Robert R. see Bergquist, Paul A., 1627
Kennie, Natalie see Bowles, Susan K., 2303
Kepple, Stephen R. Pharm.D. student takes interdisciplinary path to career goals (News), 12
Keravich, Daniel P. Challenges of thalidomide distribution in a hospital setting, 1721
Kessel, Kellie K. see Leader, W. Greg, 161
Khan, Zeba M. Fax technology for collecting outcomes data in a computer database, 2540
Kielty, Michael Improving the prior-authorization process to the satisfaction of customers (Managed Care Forum), 1499
King, Jerri O. see Leaf, Emily, 454
Kirk, James see Metcalf, Marilyn, 232
Kizer, Kristin M. Blurred vision from ipratropium bromide inhalation (letter), 914
Klepser, Michael E. see Klepser, Teresa Bailey, 125
Klepser, Michael E. see also Lewis, Russell E., 525

Klepser, Teresa Bailey Unsafe and potentially safe herbal therapies, 125
Knapp, Katherine K. ASHP survey of ambulatory care responsibilities of pharmacists in managed care and integrated health systems—1999, 2431
Knapp, Katherine K. Charting the demand for pharmacists in the managed care era, 1309
Knoer, Scott J. Evaluating a benchmarking database and identifying cost reduction opportunities by diagnosis-related group, 1102
Koeller, Jim M. see Khan, Zeba M., 2540
Koh-Knox, Cynthia P. see Brockmiller, Heather, 882
Kolar, Maria M. see Moherman, Lisa J., 1540
Kondo, Jan T. Book review, 1576
Kostman, Jay R. see Gelone, Steven P., 1554
Kotabe, Sharon see Lo, Shiao-Huei Eunice, 380
Kraus, Donna M. Infant acceptance and effectiveness of a new oral liquid medication delivery system, 1094
Krauss, Ruth H. see Baluch, William M., 537
Krenzelok, Edward P. see Zed, Peter J., 1081
Krum, Henry see Rayner, Craig R., 1457
Kulick, Jennifer see Berndt, Elizabeth M., 995
Kumpf, Vanessa J. Implementation of safe practices for parenteral nutrition formulations, 815
Kuschinsky, Dick Preparing pharmacy technicians for patient-focused care (Management Consultation), 324
Kuzel, Mary D. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease, 217
Kwon, Ik-Whan G. see Rockwell, Kenneth Jr., 337

L

Lam, Nancy P. Hepatitis C: natural history, diagnosis, and management, 961
Landis, Nancy Tarleton Advocacy group targets PVC I.v. equipment (News), 937
Landis, Nancy Tarleton Alquist retires; helped "grow" state societies, 321
Landis, Nancy Tarleton Companies cooperate in emergency supply program for IGIV (News), 599
Landis, Nancy Tarleton Kenneth Avis dies; "wrote the book" on injectable drug quality (News), 507
Landis, Nancy Tarleton Pharmacy technician helps cancer patients look good (News), 208
Landis, Nancy Tarleton State board disciplines nurses for Dana-Farber overdoses (News), 707
Landis, Nancy Tarleton State boards consider outcomes-based regulation (News), 699
Landis, Nancy Tarleton Virtual pharmacies boast easy access, privacy safeguards (News), 1174
Langlass, Theresa M. Standard gentamicin dosage regimen in neonates, 440
Large, Bruce E. Providing timely discharge counseling (Frontline Pharmacist), 1074
Larijani, Ghassem E. Evaluating neuromuscular blocking agents. Introduction, Jun 1 suppl 53
Leach, Al see Moisan, Jocelyne, 1437
Leader, W. Greg Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants, 161
Leader, W. Greg see also Stamatakis, Mary K., 246
Leaf, Emily Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets, 454
Lemoine, Karen see Cano, Steven B., 858
Letrent, Kristen J. see Scott, Mollie A., 1890
Lewis, Kelly S. Neuromuscular blockade in the intensive care unit, 72
Lewis, Kelly S. Prolonged neuromuscular blockade associated with rocuronium, 1114
Lewis, Russell E. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy, 525
Liebert, Liz see Bryant-Wimp, Jay, 1974
Lin, Jennifer C. see Ito, Matthew K., 1107
Lindsey, D. Craig see Pettit, Herbert E., 2537
Ling, Con Ann Guiding patients through the maze of drug information (Frontline Pharmacist), 212
Lo, Shiao-Huei Eunice Azithromycin-induced hearing loss, 380
Loos, Bonnie see Murray, Michael D., 225
Lothian, Scott T. Cancer pain management through a pharmacist-based analgesic dosing service, 1119
Louie, Marie see Bowles, Susan K., 2303
Lukes, Anita see Overhage, J. Marc, 2444

Annual Index

Lunik, Maurice C. Clinical research: managing the issues, 170
Lyons, John see Lothian, Scott T., 1119

M

Mabry, George see Metcalf, Marilyn, 232
MacKinnon, George E. III Preliminary survey of pharmacists' use of the Internet (letter), 1675
MacLaughlin, Eric J. Importance of identifying foreign drugs (letter), 2349
Maddox, Frances C. see Stewart, James T., 457, 1134
Magnus, Gary H. Changing the routine to suit an automated compounder (Frontline Pharmacist), 25
Magnus, Gary H. Labeling on parenteral nutrient admixtures (letter), 1460
Magnus, Gary H. Planning for Y2K (Management Consultation), 1922
Malesker, Mark A. Extravasation of i.v. promethazine, 1742
Malinowski, Jennifer M. Lipophilic nature of atrovastatin, 1988
Malone, Patrick M. see Anderson, Kelly J., 1351
Malone, Patrick M. see also Malesker, Mark A., 1742
Manasse, Henri R. Jr. Reaching ever higher: positioning ASHP to more effectively meet member needs, 1653
Mannebach, Mark A. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals, 622
Mansur, Jeannell Book review, 1900
Marcus, David B. see Ito, Matthew K., 1107
Markoff, Jeffrey S. see Hatfield, Catherine L., 2308
Marnocha, Rebecca M. Clinical research: business opportunities for pharmacy-based investigational drug services, 249
Martz, Michael D. see Scott, Mollie A., 1890
Mason, Nancy A. Trainees' activities and experiences after a clinical pharmacy dialysis traineeship, 1623
Matzke, Gary R. Book review, 1468
May, Sondra K. see Hatfield, Catherine L., 2308
Mayron, David Stability and compatibility of topecan hydrochloride with selected drugs, 875
McAndrews, Kenneth L. Jr. Omeprazole and lansoprazole suspensions for nasogastric administration (letter), 81
McClain, Brian W. see Nesbit, Suzanne A., 872
McCloskey, William W. see Waning, Brenda J., 1989
McCombs, Janet Book review, 1900
McConnell, Scott A. see Gubbins, Paul O., 1929
McDaniel, Michael R. Justifying pharmacy staffing by presenting pharmacists as investments through return-on-investment analysis, 2230
McDermott, June H. Complementary lipid-lowering therapies, 1668
McKinney, Patrick E. see Pettit, Herbert E., 2537
McKinney, W. Paul see Weideman, Rick A., 1524
McNicholl, Joan Jovero Heart failure management program in a group-model HMO (letter), 2553
Meadows, Andrew B. Integrating pharmacy technicians into the health care team (Management Consultation), 1602
Medicis, Joseph J. Book review, 585
Medicis, Joseph J. see also Schachtner, Jill M., 1999
Mehl, Bernard Projecting future drug expenditures—1999, 31
Meram, Jennifer M. see VandenBussche, Heather L., 2316
Metcalf, Marilyn Health care costs associated with chronic hepatitis B, 232
Micek, Scott T. Tolcapone: a novel approach to Parkinson's disease, 2195
Michaud, Jill see Schumcock, Glen T., 1945
Mickle, Tim R. see Langlass, Theresa M., 440
Miller, Jane L. Advisory panel hears contradictory evidence, backs keeping troglitazone on market (News), 840
Miller, Jane L. Decisions loom on selective COX-2 inhibitors (News), 106
Miller, Jane L. FDA drug-review, surveillance processes under scrutiny (News), 404
Miller, Lisa C. Book review, 1370
Miller, Sarah J. Labeling on parenteral nutrient admixtures (letter), 1460
Min, David I. see Vasquez, Eva M., 615
Mitchell, Amy see Saltsman, Connie L., 1458
Mitsunaga, Lisa see Lo, Shiao-Huei, 380

Moherman, Lisa J. Complication rates for a telephone-based anticoagulation service, 1540
Moisan, Jocelyne Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes, 1437
Mologousis, Nicole M. see MacKinnon, George E., 1675
Montello, Michael J. Therapeutic selection during an emergency response, 236
Montello, Michael J. see also Ames, Timothy W., 716
Moore, David B. see Cato, Martha A., 1672
Moore, Michele see Pihong, Al, 1978
Moran, Errol L. see Normark, James W., 568
Moroso, Richard S. see Nahata, Millap C., 240
Morreale, Anthony P. see Ito, Matthew K., 1107
Mouser, Jay F. Chromium and zinc concentrations in pediatric patients receiving long-term parenteral nutrition, 1950
Mrosz, Nicole see Valdez, Connie, 1710
Mueller, Bruce A. Pharmacy-buzzword bingo (letter), 2464
Mullins, C. Daniel see Amin, Sejal P., 1515
Mullins, Richard E. see Akkerman, Shawn R., 63
Muniz, Edmundo Finding drug link to reaction (letter), 1559
Munshi, Onita see Hogue, Susan, 551
Murphy, Dale P. see Nesbit, Suzanne A., 872
Murphy, John E. A call to arms, 672
Murphy, John E. Opportunities for pharmacy specialists as the delivery of health care changes, 1342
Murray, Michael D. Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions, 225
Myers, Charles E. Artificial shortages of drug supplies (editorial), 727
Myers, Charles E. Medication misadventures: a policy of openness and learning (editorial), 863

N

Nahata, Millap C. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 °C, 240
Nahata, Millap C. see also Abdel-Rahman, Susan M., 243, 547
Nash, Lois see Chellam, Kezia, 2290
Nebel, Anita see Valdez, Connie, 1710
Nelson, Kent M. Improving ambulatory care through therapeutic interchange (editorial), 1307
Nelson, Winnie W. Physician attitudes toward human growth hormone products, 51
Nesbit, Suzanne A. Comparison of two concentrations of amphotericin B bladder irrigation in the treatment of funguria in patients with indwelling urinary catheters, 872
Nicolau, David P. Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: optimizing antimicrobial therapy in respiratory-tract infections, Nov 15 suppl S16
Nil, Leslie J. Stability of sumatriptan succinate in polypropylene syringes, 983
Nimmo, Christine M. Transitions in pharmacy practice, part 2: who does what and why, 1981
Nimmo, Christine M. Transitions in pharmacy practice, part 4: can a leopard change its spots? 2458
Nimmo, Christine M. see also Holland, Ross W., 1758, 2235
Normark, James W. Redefining the practice of military pharmacy, 568
Normoyle, Donald L. see Lewis, Kelly S., 1114
Norton, Linda L. see Yee, William P., 477
Noviasky, John A. Evidence-based pharmacy versus opinion on generic product selection of warfarin (letter), 2246
Nowobilski-Vasilios, Anna Development and preliminary outcomes of a program for administering antimicrobials by i.v. push in home care, 76

O

O'Donnell, Danielle C. Book review, 1272
O'Donnell, Katie see Reese, Lee, 884
Ohlrogge, Kristen D. see Sachdev, Gloria P., 1505
O'Malley, Colleen H. see Knapp, Katherine K., 2431
Osborne, Joel see Weinhold, Frank E., 1190
Ostrander, John Book review, 2495

Overhage, J. Marc. Practical, reliable, comprehensive method for characterizing pharmacists' clinical activities, 2444
Overstreet, Karen M. FDA's guidelines on educational programs (letter), 1775

P

Paladino, Joseph A. Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Pharmacoeconomics of antimicrobial therapy, Nov 15 suppl S25
Paladino, Joseph A. see also Rifenburg, Robert P., 2217
Patel, Avni Students' reactions to ASHP MCM (letter), 1991
Patel, Paru see Higgins, Barbara, 977
Patterson, Heather see Baran, Robert W., 1535
Pearson, Robert E. see Flynn, Elizabeth Allan, 1319
Peckman, Howard J. Alternative method for administering proton-pump inhibitors through nasogastric tubes (letter), 1020
Peek, Brian T. Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination, 1835
Penzak, Scott R. see Gubbins, Paul O., 1929
Pepping, Joseph Black cohosh: *Cimicifuga racemosa* (Alternative Therapies), 1400
Pepping, Joseph Coenzyme Q₁₀ (Alternative Therapies), 519
Pepping, Joseph Creatine (Alternative Therapies), 1608
Pepping, Joseph Echinacea (Alternative Therapies), 121
Pepping, Joseph Kava: *Piper methysticum* (Alternative Therapies), 957
Pepping, Joseph Melatonin (Alternative Therapies), 2523
Pepping, Joseph Milk thistle: *Silybum marianum* (Alternative Therapies), 1195
Pepping, Joseph Omega-3 essential fatty acids (Alternative Therapies), 716
Pepping, Joseph Phosphatidylserine (Alternative Therapies), 2038
Pepping, Joseph St. John's wort: *Hypericum perforatum* (Alternative Therapies), 329
Perry, Paul J. see Stille, Kristine A. Bever, 1560
Peterson, Steven see Metcalf, Marilyn, 232
Petroff, Barbara see Filibeck, Donald J., 1348
Pettit, Herbert E. Toxicology cart for stocking sufficient supplies of poisoning antidotes, 2537
Phillips, Beth Bryles see Hise, Tina, 1445
Phillips, Marjorie Shaw Clinical research: ASHP guidelines and future directions for pharmacists, 344
Piccoro, Lance T. Creating a computerized database from administrative claims data, 1326
Pihong, Al Conversion to isolators in a sterile preparation area, 1978
Piñon, Michael see Geletko, Sandra, 420
Piscitelli, Stephen C. Update on the treatment of neutropenia in HIV-infected patients. Introduction, Dec 15 suppl S3
Piscitelli, Stephen C. see also Struble, Kimberly, 2343
Pitrak, David L. Update on the treatment of neutropenia in HIV-infected patients. Neutrophil deficiency and dysfunction in HIV-infected patients, Dec 15 suppl S9
Poole, Susan Markel see Nowobilski-Vasilios, Anna, 76
Porter, Julie see McNicholl, Joan Jovero, 2553
Porterfield, Pat see Sauder, Chris, 1259
Portuese, Enrico see Carlson, Dawn L., 1303
Possidente, Carl J. Disruptions in drug therapy in long-term dialysis patients who require hospitalization, 1961
Potti, Gopal K. see Wolfe, Janet L., 985
Power, Luci A. see Connor, Thomas H., 1427
Prichard, John G. see Kang-Birken, S. Lena, 1674
Prosser, Theresa see Murphy, John E., 1342

Q

Quercia, Robert A. see Dunn, Alisha, 2327

R

- Rainville, Edward C.** Impact of pharmacist interventions on hospital readmissions for heart failure, 1339
- Rajewski, Roger A.** see Haslam, John L., 333
- Raleigh, Fred R.** Book review, 94
- Ramey, Mark** see Normark, James W., 568
- Rancourt, Melissa D.** see Wong, Bruce J., 1398
- Rankin, Jan** see Hunter, Barney H., 674
- Ranz, Thomas T.** Prevalence and treatment of heart failure in elderly long-term-care patients, 1334
- Rapp, Robert P.** see Howard, Kimberly B., 1521
- Rascati, Karen L.** see Khan, Zeba M., 2540
- Raskind, Jackie** see Botts, Sheila R., 1939
- Rayner, Craig R.** Effect of collection tube on measured gentamicin and vancomycin concentrations (letter), 1457
- Rector, Nancy T.** Be wary of computer interfaces and Y2K (letter), 675
- Reddy, Prabhshni** Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery, 2211
- Reddy, Prabhshni** see also Dunn, Alisha, 2327
- Reed, Cambria** Accuracy of International Normalized Ratio determined by portable whole-blood coagulation monitor versus a central laboratory, 1619
- Reed, Michael D.** High-dose amoxicillin in new guidelines for treatment of otitis media in children (letter), 2351
- Reese, Lee** Use of pharmacists' cognitive services in home health care assessment, 884
- Reese, Pat Ray** see Hogue, Susan, 551
- Regalado, Antonio** Inventing the pharmacogenomics business, 40
- Reichert, Shay L.** Developing a protocol for collaborative drug therapy management (Frontline Pharmacists), 1715
- Reilly, Cynthia** Useful prescription drug information (letter), 478
- Reilly, Joseph P.** Update on the use of proton-pump inhibitors in the hospital setting. Safety profile of the proton-pump inhibitors, Dec 1 suppl S11
- Renes, Paul** see Weinhold, Frank E., 1190
- Resch, Nina D.** see Jansen, David J., Jr., 1351
- Rhee, Walter** see Wutoh, Anthony K., 1314
- Rhoney, Denise H.** Urokinase activity after freezing: implications for thrombolysis in intracranial hemorrhage, 2047
- Richerson, Mark** see Reddy, Prabhshni, 2211
- Rickman, Holly** see Reed, Cambria, 1619
- Rifenburg, Robert P.** Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and *Pseudomonas aeruginosa* susceptibility, 2217
- Ringold, Debra Jones** ASHP national survey of pharmacy practice in acute care settings: prescribing and transcribing—1998, 142
- Robinson, Norbert L.** Benchmarking the allocation of pharmacists' time (Management Consultation), 516
- Rockwell, Kenneth Jr.** Clinical research: national survey of U.S. pharmacy-based investigational drug services—1997, 337
- Rodgers, Jo E.** Phenobarbital for alcohol withdrawal syndrome, 175
- Rohal, Gina M.** see Armstrong, Todd A., 1774
- Rorstad, Amy** Self-study material review, 1273
- Rothenberg, David M.** see Lewis, Kelly S., 72, 1114
- Rublein, John** Book review, 1033
- Rucker, T. Donald** A public-policy strategy for drug formularies: preparation or procrastination? 2338
- Runkel, David R.** Glucosamine sulfate use in osteoarthritis, 267
- Rupp, Michael T.** Establishing realistic performance standards for community pharmacists' drug-use-review activities in managed care contracts, 566
- Ruston, Lisa** see Bowles, Susan K., 2303
- Ryan, Kathleen D.** Driving fear out of the medication-use process so that improvement can occur, 1765
- Ryan, Michael L.** see Mannebach, Mark A., 622

S

- Sabb, Patricia C.** Acetohexamide-acetazolamide mix-up during emergency treatment (letter), 2463

- Sachdev, Gloria P.** Review of the Fifth American College of Chest Physician Consensus Conference on Antithrombotic Therapy: outpatient management for adults, 1505
- St. Peter, Wendy M.** see Mason, Nancy A., 1623
- Saltsman, Connie L.** Compatibility of levofloxacin with 34 medications during simulated Y-site administration (letter), 1458
- Saltsman, Connie L.** Confidence about an odds ratio (letter), 1990
- Saltsman, Connie L.** Risk factors for patient hospitalization, 450
- Sanchez, Lisa A.** Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature, 1630
- Sankari, Bashir** see Walton, Ted, 1831
- Sanks, Ralph J.** A pharmacy manager's perspective on a serious adverse drug event, 907
- Santell, John P.** see Mehl, Bernard, 31
- Santell, John P.** see also Ringold, Debra Jones, 142
- Santucci, Vincent N.** see Lewis, Kelly S., 1114
- Saseen, Joseph** see MacLaughlin, Eric J., 2349
- Sasich, Larry D.** Useful prescription drug information (letter), 477
- Sauder, Chris** Subcutaneous administration of loxapine, 1259
- Schachtner, Jill M.** Book review, 1999
- Schentag, Jerome J.** Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Introduction, Nov 15 suppl S3
- Schentag, Jerome J.** Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients, Nov 15 suppl S21
- Schentag, Jerome J.** see also Rifenburg, Robert P., 2217
- Schneider, Philip J.** Creating an environment for improving the medication-use process, 1769
- Schneider, Philip J.** Five worthy aims for pharmacy's clinical leadership to pursue in improving medication use, 2549
- Schneider, Philip J.** Medication errors: integrating individual and system accountability (letter), 1262
- Schneider, Philip J.** Mirror to health-system pharmacy (editorial), 123
- Schneider, Philip J.** see also Ringold, Debra Jones, 142
- Schoch, Patricia H.** see Foss, Melissa T., 443
- Scholes, Delia** see Baluch, William M., 537
- Schultheis, Naomi** Continuing education in *AJHP* (Questions and Answers), 21
- Schumock, Glen T.** Re-engineering: an opportunity to advance clinical practice in a community hospital, 1945
- Scott, Bruce E.** Keep your eyes on the prize, 1641
- Scott, Mollie A.** Negative outcomes from drug interactions involving cimetidine in older ambulatory care patients (letter), 1890
- Scranton, Shawn S.** see Fawell, Nabeel G., 2542
- Sellers, Jill A.** Keeping up with drug information (editorial), 613
- Sellers, Jill A.** Medicare drug benefit (editorial), 1503
- Sen, Shuvayu S.** Selecting among health-related quality-of-life instruments, 1965
- Sessink, Paul J. M.** see Connor, Thomas H., 1427
- Setter, Stephen M.** Responsible use of analgesics (editorial), 1079
- Shalansky, Karen F.** see Sauder, Chris, 1259
- Shane, Rita** see Gouveia, William A., 2533
- Sharma, Virender K.** Update on the use of proton-pump inhibitors in the hospital setting. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole, Dec 1 suppl S18
- Shaw, James** see Baran, Robert W., 1535
- Shepherd, Michele F.** Rectal administration of warfarin (letter), 2140
- Shirley, Kara Lee** Effect of an automated dispensing system on medication administration time, 1542
- Sickels, Jennifer** see Murphy, John E., 1342
- Simor, Andrew** see Bowles, Susan K., 2303
- Singh, Christine M.** Book review, 1791
- Sintek, Charles D.** see Foss, Melissa T., 443
- Sisca, Thomas S.** see Dib, Jean G., 997
- Sitzman, Scott J.** see Aparasu, Rajender R., 433
- Sloan, Alice S.** see Goldfarb, Scott D., 2206
- Small, Franklin J.** see Geleiko, Sandra, 420
- Smeeding, James** see Khan, Zeba M., 2540
- Smetzer, Judy L.** Medication errors: integrating individual and system accountability (letter), 1263
- Smith, Leo A.** see Flynn, Elizabeth Allan, 1319

- Sonnenschein, Larry** see Weinhold, Frank E., 1190
- Sosnowski, Lorraine** see Filibeck, Donald J., 1348
- Spicer, W. John** see Rayner, Craig R., 1457
- Spooner, Joshua J.** Communicating with plan members by e-mail (Managed Care Forum), 2391
- Stamatakis, Mary K.** Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions, 246
- Stassinis, Martha G.** Book review, 1789
- Stavris, Martha A.** see Berndt, Elizabeth M., 995
- Stedl, Scott** see Wutoh, Anthony K., 1314
- Stella, Valentino** see Haslam, John L., 333
- Stephens, Mark A.** see Byrd, Debbie C., 2312
- Sterner-Allison, Jennifer L.** Management of adolescent and adult inpatients with cystic fibrosis, 158
- Stewart, James T.** Stability of cefepime hydrochloride injection in polypropylene syringes at -20 °C, 4 °C, and 22-24 °C, 457
- Stewart, James T.** Stability of cefepime hydrochloride in polypropylene syringes (letter), 1134
- Stille, Kristine A.** Bever Benefits of olanzapine as first-line schizophrenia therapy (letter), 1560
- Stoblmeier, Leslie A.** see Kraus, Donna M., 1094
- Stolley, Stephen N.** Lipophilic nature of atorvastatin (letter), 1988
- Stolley, Stephen N.** see also Ito, Matthew K., 80, 1107
- Storm, Michael C.** see Mouser, Jay F., 1950
- Struble, Kimberly** Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients, 2343
- Stump, Lisa S.** see Robinson, Norbert L., 516
- Summerfield, Marc R.** Twenty qualities of a desirable pharmacy environment, 909
- Swartwood, Deborah E.** Book review, 1469
- Swenson, Chad F.** Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid, 2224
- Swenson, Chad F.** see also Anaizi, Nasr H., 1738

T

- Taulbee, Michael** see Hunter, Barney H., 674
- Teahan, Jim** see Filibeck, Donald J., 1348
- Thoma, Laura A.** see Wolfe, Janet L., 985
- Thomas Joseph III.** see Sen Shuvayu S., 1965
- Thomas, Kimberly V.** Citalopram versus other selective serotonin-reuptake inhibitors, 2242
- Thomas, Mark** see Weinhold, Frank E., 1190
- Thompson, Cheryl A.** Hospitalists offer prospect for increased efficiencies (News), 596
- Thompson, Cheryl A.** Internet-based prescribing and dispensing trouble medical and pharmacy boards (News), 500
- Thompson, Cheryl A.** Movement to temperature monitoring loses steam (News), 2008
- Thompson, Cheryl A.** Scientific and trade groups clash over 'authoritative' statements for health claims (News), 1286
- Thompson, Cheryl A.** Serious surveillance (editorial), 426
- Tierney, William M.** see Murray, Michael D., 225
- Tillett, Lance** Barrier isolators as an alternative to a cleanroom, 1433
- Tiu, Raquel M.** see Dib, Jean G., 997
- Tom, Catherine M.** Management of toenail onychomycosis, 865
- Tom, Catherine M.** see also Saltsman, Connie L., 1458
- Tong, Kevin L.** see Sauder, Chris, 1259
- Touchette, Mark** see Kuschinsky, Dick, 324
- Tousignant, Dwight R.** Pharmacy's database—in its 30th year (editorial), 1719
- Tracy, Timothy S.** see Stamatakis, Mary K., 246
- Trissel, Lawrence A.** Medication errors: integrating individual and system accountability (letter), 1263
- Trissel, Lawrence A.** Other sources of stability research (letter), 179
- Tu, Wanzhu** see Murray, Michael D., 225
- Turco, Salvatore J.** Removal of pyrogens by filtration? (letter), 477

V

- Vaillancourt, Régis** see Moisan, Jocelyne, 1437
- Valdez, Connie** Determining the most economical SSRI for a Medicare risk contract (Managed Care Forum), 23

Annual Index

- Valdez, Connie** Reducing drug costs of a Medicare-risk population (Managed Care Forum), 1710
- VandenBussche, Heather L.** Stability of levofloxacin in an extemporaneously compounded oral liquid, 2316
- VandenBussche, Heather L.** see also Johnson, Cary E., 164
- Varav, Harry** Simultaneous use of two protease inhibitors in HIV infection, 273
- Vasquez, Eva M.** Transplant pharmacists' opinions on generic product selection of critical-dose drugs, 615
- Veatch, Robert M.** The pharmacist and assisted suicide, 260
- Verzino, Kelly C.** see Connelly, Julie F., 1546
- Vidaurre, Vincent A.** see Fish, Douglas N., 1957
- Vlasses, Peter H.** Clinical research: trends affecting the pharmaceutical industry and the pharmacy profession, 171
- Vogel, David P.** see Smetzer, Judy L., 1263
- von Gunten, Charles F.** see Lothian, Scott T., 1119
- Von Reena, Jamie H.** see Lothian, Scott T., 1119

W

- Wade, William E.** see Chisholm, Marie A., 2330
- Wade, William E.** see also Reese, Lee, 884
- Walton, Ted** Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants, 1831
- Wang, Lorinda S.** see Piccolo, Lance T., 1326
- Waning, Brenda J.** Confidence about an odds ratio (letter), 1989
- Warner, Allen** see Isabelle, Carol, 555
- Warren, Flynn W.** see Stewart, James T., 457, 1134
- Wavrin, Therese M.** see Cato, Martha A., 1672
- Webster, Kathy D.** see Peek, Brian T., 1835
- Weideman, Rick A.** Pharmacist recognition of potential drug interactions, 1524
- Weingarten, Cindy M.** see Rhoney, Denise H.,

2047

- Weinhold, Frank E.** Tracking medication dispensed from a hospital pharmacy (Management Consultation), 1190
- Weir, David R.** see Elliott, William J., 1726
- Weitzman, Sigmund A.** see Lothian, Scott T., 1119
- Weich, Cara Woodson** Robinson-Patman Act and the own-use exemption in health systems, 990
- Werkman, Robert F.** see Brown, Rex O., 2324
- Wermeling, Daniel P.** Clinical research: regulatory issues, 252
- White, C. Michael** see Dunn, Alisha, 2327
- White, C. Michael** see also Reddy, Prabashni, 2211
- White, Paul F.** Evaluating neuromuscular blocking agents. Pharmacoeconomic issues related to selection of neuromuscular blocking agents, Jun 1 suppl S18
- Williams, Bradley R.** Metrifonate: a new agent for the treatment of Alzheimer's disease, 427
- Williams, Karl G.** Labor law and salaried employees (Management Consultation), 2518
- Williams, Karl G.** The need for legal compliance plans in health institutions (Management Consultation), 952
- Williams, Karl G.** New sexual harassment rules under Title VII of the Civil Rights Act of 1964 (Management Consultation), 117
- Williams, Roger F.** see Normark, James W., 568
- Wolfe, Janet L.** Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection, 985
- Wolfgang, Sally A.** Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia (letter), 2245
- Wong, Bruce J.** Choosing an automated dispensing machine (Management Consultation), 1398
- Wong, Roberta J.** Update on the treatment of neutropenia in HIV-infected patients. Treatment of HIV-related neutropenia, Dec 15 suppl S17
- Woo, Olga F.** Book review, 1271
- Woolley, Thomas** see Cates, Marshall, 2139

- Wutoh, Anthony K.** Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994, 1314
- Wylie, J. Douglas** see Baran, Robert W., 1535
- Wyner, Lawrence** see Walton, Ted, 1831

Y

- Yarde, Keith** see Restor, Nancy T., 675
- Yaughn, Kathy** see Akkerman, Shawn R., 63
- Yee, William P.** Removal of pyrogens by filtration? (letter), 477
- Young, Terri** see Hogue, Susan, 551

Z

- Zalani, Sunita** see Glazer, N. Bradley, 542
- Zappala, Fern N.** Are you ready for January 1, 2000? (Questions and Answers), 1066
- Zappala, Fern N.** FDA's guidelines on educational programs (letter), 1775
- Zaran, Frank K.** see Rhoney, Denise H., 2047
- Zed, Peter J.** Treatment of acetaminophen overdose, 1081
- Zhang, Huizhen** see Akkerman, Shawn R., 63
- Zhou, Xiao-Hua** see Murray, Michael D., 225
- Zill, David A.** Financial position: strengthened services and record revenue, 1649
- Zimmerman, Jeffery** see Bergquist, Paul A., 1627
- Zinner, Stephen H.** Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. In vitro dynamic model for determining the comparative pharmacology of fluoroquinolones, Nov 15 suppl S12

Advertising Index

A

- Abbott Laboratories**
Institutional, 103
- Advocate Health Care**
Positions Available, 85, 827
- Albemarle Hospital**
Position Available, 2562
- Allegheny General Hospital**
Positions Available, 185, 1029
- Allergan, Inc.**
Positions Available, 1779
- Alpha Therapeutic Corporation**
Venoglobulin-S, 1151-1152, 1283-1284
- American MECCA**
Position Available, 580
- American Pharmaceutical Partners, Inc.**
Cisplatin, 2373-2374
Institutional, 87-88, 209-210
- American Regent Laboratories, Inc.**
Dexferrum, 101-102, 305-306, 497-498, 721-722, 949-950, 1155-1156, 1377-1378, 1497-1498, 1817-1818, 2045-2046, 2301-2302, 2485-2486
Position Available, 918
- American Society for Parenteral and Enteral Nutrition**
24th Clinical Congress, 2115
- American Society of Consultant Pharmacists**
Institutional, 1053
- American Society of Health-System Pharmacists**
AHFS Drug Information 1999, 86, 291, 524, 871
AHFS Drug Information 2000, 2257, 2267, 2385, 2532
AHFSfirstFAX, 317, 399, 1030, 1718, 1828, 2156
A/HP Reprints, 118, 383, 557, 609, 1035, 1113, 1371, 1402, 2142, 2247, 2561
Ambulatory Care Clinical Skills Program, 550, 775, 913, 1068, 1185, 1304, 1347, 1402, 1502, 1716, 1964, 2130, 2318
Annual Meeting '99, 522, 771, 886, 1021
Appleton & Lange's Review of Pharmacy, Sixth Edition, 1705
ASHP Membership, 95
ASHP Pharmacy Software, 1819, 2154, 2416, 2563
ASHP Section of Clinical Specialists, 489, 587, 2158
ASHP Web Site, 22, 285, 1593
Basic Skills in Interpreting Laboratory Data, 214, 820, 2348
Clinical CQI: A Book of Readings, 180
CliniTrend, 472, 1028
The Complete German Commission E Monographs, 1534
Competence Assessment Tools for Health-System Pharmacists, 28, 287, 332, 419, 521, 1308, 1568, 2150
The Competitive Edge 1999, 679, 915, 982
Concepts in Oncology Therapeutics, Mar 1 IBC, 581, 859, 943
DataKinetics, 256, 1495, 1607
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, Fourth Edition, 1991
Drugs in Pregnancy and Lactation, 574
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 1777, 1826
Handbook of Clinical Drug Data, 1889
The Healthcare Executive Update, 1741, 2548
Herbal Therapy, Medicinal Plants, and Natural Products, 1058, 1603
Home, Hospice, and Long-Term-Care '99, 953, 1198
International Pharmaceutical Abstracts, 1444, 2165
Leadership Conference on Pharmacy Practice Management, 1548, 1629
The Managed Health Care Dictionary, Second Edition, 269, 1426
Managing Oral Anticoagulation Therapy, 272, 479, 2163, 2335
Manual for Pharmacy Technicians, 169
Medication Teaching Manual, 122, 683, 1035, 2142
MedTeach, 26, 513, 1070, 1293
Midyear Clinical Meeting, 1709, 1821, 1928, 2064, 2259, 2283
1998 Oncology Pharmacy Practice Specialty Exam Review Materials, 259, 533
1999 Oncology Pharmacy Practice Specialty Examination Review Materials, 1000
Pharmacoeconomics and Outcomes: Applications for Patient Care, 576
Pharmacology for Technicians, 1673
Pharmacotherapy: A Pathophysiologic Approach, Third Edition, 1944

- Pharmacy Technician Certification Review and Practice Exam, 927, 1026, 1577, 1997, 2403
Pocket Guide to Injectable Drugs, 864, 959, 1060, 1187, 1302, 2557
Positions Available, 282, 820, 1464, 1898
Practical Pharmacokinetics, 449
Preparing the Pharmacy for a Joint Commission Survey, 289, 388, 432, 583, 2143
PSAP III-Pharmacotherapy Self-Assessment Program, 1356, 2490
Psychiatric Pharmacy Practice, 1250
Publications, 1998, 574
Résumés and Personal Statements for Health Professionals, 1261, 2226
The Rx Consultant, 1563, 2358
Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals, Second Edition, 191, 1017, 2073

- AmeriSource**
Institutional, 2287
- Ansell Perry**
Institutional, 2192
- Antelope Valley Hospital**
Positions Available, 2357
- Appalachian Regional Healthcare**
Positions Available, 822, 1995
- Applied Clinical Communications/Novartis**
Symposium, 2063
- ASHP Research and Education Foundation**
Institutional, 2133, 2560
Position Available, 386
- ASHP/Pfizer**
Awards, 2534
- Astra Pharmaceuticals**
Position Available, 1025
- AstraZeneca**
Institutional, 2091
Seroquel, 1487-1488, 2017-2018, 2399-2402
Public Service, 191
- Audubon Center for Birds of Prey**
Public Service, 191
- Aurora Health Care**
Positions Available, 922, 1154, 2471
- AutoMed Technologies**
Institutional, 124, 407, 1080, 2015, 2473
- Avera McKennan**
Positions Available, 2160

B

- Baptist Hospital East**
Positions Available, 84
- Baxter Healthcare Corporation**
Institutional, 2007
Multisource Injectables, 216, 405
Propofol, 695-698, 835-838, 1161-1164, 1287-1290, 1491-1494, 2382-2384
- Bayer Corporation, Pharmaceutical Division**
Position Available, 1146
- Baylor University Medical Center**
Positions Available, 1780, 2153
- B. Braun/McGaw Infusion Systems**
HyperFormer ESP, 595, 1133, Aug 1 IBC
- Becton Dickinson**
Institutional, May 1 IBC, 1135, 1295
- Bedford Laboratories**
Butorphanol Tartrate Injection, 843-844
Daunorubicin HCl, 2083-2084
GluGen for Injection, 2492-2494
Ketorolac Tromethamine, 1071-1072
- Beebe Medical Center**
Position Available, 2155
- Benefits Healthcare**
Position Available, 1027, 1360
- Bergen Brunswick Health Systems**
Institutional, 2035, 2481
- Beth Israel Deaconess Medical Center**
Positions Available, 1678
- Blue Cross and Blue Shield of Michigan**
Position Available, 1786
- Bon Secours Richmond Health System**
Positions Available, 2562
- Boston Medical Center**
Positions Available, 823
- Boston VA Medical Center**
Fellowship Program, 580
- Bowdoin Group, Inc.**
Positions Available, 2254
- Braintree Laboratories, Inc.**
Miralax, 862, 1200, 1297, 1585, 1711, 2125, 2194, 2509
- Brazosport Memorial Hospital**
Position Available, 1678

- Bristol Laboratories Oncology Products, A Bristol-Myers Squibb Company**
Paraplatin, Jan 1 IBC, 1, Mar 1 IBC, 393, May 1 IBC, 831, Jul 1 IBC, 1275, Sep 1 IBC, 1687, Nov 1 IBC, 2167
Taxol, Feb 1 IBC, 193, Apr 1 IBC, 589, Jun 1 IBC, 1037, Aug 1 IBC, 1471, Oct 1 IBC, 1903, Dec 1 IBC, 2361
- Bronx VA Medical Center**
Positions Available, 2250
- Brother to Brother International**
Institutional, 1563
- BryanLGH Medical Center**
Position Available, 486

C

- Cardinal Health System, Inc.**
Institutional, 2377
Position Available, 1361, 1679, 1780
Symposium, 785, 2065
- Carroll County General Hospital**
Position Available, 2354
- Catawba Memorial Hospital**
Position Available, 2474
- Catholic Health Partners**
Positions Available, 486
- Cedars-Sinai Medical Center**
Position Available, 2471
- Centeon**
Institutional, 701, 1145
- Centocor, Inc.**
Remicade, 5-6, 401-402, 789-790
Retavase, 326-328, 422-424, 855-856, 2011-2102
- Centra Health**
Positions Available, 2356
- Central Washington Hospital**
Positions Available, 1361, 1463
- Centre Community Hospital**
Position Available, 2152
- Centura Health**
Position Available, 484, 823
- Charles Sturt University**
Position Available, 1024
- Children's Hospital Columbus**
Position Available, 1465
- Children's Hospital Los Angeles**
Positions Available, 579
- Children's Hospitals and Clinics (Minneapolis)**
Position Available, 920
- Children's Mercy Hospital**
Position Available, 2157
- Christus Santa Rosa Health Care**
Positions Available, 1362
- City Hospital, Inc.**
Position Available, 1266
- College of Psychiatric and Neurologic Pharmacists**
Symposium, 2483
- Columbia Hospital**
Positions Available, 1154
- Columbus Regional Healthcare System**
Position Available, 285
- Consumer Health Information Corporation**
Position Available, 2161
- ContinuingEducation.Com**
Continuing Pharmacy Education, 2285
- Coral Gables Hospital**
Positions Available, 2559
- Corporate Express**
Institutional, 1153
- Cortex Communications**
Institutional, 2060-2061
Position Available, 184
- Covenant Healthcare**
Position Available, 678, 920
- Creighton University**
Position Available, 1683
- CVPH Medical Center**
Position Available, 387, 1993

D

- Dartmouth-Hitchcock Medical Center**
Positions Available, 1462, 2476
- Department of the Army**
Civilian Positions Available, 1144
- Department of Veterans Affairs**
Positions Available, 183, 481, 681, 917, 2147, 2353
- Department of Veterans Affairs (Albuquerque)**
Position Available, 1993

Annual Index

Department of Veterans Affairs (Portland)

Position Available, 1570

Diebold, Incorporated

Institutional, 707
MedSelect, 2069, 2275, 2375

Diversified Pharmaceutical Services, Inc.

Positions Available, 918, 1023

Doctors Medical Center

Position Available, 387, 579, 2356

Duke University Hospital

Position Available, 678

E

E. Fougera & Co., A Division of Altana Inc.

Institutional, Feb 1 IBC, 614, 1073, 1917, 2189
Surgilube, 1485

Egleston Scottish Rite Children's Health Care System

Positions Available, 1570, 1780

Eli Lilly And Company

Positions Available, 2482-2483
Zyprexa, 29-30, Jan 15 IFC, 97, Feb 15 IFC, 293, Mar 15 IFC, 493, Apr 15 IFC, 687, May 15 IFC, 929, 1137-1138, Jun 15 IFC, 1167, Jul 15 IFC, 1373, Aug 15 IFC, 1579, Sep 15 IFC, 1793, Oct 15 IFC, 2001, Nov 15 IFC, 2261, 2487-2488, Dec 15 IFC, 2497

Emory Healthcare

Positions Available, 389, 922, 1996, 2354, 2479

EPS, Inc.

Filters, 711
Institutional, 1481
TampAlert, 1067

Erlander Health System

Position Available, 922

Ernst and Young LLP

Position Available, 2472

ESI Lederle Inc.

Injectables, Mar 1 OBC, Sep 1 IBC, OBC, Dec 1 IBC, OBC

Institutional, Jan 1 OBC, Feb 1 OBC, Jun 1 OBC

Express Scripts

Positions Available, 2152

F

Fallon Healthcare System

Position Available, 1897

FFF Enterprises

Institutional, 2009, 2171, 2269, 2409, 2503

FirstHealth, Moore Regional Hospital

Position Available, 2476

FirstHealth of the Carolinas

Position Available, 824

Fletcher Allen Health Care

Positions Available, 281, 919

Food and Drug Administration

Positions Available, 1896

Forest Laboratories

Positions Available, 2354

Franciscan Health System

Positions Available, 280

Froedtert Memorial Lutheran Hospital

Position Available, 1679

G

Genentech, Inc.

Symposium, 2077

Genesys Regional Medical Center

Positions Available, 680, 1897

Glaxo Wellcome

Positions Available, 578, 1141, 1682, 2475
Sunrise Seminar Series, 2121

Gold Standard Multimedia Inc.

Institutional, 1057, 1501, 2479

Good Samaritan Hospital (Dayton)

Positions Available, 188

Good Samaritan Hospital (Suffern)

Position Available, 922

Grady Health System

Positions Available, 683

Greater Baltimore Medical Center

Position Available, 2354

Group Health Cooperative of Puget Sound

Position Available, 2255

Gulf Coast Clinical Services

Alkavite, 2013, 2465

H

Halifax Medical Center

Positions Available, 484

Harris County Hospital District

Positions Available, 1781

Harry S. Truman Memorial Veterans Hospital

Positions Available, 84

HealthAmerica

Position Available, 1898

Health First/Holmes Regional Medical Center

Positions Available, 1025, 1462

Hoag Hospital

Position Available, 1360

Hoechst Marion Roussel

Anzemet, 397-398, 600-602, 850-852, 1180-1182, 1380-1382, 1590-1592, 1797-1798, 2105-2106, 2265-2266, 2505-2506

Health Outcomes Research, 207, Apr 1 IBC, 1043

Hugh Chatham HealthCare Services

Positions Available, 1355

Huntsville Hospital System

Positions Available, 1139

I

IBM

Aptiva, 2552

Idaho State University

Position Available, 921, 1146, 1359

Immunex Corporation

Positions Available, 184, 2484

Indian River Memorial Hospital

Position Available, 827

INTEGRIS Health

Positions Available, 1142

InterMetro Industries Corporation

Institutional, 795, Jun 1 IBC

International Plasma Products Industry Association

Albumin, 2093

IsoTech Design

Institutional, 1397

J

Jackson Hospital

Position Available, 1781

Janssen Pharmaceutica

Outcomes Research, 2355

Positions Available, 1150, 1678, 2149

Jefferson Health System-Main Line

Position Available, 482

The Johns Hopkins Hospital

Positions Available, 1146, 1357, 1466, 1784, 2155, 2159

Joint Commission on Accreditation of Healthcare Organizations

National Conference and Exhibition for Home Care and Hospice, 1257

K

Kaiser Permanente

Positions Available, 184, 282, 482, 919, 1569, 1682, 2255, 2480

Kaweah Delta Health Care District

Position Available, 187

King Guide Publications

Institutional, 2489

King Guide to Parenteral Admixtures, 2085

Kingsbrook Jewish Medical Center

Residency-Fellowship Program, 921

L

Lab Safety Corporation

Valitek, 2075, 2519

Lakeland Regional Medical Center

Position Available, 1358

Lakes Region General Hospital

Position Available, 827

Legacy Health System

Position Available, 84

Lexington Medical Center

Position Available, 825

Lovelace Health Systems

Positions Available, 1994

Loyola University Medical Center

Position Available, 83, 387, 485, 921, 1025, 1149, 1266, 1463, 1569

M

Maginnis & Associates, Inc.

Institutional, 309, 693, 1065

Management Search and Consulting, Inc.

Position Available, 2471

Marshfield Clinic

Position Available, 85

Martin Memorial Health Systems, Inc.

Positions Available, 2480

Mayo Clinic

Position Available, 188, 2474

McGraw-Hill

Drug Therapy 1999, 415

McKenzie-Williamette Hospital

Position Available, 1786

McKesson HBOC MedManagement

Positions Available, 1784

Medical Communications Media

Education 2000, 17

Medi-Dose, Inc.

Institutional, 2011, 2387

Medimmune, Inc.

Synagis, 19-20, 283-284, 409-410, 1703-1704

Mediware Information Systems, Inc.

Position Available, 680

Med Options USA

Positions Available, 85, 286, 385, 487, 582, 683, 827, 924, 1029, 1159, 1269, 1363, 1466, 1573, 1683, 1787, 1898, 1997, 2162, 2248, 2359, 2490, 2562

Memorial Hermann Healthcare System

Positions Available, 1894

Memorial Hospital Jacksonville

Position Available, 2161

Memorial Medical Center

Position Available, 486

Memorial Sloan-Kettering Cancer Center

Position Available, 1463

Merck & Co., Inc.

Aggrastat, 301-302, 779-780, 1147-1148
Crixivan, 1061

Mercy Healthcare Sacramento

Positions Available, 2484

Merle West Medical Center

Position Available, 2354, 2484

Methodist Healthcare

Positions Available, 2250

The Methodist Hospital

Positions Available, 487

Methodist Hospital/HealthSystem Minnesota

Positions Available, 1360

Micromedex, Inc.

Institutional, 1799, 2111, 2289, 2371

Midwestern University

Nontraditional Pharm.D. Program, 826, 2472

Mission St. Joseph's Health System

Position Available, 1573

Mobile Infirmary Medical Center

Position Available, 920, 1025

MultiCare Health System

Position Available, 1572

Munson Medical Center

Positions Available, 483

Muscular Dystrophy Association

Institutional, 1302

N

Nabi

Nabi-HB, 934-936, 1054-1056, 2404-2406

National Eye Health Education Program

Institutional, 1991

National PharmPak Services, A Cardinal Health Company

AccessPak, 319, 807

The Nielsen Healthcare Group

Positions Available, 1787, 2162, 2359

New York Presbyterian Hospital

Positions Available, 924

New York State Council of Health-system Pharmacists

Position Available, 187

The North Carolina Baptist Hospitals, Incorporated

Position Available, 1362

Northeast Georgia Health System, Inc.

Position Available, 823

North Mississippi Medical Center

Position Available, 2160

Northside Hospital

Positions Available, 286

Northwestern Memorial Hospital

Position Available, 1780, 2161

Norton Healthcare

Positions Available, 2153, 2356, 2474

Nova Southeastern University

Training Program, 826

Novant Health

Position Available, 682

Novartis Pharmaceuticals Corporation

Neoral, 91-92

Sandimmune, 197-198, 413-414

Novation, The Supply Company of VHA and UHC

Position Available, 1893

O**Ohio Northern University**

Residency Program, 825

OmniCell Technologies, Inc.

SureMed, 941, 1077

Oregon Health Sciences University

Position Available, 824

Organon Inc.

Raplon, 1059, 1306, 1475, 1720, 1907, 2291, 2369-2370

Zemuron, 311-312, 797-798, 1175-1176, 1605-1606,

2097-2098, 2521-2522

Orphan Medical, Inc.

Antizol, 1697-1698, 2023-2024, 2407-2408

Ortho Biotech Inc.

Procrit, 200-202, Apr 1 OBC, May 1 OBC, Jul 1 OBC,

OBC, 1565-1566, 1693-1694

Ortho Biotech, A Johnson & Johnson Company

Position Available, 1894

Ortho-McNeil Pharmaceutical, Inc.

Positions Available, 1464

Ortho-McNeil/Johnson & Johnson

Positions Available, 484

P**Pace, Inc., A Lowe Healthcare Company**

Position Available, 389

Paddock Laboratories, Inc.

Bacitracin, 717-718, 1075-1076, 1571-1572, 2123-2124

Pandora Data Systems

Institutional, 709, 1165

Pelton's Health Education Center

Position Available, 1682

Peninsula Regional Medical Center

Position Available, 187

Penn State Geisinger Health System

Position Available, 280

Pfizer Inc.

Positions Available, 1027, 1149, 1269

Pfizer Pharmaceuticals

Norvasc, Jan 15 IBC, OBC, 297-298, Mar 15 IBC,

OBC, 691-692, May 15 IBC, OBC, 1385-1386, 1595-

1596, Sep 15 IBC, OBC, 2033-2034, 2365-2366, Nov

15 IBC, OBC, 2511-2512

www.norvasc.com, 1041-1042

Pharmaceutical Placement Service

Positions Available, 84, 286, 487, 678, 919, 1144, 1358,

1572, 1784, 1993, 2254, 2476

Pharmacy Technician Certification Board

1999 Exam Dates, 819, 1077, 1397

Phoenix Memorial Health System

Position Available, 2255

Piedmont Healthcare System

Positions Available, 683

Pitt County Memorial Hospital

Positions Available, 822, 919

Premier Health Alliance

Positions Available, 2148

ProMetric Pharma USA, Inc.

Institutional, Jan 1 IBC, 105, 299

Providence Health System Alaska

Positions Available, 822, 920, 1027, 1140, 1360, 1569,

1782

Providence Hospital (Columbia)

Positions Available, 2152

Purdue University/Parkview Hospital

Positions Available, 1785

Q**QS/I Data Systems**

Institutional, 13, 205, 417, 593, 841, 1047, 1281, 1483,

1691, 1909, 2173, 2397

R**Rapid City Regional Hospital**

Positions Available, 2357

Regional Medical Center

Positions Available, 2255

Resurrection Health Care System

Positions Available, 1154

Rhône-Poulenc Rorer Pharmaceuticals Inc.

RPR Oncology, 612, Oct 1 IBC

Symposium, 2145

Synecid, 2277-2280, 2379-2381, 2555-2557

Taxotere, 845, 945-946, 1069, 1193-1194, 1285, 1389-

1390, 1504, 1587-1588, 1701, 1813-1814, 1919-1920,

2025, 2117-2118

Riverside County Regional Medical Center

Positions Available, 282, 923

Roche Laboratories, A Division of Hoffmann-La Roche Inc.

Rocephin, Feb 15 IBC, OBC, Apr 15 IBC, OBC, Jun 15

IBC, OBC, Aug 15 IBC, OBC, Oct 15 IBC, OBC, Dec

15 IBC, OBC

Roferon, 725-726, 2087-2088, 2525-2526

Roferon-A, 109-110, 315-316, 1171-1172, 1611-1612

Xeloda, 119, 803, 1049-1052, 2039-2042, 2393-2396

Ross Laboratories

Survanta, 2067-2068, 2179-2180, 2273-2274, 2477-2478

Rutgers, The State University of New Jersey

Fellowship Programs, 2359

Positions Available, 2357

Rutland Regional Medical Center

Position Available, 823

S**St. Agnes HealthCare**

Positions Available, 84, 185, 281, 582, 824, 1029, 1681,

2253, 2480

Saint Barnabas Medical Center

Position Available, 682

St. Claire Medical Center

Position Available, 1569

St. Dominic-Jackson Memorial Hospital

Position Available, 185

St. Francis Medical Center

Position Available, 1139

St. Joseph Hospital (Lancaster)

Positions Available, 1681, 1780

St. Joseph's Hospital, Member of Covenant Healthcare

Position Available, 482

St. Jude Children's Research Hospital

Position Available, 84, 1268

St. Luke's Regional Medical Center

Position Available, 1149

St. Mary Medical Center, Part of Catholic Health Initiatives

Position Available, 1029

Saint Vincent Health System

Positions Available, 1144, 2253, 2484

St. Vincent Hospitals and Health Services (Indianapolis)

Position Available, 922

Samaritan Health System

Positions Available, 682

San Francisco VA Medical Center

Position Available, 2253

SangStat Medical Corporation

SangCya Oral Solution, 703-704, 955-956, 1157-1158,

1299-1300, 1561-1562, 2079-2080

Schein Pharmaceutical, Inc.

Fertilec, 1583-1584, 1713-1714, 1801-1804, 2027-2030,

2183-2186, 2467-2470

INFeD, 510-512, 768-770

Scientific Therapeutics Information, Inc.

Positions Available, 83, 281, 483, 2153, 2253, 2357

Scott & White Memorial Hospital

Positions Available, 1782

ScriptPro

Institutional, 2113, 2367

Searle

Celebrex, 1279-1280, Jul 15 IBC, OBC, 1477-1478,

1599-1600, 1707-1708, 1807-1808, 1913-1914, 2131-

2132, 2175-2176, 2281-2282

Seton Healthcare Network

Positions Available, 1266

Shands Hospital at the University of Florida

Position Available, 918

Sierra Staffing

Positions Available, 487, 683, 924, 1150, 1363, 1573,

1787, 1997, 2162, 2248, 2490

SmithKline Beecham

Fellowship Program, 2160

Kytril, 1824-1826, 2020-2022

Positions Available, 1150, 1679, 1681, 2559

Timentin, 2071-2072

Southern Regional Health System

Position Available, 1268, 2254, 2479

South Fulton Medical Center

Position Available, 824, 1357

Southwest Washington Medical Center

Position Available, 1359

Sparrow Hospital

Positions Available, 483

Spartanburg Regional Healthcare System

Positions Available, 182, 485, 580, 682

Spohn Health System

Positions Available, 83, 387

Sunrise Hospital and Medical Center

Positions Available, 2559

Sutter Health

Positions Available, 1995

T**TAP Pharmaceuticals Inc.**

Prevacid, 605-606, 847-848, 1063-1064, 2107-2108,

2251-2252, 2389-2390

Temple University Health System

Positions Available, 579, 2146

Tenet Healthcare Corporation/Hahnemann University Hospital

Position Available, 1681

Tenet Healthcare Corporation/Medical College of Pennsylvania Hospital

Position Available, 83

Tenet HealthSystem/Atlanta Medical Center

Position Available, 822, 1465

Texas Children's Hospital

Position Available, 2153, 2474

Texas Health Resources

Positions Available, 1897

Texas Tech Health Sciences Center

Positions Available, 1357

Tuba City Indian Medical Center

Positions Available, 582, 825

Tulane University

Position Available, 1154

Tulane University Hospital and Clinic

Positions Available, 2472

U**The Uniontown Hospital**

Position Available, 84

University Hospital-Stony Brook

Positions Available, 1355

University Medical Center (Jacksonville)

Positions Available, 286

University Medical Center of Southern Nevada

Positions Available, 2157

University Medical Center (Tucson)

Position Available, 1140

University of Arizona

Fellowship Program, 2160

University of Cincinnati

Position Available, 1995

University of Florida

Doctor of Pharmacy Degree Program, 921, 1359,

1466, 1573, 2159, 2399, 2471

University of Georgia College of Pharmacy

Position Available, 280

University of Houston College of Pharmacy

Positions Available, 186, 579, 1570

University of Illinois at Chicago

Anticoagulation Training Program, 182, 1682, 1896

Continuing Education, 482, 2151

Positions Available, 389

University of Illinois at Chicago Medical Center

Position Available, 1570

University of Iowa Hospitals and Clinics

Positions Available, 2250

University of Maryland at Baltimore

Position Available, 826

Annual Index

University of Michigan College of Pharmacy

Position Available, 1267, 1680, 1783

University of Michigan Health System

Positions Available, 186, 825

University of Oklahoma

Position Available, 182

University of Pittsburgh Medical Center

Position Available, 1358

University of Pittsburgh School of Pharmacy

Position Available, 2249

University of Southern California School of Pharmacy

Position Available, 1570, 2561

University of Tennessee, Memphis

Position Available, 578

University of Texas El Paso Cooperative Pharmacy Program

Positions Available, 2255, 2476

University of Texas, M. D. Anderson Cancer Center

Position Available, 1144, 1895

University of Washington

Position Available, 2249

University of Washington Medical Center

Positions Available, 582, 1143

University of Wisconsin Hospital and Clinics

Positions Available, 2157

University of Wyoming School of Pharmacy

Position Available, 1139

U.S. Pharmacopeia

MedMARx, 15, 115, 213, 685, 813, 1078, 1575, 1811, 1911, 2095, 2271

V

Valley Medical Center

Positions Available, 2359

Vanderbilt University Medical Center

Positions Available, 1269

VA New York Harbor Healthcare System

Position Available, 2255

Vencor Hospital-Northlake

Position Available, 582

ViaHealth

Positions Available, 826

Virginia Commonwealth University

Position Available, 678

Virginia Mason Medical Center

Position Available, 1786

W

Wake Forest University School of Medicine

Position Available, 185, 2162, 2562

Warren Hospital

Position Available, 1996

Waukesha Memorial Hospital

Position Available, 1140

Wausau Hospital

Positions Available, 1139, 2561

Wayne State University

Position Available, 2148

Winter Haven Hospital

Positions Available, 187

www.pharmacistplacement.com

Positions Available, 1993, 2155, 2476

Wyeth-Ayerst Laboratories, Inc.

Sonata, Aug 1 OBC, Oct 1 OBC, 2294-2296, 2412-2414
Symposium, 2129

X

Xavier University of Louisiana

Position Available, 923, 1683

Z

Zablocki Department of Veterans Affairs Medical Center

Position Available, 1994

Zeneca Pharmaceuticals

Institutional, 811
Seroquel, 9-10, 475-476, 713-714, 1045-1046

